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Abstract: 
Aim: This thesis aimed to evaluate the performance and usage of ICT Pf Malaria 
Rapid Diagnostic Test (MRDT), in an operational setting in the Limpopo Province, 
South Africa. 
Methods: Four studies were conducted to: assess factors affecting MRDT use 
(exploratory study- conducted as part of formative work); determine ICT Pf accuracy 
(cross-sectional study amongst 405 patients with prospective observational cohort 
component for follow-up); determine the performance of MRDT end-users (cross-
sectional observational study) and assess the suitability of using positive control 
antigen wells (PCWs) for routine quality control. 
Results: Key informants reported that MRDT accuracy, end-user proficiency and 
MRDT quality affect MRDT use and impact. The accuracy study found that 
sensitivity, specificity, positive and negative predictive values of ICT Pf test were 
99.48% (99% Cl; 96.17-100.00%), 96.26% (99% Cl; 94.7-100%) 98.48 (99% Cl 
98.41 -100.00%) and 96.26% (99% Cl 91.53-98.79%) respectively. Febrile patients 
with 'sweating' were 5 times more likely to be ICT Pf positive than those without 
sweating. Among the 68 patients who returned for day-seven follow up 23 (33%) 
were ICT Pf positive; however all were microscopy-negative. End-user proficiency: 
of the 15 recommended steps for MRDT use, 50% of end-users performed 11 or 
more steps correctly; 50% of end-users interpreted 90% of pre-prepared tests 
correctly. The false negative interpretation rate was 15%. The quality control study 
revealed that diluting PCWs with MRDT-negative blood gave better signals than 
diluting with citrate buffer. PCWs maintain signal strength when stored up to 30 days 
at 25°C at rural health clinics. 
Conclusions: Although ICT Pf MRDT can be used for malaria diagnosis in 
Limpopo, test sensitivity at low level parasitaemias in field settings need to be 
established. The ICT Pf test should not be used for assessing cure post-treatment. 
End-user proficiency needs improvement. PCWs can be used to monitor MRDT 
quality at PHC level. 
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Combination therapy 
Diagnostic accuracy 
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False positive rate: 
False Negative rate: 
Gold Standard 
Health workers 
Jindex 
Glossary of Terms 
Parasite specific antigens present in malaria infected 
blood. 
Artemisinin based therapy, using 2 drugs 
co-artemether and Lumefantrine (in the study context). 
The test accuracy as measured by sensitivity and 
specificity . 
Health workers performing MRDTs. 
The proportion of individuals without infection being 
missed by the test and falsely ascribed a positive status. 
The proportion of the infected individuals being missed 
by the test and falsely ascribed a negative status. 
A method or procedure that is widely accepted and 
recognized, microscopy was the gold standard for 
diagnosis in this study. 
Persons working at health facilities; e.g. nurses and 
nursing assistants. 
Overall measure of the reliability of a diagnostic test 
which summaries both sensitivity and specificity. 
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Low transmission setting Malaria cases, less than 10 per 1000 population at risk. 
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Likelihood Ratio Test - The likelihood ratio incorporates 
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the odds of having a disease. The likelihood ratio for a 
positive result (LR+) tells you how much the odds of the 
disease increase when a test is positive. The likelihood 
ratio for a negative result (LR-) tells you how much the 
odds of the disease decrease when a test is negative. 
Officials responsible for co-ordinating programmatic 
activities, in this study context the malaria programme 
managers at district level were responsible for 
coordinating malaria operations at the implementation 
level. 
Antimalarial treatment with a single medicine. 
Negative predictive value The proportion of the test's negative reading which is 
true. 
Overdiagnosis 
Parasitaemia 
Periurban 
False positive diagnosis, when diagnosis takes place 
incorrectly sometimes on a clinical basis rather than 
through definitive diagnosis (laboratory or rapid test). 
When malaria parasites are present in the blood stream. 
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1.0 Chapter 1: Introduction 
The prompt and accurate diagnosis of malaria is crucial to prevent malaria-related 
complications and mortality. In South Africa, in most primary and secondary health 
facilities, Malaria Rapid Diagnostic Tests (MRDTs) are used to make a definitive 
diagnosis of malaria. The national malaria treatment guidelines recommend giving 
anti-malaria treatment to MRDT positive cases only. Thus the performance and use 
of MRDTs play an important role to prevent malaria-related complications and 
mortality in South Africa. This study aimed to evaluate the performance and usage of 
ICT Pf Malaria Rapid Diagnostic Test (MRDT), in an operational setting in the 
Limpopo Province, South Africa. Specifically it aimed to assess factors affecting 
MRDT use, determine the accuracy of MRDTs in the field, assess the performance 
of MRDT end-users (cross-sectional observational study) and assess the reliability 
of using positive control antigen wells for routine quality control of MRDTs in the 
field. 
Chapter 2 presents the background to the study: It provides a comprehensive review 
of the literature on MRDT accuracy, end-user proficiency and quality control of 
MRDTs as well as the aims and objectives of the study, the problem statement, and 
the epidemiology and control of malaria in South Africa, with emphasis on the study 
area. 
In chapter 3, the results of an exploratory study that was undertaken as formative 
work to identify factors that affect the performance and use of MRDTs at primary 
health care level in South Africa, are presented. The key findings from the 
exploratory study were that the accuracy of MRDTs, end-user proficiency and the 
quality of the MRDT test kit, were major factors that affect the usage and impact of 
MRDTs. 
Acknowledging the results from the formative work (presented in chapter 3) the main 
study therefore focused on 3 key aspects: (1) accuracy of the MRDT, (2) end-user 
19 
proficiency and (3) use of positive control wells to assess the quality of the MRDTs 
in the field. 
Chapter 4 presents the results of the study that assessed the accuracy of MRDTs. 
Chapter 5 presents the results of the study that assessed MRDT end-user 
proficiency. 
Chapter 6 reports the use of positive control wells for routine quality control of 
MRDTs. 
Chapter 7 summarises and discusses the key findings of this work. 
The appendices present more details on procedures and tools used for the study. 
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2.0 Chapter 2: Background 
2.1 Statement of the Problem 
The 2005 World Malaria Report estimates around 350-500 million clinical episodes 
of malaria and one million deaths due to malaria occur annually and that around 
60% of the clinical cases and 80% of malaria deaths occur in Africa.(1) Malaria 
contributes to anaemia in children and pregnant women and to adverse pregnancy 
outcomes such as abortion, still births, and low birth weights. Furthermore it is well 
documented that malaria hampers economic growth and development.(2) 
Ten percent of South Africa's population (approximately 4.4 million people) live in 
malaria endemic areas. The transmission of malaria is seasonal and epidemic 
prone in South Africa.(3) Malaria epidemics can cause large numbers of infections 
and deaths in a relatively short period of time.(4) Diagnosing malaria accurately and 
promptly is therefore paramount to preventing malaria-related morbidity and 
mortality.(5) 
Malaria Rapid Diagnostic tests (MRDTs) are a fast and easy way to diagnose 
malaria particularly in the peripheral areas where there is limited access to skilled 
laboratory personnel.(6) Since 2003 MRDTs are being used for the diagnosis of 
malaria at primary health care level in the Limpopo Province, South Africa.(3) 
However the field accuracy of MRDTs and end-user proficiency in MRDT use, are 
unknown.(7) Furthermore there is no system in the Limpopo Province to monitor the 
quality of MRDTs after the test has been exposed to field conditions. 
The South African malaria treatment policy stipulates that all patients with a positive 
MRDT should receive anti-malarial treatment and that antimalarial drugs should be 
given only to those patients who have a definitive diagnosis of malaria reached 
through MRDT or microscopy.(8) This latter aspect of this policy raises concerns, 
given the possible limitations of MRDTs and especially the fact that MRDTs can give 
false negative results.(9) It is therefore important to estimate the accuracy of MRDTs 
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under field conditions. It is also important to understand the factors that affect the 
accuracy and use of MRDTs and to determine how to set up a quality control system 
to ensure appropriate use of MRDTs in South Africa. 
2.2 Literature review 
2.2.1 The Malaria profile in South Africa 
Malaria transmission in South Africa can be defined as low to moderate and 
seasonal. The transmission of malaria occurs mainly during the rainy season from 
October to May and three out of nine provinces are affected by malaria.(3) The 
limpopo Province, situated in the north-eastern part of South Africa, is one the three 
provinces where malaria transmission occurs, (Figure 1). From 2003 - 2006 the 
limpopo has had higher numbers of reported malaria cases compared to the other 
two malaria-affected provinces (Figure 2). Malaria transmission decreased from 
about 41 786 cases in Kwa-Zulu Natal in the year 2000 to 2042 cases in the year 
2003. This decrease can be attributed to change in drug policy - from monotherapy 
to ACTs; change in insecticide policy - from pyrethroids to DDT (Dichloro-Diphenhyl-
Trichloroethane); establishing a cross-border malaria collaboration between Kwa-
Zulu in South Africa, Maputo Province in Mozambique and Lubombo District in 
Swaziland.(3) 
During the past five years (2001-2006), the Vhembe district, followed by the Mopani 
district has had on average, the highest number of malaria cases in the Limpopo 
province (Figure 3).(10) In a review of malaria data from the limpopo province 
between 1999 to 2006, Gerritsen et a/. states that the incidence of malaria in the 
Vhembe district is approximately 328.2 per 100 000 population at risk; more males 
than females are at risk of contracting malaria - the mean incidence of malaria was 
higher in males than females (145.8 vs 105.6 per 100 000 population at risk; 
p<0.001 ).(11) Their findings also point to malaria incidence being the lowest in the 0-
4 year olds, peaking in the 35-39 age groups. 
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2.2.2 Demographics of the Vhembe District 
The Vhembe District is one of Limpopo's six district municipalities established in 
2000. It incorporates four local municipalities, namely: Makhado, Thulamela, Musina 
and Mutale. The Vhembe District Municipality (VDM) is situated in the northern part 
of Limpopo Province and is bordered to its south, east and west mainly by Central, 
Mopani and Botshabelo district municipalities; to its north lies Zimbabwe (Figure 4). 
The Vhembe district covers 21 407 square kilometers of land and has a population 
over 1.1 million. The major languages spoken in Vhembe district are Xitsonga, 
Tshivenda, Sepedi, English and Afrikaans. Vhembe has a competitive advantage in 
agriculture, tourism and mining potentials, compared with the other Limpopo 
province districts. Malaria can affect income generation in Vhembe District, as all the 
potential economic development sectors, viz. agriculture, tourism and mining can be 
adversely affected by an increase in malaria.(2) 
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2.2.3 Strategies for controlling malaria 
Study 
districts" 
The World Health Organization's Global Malaria Strategy stipulates that early 
detection of cases or epidemics, rapid response to malaria epidemics and effective 
case management are key strategies for controlling malaria.(5) Definitive diagnosis 
using appropriate diagnostic tools is important to ensure early detection of malaria 
cases , ensure effective case management, prevent epidemics and reduce malaria-
related mortality.(4-6) 
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2.2.4 Tools for the diagnosis of malaria 
Malaria can be diagnosed using several approaches including clinical presumptive 
diagnosis, microscopy, peR, ELlSA and MRDTs.(12) Microscopy remains the 'Gold 
Standard' for malaria diagnosis.(9) Microscopy, however, requires highly skilled 
staff, electricity, microscopes and laboratory reagents. Its use is therefore restricted 
to laboratories with skilled personnel and appropriate equipment. In primary health 
care settings, usually clinics and health centers at district level, MRDTs are more 
applicable for diagnosis because they are easy to use and are relatively low-cost, as 
there is no need for electricity or highly skilled staff.(12) The current market price of 
MRDTs in developing countries is approximately U.S.$ 0.SS-U.S.$1.S0 
(depending on the species and order quantity) compared to microscopy cost of 
U.S.$ 0.12- $0.40 per malaria smear.(13). Although the direct cost (cost of the test) 
of MRDT may be higher than microscopy the indirect costs of microscopy (electricity, 
microscopes and technician time) would make microscopy more expensive. More 
importantly, the time taken to produce a microscopic diagnosis is much longer than 
using MRDTs - hence the latter technology is most appealing for primary health care 
settings. Shillcutt et al. evaluated the cost effectiveness of malaria diagnostic 
methods in sub-Saharan Africa in an era of combination therapy.(14) The objective 
of their study was to estimate the relative cost-effectiveness of MRDTs, presumptive 
treatment and field standard microscopy in different epidemiological settings of sub-
Saharan Africa where Plasmodium falciparum predominates, using a decision-tree 
model and probabilistic sensitivity analysis. Their findings revealed that MRDTs were 
cost-effective compared with presumptive treatment and microscopy. 
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2.2.5 Malaria diagnosis and treatment in South Africa 
In South Africa the health-care system is decentralised, whereby policy is set at the 
national level and implementation takes place at the district level. In the district 
health-care system, commodities such as MRDTs are purchased through the district 
health budgets and distributed to the clinics via the district pharmacy stores. At the 
primary health-care level the first point of call for patients is the clinic, clinics refer 
severely ill patients to district hospitals. 
The Limpopo Province, in keeping with the National Department of Health's malaria 
policy, has adopted appropriate case management (definitive diagnosis and prompt 
treatment) as one of its key strategies for controlling malaria.(3) In 2001, South 
Africa changed its drug policy from monotherapy to Artemesinin Combination 
Treatment (ACT), this warranted the need for definitive diagnosis.(3) MRDTs was 
chosen as the routine diagnostic tool, especially at primary health care settings 
throughout the malaria affected provinces, including Limpopo. MRDTs have 
therefore become an important diagnostic tool for the management of malaria, 
especially in remote areas of South Africa. 
2.2.6 Consequences of inaccurate diagnosis of malaria 
The misdiagnosis of malaria can lead to medical, social, and economic 
consequences.(15) Medical consequences of misdiagnosis at the individual level, 
include inappropriate treatment resulting in prolonged illness. Social consequences 
could include loss of faith in health care services and delayed care-seeking. 
Economic consequences could include loss of earnings or increased expenditure on 
transport, drugs and consultations. 
The consequences of over-diagnosis of malaria could result in higher mortality from 
diseases other than malaria. Reyburn and colleagues demonstrated in a study from 
Tanzania that clinical diagnosis of malaria yielded more false positives than 
diagnosis using microscopy.(16) Over-diagnosis of malaria can lead to overuse of 
antimalarial drugs, and may even prevent diagnosis and treatment of other 
diseases.(15, 17-19) On the other hand, the under-diagnosis of malaria or false 
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negatives could result in lack of treatment of patients and can lead to malaria-related 
complications and even death.(6, 20, 21) 
Ensuring diagnostic accuracy of MRDTs is therefore essential to preventing the 
unnecessary and avoidable consequences of over- or under- diagnosis of malaria. 
2.3 MRDTs for the diagnosis of malaria 
2.3.1 Background to MRDTs 
MRDTs, sometimes called Dipsticks or "Malaria Rapid Diagnostic Devices" 
(MRDDS), detect specific antigens (proteins), produced by malaria parasites.(6) 
There are currently 3 malaria parasite target antigens that can be detected by RDT 
technology; these are: the Histidine Rich Protein 11 (HRPII) - found only in P. 
falciparum, Parasite Lactate Dehydrogenase (PLDH) and Aldolase.(12) Thus the 
HRPII antigen detection test is specific for P. falciparum, whilst the PLDH and the 
Aldolase antigen detection test can be used for all Plasmodium species (P. vivax; P. 
ovale and P. malariae). The antibodies in the test kits for antigen detection can 
therefore be species- specific. 
MRDTs are manufactured in 3 formats.(22) The basic form is a dipstick, in which the 
absorbent nitrocellulose strip is placed in wells containing blood and or buffer. The 
nitrocellulose strip can either be placed in a plastiC cassette or on a card. The mode 
of action for an MRDT is summarized in Figure 5. 
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1. Dye-Iabeled antibody, specific for target antigen, is present on the lower end of nitrocellulose strip or in a 
plastic well provided with the strip. Antibody, also specific for the target antigen. is bound to the strip in a 
thin (test) line, and either antibody specific for the labeled antibody, or antigen, is bound at the control line. 
~ Bound 
••••• , .... An1ibody 
Ttstband 
(bO\D\dAb). 
~ 
NitroceJ.lulose strip. 
Con1rol band 
(bOlD'\dAb). 
-t 
2. Blood and buffer, which have been placed on strip or in the well , are mixed with labeled antibody and are 
drawn up the strip across the lines of bound antibody. 
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3. If antigen is present, some la be led antibody will bind to the antibody on the test line. Excess-Iabeled 
antibody is trapped on the control line. 
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Fig 5: Mode of action of common malaria ROTs format, adapted from WHO 
Guidelines (23, 24) 
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Experts at a WHO informal consultative meeting on field trials and quality assurance 
of malaria rapid diagnostic tests, have listed several factors that may affect the 
accuracy of MRDTs, including: the manufacturing quality of MRDT; the environment 
(temperature and humidity) during transport and storage and the end-user's 
proficiency. (9) 
2.3.2 Accuracy and field evaluations of MRDT's 
Although HRPII antigen detection is useful for P. fa/ciparum malaria diagnosis, the 
antigen persists in the blood of infected individuals for more than 4 weeks after 
successful treatment.(23) These tests may therefore not be useful for monitoring 
treatment success, as a false positive - which could be interpreted as treatment 
failure - is possible.(9) However if all MRDT positive cases are confirmed by 
microscopy as in South Africa the H RPII antigen detection test can be used as a 
screening test, for initial diagnosis of malaria .(7) 
The accuracy of a MRDT is judged mainly by its level of sensitivity and 
specificity.(6) The World Health Organisation's guidelines on MRDT recommends 
that for an MRDT to be deemed 'accurate', it should have a sensitivity of ~95% and 
a specificity of ~90% at a level of ~1 00 parasites per J..l1 of blood using microscopy as 
the gold standard. (9, 23) This means that an accurate test would still underdiagnose 
up to 5% of malaria cases. The implications of having up to 5% of malaria cases 
under-diagnosed in a low transmission setting, such as in South Africa are grave 
and could result in loss of life, should cases go untreated. It is therefore imperative 
for a diagnostic test to have sensitivity close to 100%. If the test sensitivity and 
specificity is not 100% in a malaria endemic area, then the guidelines for treatment 
and referral of patients to the next level need to be reviewed.(9) 
MRDTs that detect HRP 11 antigens are currently commercially available from 
several manufacturers and many have been evaluated globally in field and 
laboratory settings. In a systematic review of 32 studies of multiple settings, 
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Cruciani and colleagues reported an overall sensitivity of 90% and specificity of 94 
% for Parasight F MROT, an HRP (11) based antigen detection test to detect P. 
falciparum malaria.(25) 
Results of studies on the diagnostic accuracy of ICT Pf MROTs, the test currently 
used in South Africa, are summarized in Table 1 and 2. Iqbal and co-workers tested 
the accuracy of ICT Pf MROTs in 515 patients in Kuwait using microscopy results as 
the gold standard and found a sensitivity of 82% and a specificity of 99%. (26) Singh 
and colleagues reported sensitivity of 100% and specificity of 85% in 353 patients in 
India.(27) Pieroni et. al. compared ICT Pf test and Parasight F test using PCR as the 
gold standard, among 200 febrile travelers in Toronto, Canada, and reported a 
sensitivity of 94% and specificity of 97%. (28) Thepsamarn et. a/. found a sensitivity 
of 95% and a specificity of 92.7% in 305 participants in Thailand.(29) Among 98 
participants Kumar and co-workers observed a sensitivity of 100% and a specificity 
of 100% using slide microscopy in another study from India.(30) Wonsrichanalai et. 
al. found a sensitivity 95% and specificity was 89% compared ICT Pf with malaria 
microscopy in 551 patients in Thailand using microscopy as the gold standard, (31) 
Bell et al. found in a study in the Philippines that the ICT Pf had a sensitivity of 
98.7% when they tested 350 symptomatic patients however their specificity was low 
(74.1 %). (32) Toma et. al. demonstrated in a study of 2 066 persons from a village in 
Lao POR, that the sensitivity of the ICT Pf test was 92.2% and the specificity was 
93.5%, see Table 1.(33) 
Comparison of the sensitivity and specificity across settings is complex, due to the 
variability in epidemiological settings and reference standards; however Irwig et.al 
point out that there is indeed variability in the field accuracy of the leT Pf test in 
different settings.(34) 
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2.3.3 Studies of accuracy of MRDTs in Africa 
Studies in Africa also show variability in sensitivity and specificity of the HRP 11 
antigen detection tests. Results of key African studies on HRP 1I antigens are 
summarized in Table 2. 
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Reference Test Country Sensitivity (%) Specificity PPV NPV 
Setting (%) (%) (%) 
Parasite Parasite Any 
density density parasite 
S100/J.JI of >100/J,llof density 
blood blood 
(26) ICT Kuwait NR NR 82.0 99.0 98.0 83.0 
(35) ICT (Amrad India NR NR 100 98.7 95.0 100 
leT, 
Sydney) 
(28) leT Pf Test Canada ? ? 94.0 97.0 98.0 95.0 
(29) leT Thailand ? ? 92.7 95.0 93 96 
(30) leT India 100 100 95.4 100 
(31) ICT Thailand ? 100 100 100 
(32) leT Philippines 98.7 64 42 99.0 
(33) leT (Amrad Lao PDR ? ? 92.2 93.5 84.0 97 
leT, Sydney 
Footnote: ? - not Included In the study; NR= not reported 
Table 1: Accuracy of ICT Pf test for diagnosing P fa/ciparum malaria outside Africa 
Reference 
(36) 
(37) 
(38) 
(39) 
(40) 
Test Country Specificity 
Setting Sensitivity (%) % 
Parasite Parasite Any 
density density parasite 
S100/1J10f >100/1J10f density 
blood blood 
Parasight' M F Gambia 1 NR NR 96.5 90.5 
ICT Malaria Pf Uganda 1 71.4 100 100* 92.2 
Parasight F 71.4 97.1 97.1* 96.1 
Paracheck dipstick Uganda 2 86.3 98.9 97.4 88.1 
Paracheck device 88.2 98A 97.2 87.7 
ParaHIT f 88.2 98.9 97.6 87.3 
Sio PF. 62.7 93.2 89.5 93.1 
Malaria rapid 90.2 99.5 98.3 75.3 
Parasight 'M F Zimbabwe NR NR 93.0 83.5 
(Meso-
endemic zone) 
Parasight' M F Tanzania NR NR 88.9 87.5 
Footnote: NR= not reported In the study; * parasite density of :::500 parasites 11-/1 of blood 
Table 2: Accuracy of HRP 11 antigen test in Africa 
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Positive Negative 
Predictive Predictive 
Value % Value % 
94.2% 94.3 
90.0 94.0 
89.7 92.2 
91 .5% 96.1 
91 .2 96.5 
83% 87.5% 
87.7 88.0 
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Fig 6: Specificities and Sensitivities of MRDTs in African settings against the WHO recommended thresholds. 
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Studies in Africa show MRDTs overall sensitivity ranges from 88.9% to 100% and 
specificity from 83.5% to 90.5%, for detecting P. falciparum HRP 11 antigen.(36-40) 
As stated previously the WHO recommends a sensitivity and specificity, 
respectively, of =::95% and =::90% respectively. Two studies of the six identified 
showed that MRDTs were suitable for malaria diagnosis in the field, when comparing 
it to the WHO acceptable levels for overall sensitivity and specificity. The first study 
was from The Gambia by Bojang et al using Parasight™ F; sensitivity was 96.5% 
and specificity was 90.5%. The second by Killian et al. in Uganda used leT Pf and 
Parasight F tests; both tests were in keeping with the recommendations for 
acceptable tests: sensitivity and specificity, respectively were 100% and 92.2% (leT 
Pf) and 97.1 % and 96.1 % (Parasight F).(36, 37) 
The other studies from Tanzania, Uganda and Zimbabwe showed unacceptable 
levels of accuracy in terms of either sensitivity or specificity or both (Table 2).(38, 39) 
Some MRDTs have shown to compare favourably with microscopy. (41-43) However 
variability in sensitivity has been observed in several studies, when the same test 
was used in different locations. (44-47) Interestingly most variations occurred in 
settings where parasitaemias were low (100-500 parasites/lJl), albeit significant 
enough to result in symptomatic malaria, especially among non-immune 
patients.(42, 48-52) 
2.3.4 Evaluations of MRDTs in South Africa 
MRDTs that are currently supplied in South Africa are based mainly on the HRP 11 
antigen detection system with only one test using species antigen detection system 
(personal communication provincial malaria programme managers). In South Africa 
the KAT Quick, Makromed (MM), Assure, One step and leT Pf are supplied for 
public health use. Kits are purchased on the basis of a tender system. 
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MRDT tenders should be awarded, using the main criteria of costs, test accuracy in 
the field and laboratory, stability of the test and ease of use of the test.(9, 53) The 
current MRDT in use in South Africa (ICT Pf ) that was accepted in the tender did 
not undergo field evaluation for sensitivity and specificity on symptomatic untreated 
malaria patients. This was reportedly due to the fact that the tender needed to be 
awarded outside the malaria transmission periods, hence due to insufficient malaria 
patient numbers a field assessment was not possible.(7) The laboratory 
investigations of ease of use, diagnostic thresholds and mUlti-center health stability 
tests were however considered.(54) The heat stability results for the current MRDT 
revealed that the test could pick up parasites at levels of 100 parasitesl IJI after 90 
days exposure of the test at a temperature of 35°C. 
Durrheim et al. conducted a study in the Mpumalanga Province of South Africa to 
evaluate the accuracy and the usefulness of the ICT Malaria PfTM card test (ICT 
Diagnostics Sydney Australia) - a test previously used by the National Department 
of Health, South Africa.(55) The test was evaluated on 264 consecutive patients with 
signs and symptoms of malaria and the results were compared to microscopy. Their 
results revealed that the test sensitivity was 98.6% and the test specificity was 
97.9%. Although the overall test accuracy was above the WHO acceptable threshold 
levels, the paper does not state the parasite detection level in the study setting.(9) 
This test is however no longer in use in South Africa as it was not selected by the 
National Department of Heath in its recent tenders. 
Craig et al. evaluated the MRDT currently used in SA - ICT Pf MRDT; Global 
Diagnostics manufactured in Johannesburg, South Africa - to determine parasite 
detection limit in the laboratory using 19 serial dilutions of EDTA P.fa/ciparum 
infected blood - ranging from 500 to 0.1 parasites/lJl of blood). They also tested post-
treatment specificity of the test. (56) The 50% detection limit of the ICT pf test was 
3.28 parasites per IJI of blood, whilst the test specificity post-treatment (following 7 
days of treatment) was 30% In this study, however the ICT Pf kit was not evaluated 
for accuracy in a field setting. 
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Furthermore, the concentration of the target antigen in the host blood is one of the 
critical factors that affect the accuracy of MRDTs.(57) For a good test 100 parasites 
per IJI is the acceptable threshold, hence in a low to moderate transmission setting 
such as in South Africa this may prove to be a challenge (58) as symptomatic 
patients with fewer than 100 parasites per IJI are often seen in symptomatic non-
immune patients in South Africa (58) and may be missed and thus remain untreated. 
It is therefore of vital importance to determine what percentage of patients with 
symptoms of malaria and a negative MRDT test are not treated and develop overt 
malaria. 
2.4 End-user preparation and interpretation of results 
End-user performance (preparation and interpretation) of MRDTs is key to ensuring 
accuracy of the test kits.(9, 59) To assess the end-user performance, WHO 
recommends that the ability of the end-user to preparel conduct the test and 
interpret the results should be determined. (9) A few studies were found in the, 
literature evaluating self-administered MRDTs, especially among travelers. 
Funk et al. assessed the Malaquick ™ and the Parasight F MRDT in volunteers in 
Switzerland, with the key objective of determining whether lay persons could perform 
these tests and interpret the results correctly.(60) Volunteers were asked to perform 
the test with their own blood using the test instructions. There was no significant 
difference between the two tests in end-user ability to perform them: 87% of 
participants performed the Malaquick correctly and 71 % performed the Parasight F 
test properly. PartiCipants identified blood collection - especially finger pricking - and 
identification of test components as practical difficulties experienced during test 
performance. The overall test scores for interpretation did not differ significantly 
between the tests when the prepared test strips had a parasitaemia of 0.1 % and 2% 
but major problems were encountered at low level parasitaemias «0.1 % blood 
parasites). A false negative interpretation of 72% (Malaquick) and 29.6% (Parasight 
F) was a major concern in this study as these cases could go untreated. 
Approximately 40.1 % of the study volunteers were considered to have a high level 
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of education, being at university. In spite of having the instruction manuals for the 
tests, 20-30% of participants did not perform the MRDTs optimally and interpretation 
of tests was poor, especially for the low-level parasitaemia's. Clearer instruction aids 
and examples of prepared test results may be one way of addressing the challenges 
highlighted in this study. 
Whitty et al. conducted a study in the UK among sick travelers seeking medical 
attention at a travel clinic to determine their ability to perform the ICT Malaria Pf 
using only the instruction manual and no oral instructions.(61) They were mainly 
interested in whether febrile patients with symptoms of malaria could complete the 
test (ICT Malaria pt) satisfactorily, and interpret the results correctly under simulated 
field conditions (assuming no medical assistance will be available). A questionnaire 
was also administered to determine whether travelers familiar with the tests would 
use them in the field. Eleven percent (6/153) of symptomatic patients presenting with 
malaria failed to correctly perform a test (4% patients were unable to use the lancet, 
3% obtained insufficient blood, 4% could not read the card). From those patients 
who satisfactorily completed the tests the results of their self-diagnosis was 
compared to that of slide microscopy. The specificity and sensitivity of the self-
testing was 97% (95% CI-93-99%) and 95% (95 CI-74-99%) respectively. Of the 
153 people enrolled in this study the first 107 commented on the instruction manual, 
and their suggested changes were incorporated into the manual. After changing the 
manual, the percentage of people who indicated that the test was difficult to interpret 
decreased from 20% to 7% (p=0.004), in the 46 patients subsequently tested. 
Trachsler et al. conducted a study in Switzerland to determine whether untrained 
travelers could successfully perform and interpret the results of MRDTs (using the 
Parasight F test).(62) The study involved 160 consecutively selected visitors 
attending a travel clinic in Zurich, whereby one group (n=80) received written 
instructions and the other (n=80) written and verbal instructions on how to test their 
own blood for malaria and interpret the results. The group that received both oral 
and written instructions performed the test significantly better than the group who 
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only received the written instructions 72/80 (90%) achieved satisfactory results, 
versus 60/80 (75%), p<O.O). The key issues for poor performance as cited by the 
participants were the incorrect positioning of the dipstick and difficulty with taking 
blood; the latter was experienced by 107 (66%) participants. In the next stage of this 
study each of the 160 participants were also given 5 test strips to interpret and they 
correctly interpreted 566 out of a total of 800 options (70.6%). There were no false 
positives but there were 113 false negatives (9 for dipstick positive, 53 for dipstick 
weak positive, 40 for dipstick massive positive and 12 for dipstick no result). The key 
challenge identified by the authors was the unavailability of clear instructions with 
graphic illustrations of the test results. False negative results in this study is again 
cause for concern; presuming these travelers were to act on the results, then there 
is a chance that 102 (dipstick no result would probably be retested) persons with 
malaria could potentially have gone untreated. 
Tavrow et al. in the first of a 2-phased study in Malawi, assessed how 19 health care 
providers (end-users) performed MRDT tests (Path and Flow): 8 of the end-users 
received training prior to receiving the tests and the other 11 did not. (63) Their 
findings showed that overall 15% (3/19) performed the test without any errors; those 
that were trained performed better (25%- 2 of11 in trained vs 9%1 of 11; in 
untrained). In the second phase of the study a new group of 20 partiCipants (using 
similar characteristics of participants as the first group) were selected, no training 
was provided but redesigned instructional inserts were used based on the gaps 
identified from phase 1 of the study. Eighty-five percent off end-users (17/20) 
performed all the steps in the test procedures - a significant improvement from the 
previous group. End-user interpretation of results was at 85% in phase 1 of the study 
and reportedly improved remarkably during phase 2 (no data was presented in the 
paper though). Although this study was conducted in a small number of partiCipants 
and therefore findings cannot be generalized, it does give an important indication of 
the key interventions that could improve end-user performance and interpretation of 
MRDT results. 
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A study by Maxay et al. showed that 64 village health volunteers performed 2 
malaria MRDTs (Optimal and Paracheck Pf test) with a high level of accuracy in the 
Lao People's Democratic Republic.(64) The village health volunteers were given one 
hour's training on the performance and interpretation of the MRDTs. They were 
assessed on the same day of the training for their ability to perform the test and 
interpret the results on 3 blood samples, one positive for P. falc;parum, one positive 
for P. vivax and one negative for all parasites. No written or pictorial materials were 
provided and participants did not take notes. The mean test performance scores 
were 99.6% for Optimal and 99.0% for Paracheck ™ Pf. Training as an intervention 
(without instructions or pictorials for lay persons) may have given them skills on how 
to accurately perform and subsequently interpret the results. The element of bias 
could have crept in as these were enthusiastic motivated village health volunteers 
that participated in the study. The skill retention beyond 10 months was not 
assessed in study, hence it cannot be established whether performance is sustained 
or whether retraining and the use of instruction materials would have improved 
performance. 
Rennie et al. conducted a study in the Philippines (n=152) and Laos (n=107) among 
community health workers, to determine the effect of job aids on end-user 
performance using malaria rapid diagnostic tests. The study was conducted in 2 
phases: the first group of participants used the manufacturer's instructions (English 
and local language) to conduct the MRDTs: their performance was judged using a 
standardized checklist. Subsequently, using the knowledge of the gaps identified 
from the initial observations a detailed pictorial job aid with clear instructions was 
developed. Observers used the same checklist to test the pictorial job aid in the 
Philippines on a different group of participants. This job aid then underwent minor 
modifications and was used for testing in Laos. In Laos, two groups of participants 
were randomised to either using the job aid alone or to the job aid plus one hour 
training. In this study, although the mean overall performance of end-users in 
Philippines and Laos improved significantly after introducing the pictorial job aid 
(compared with the initial performance of the Philippines group) performance still 
43 
remained below 80% in both study sites. In the Philippines the mean percentage of 
correct steps using the manufactures instructions was 42% and this improved to 
59% when the job-aid was used and in Laos it also improved from 58% to 68%. The 
group in Laos that had prior orientation coupled with use of job aids versus the group 
with the job aid only, performed the test better (mean of 80% vs 70%; P <0.001). The 
key challenges to performance and interpretation of the results listed by the authors 
in the study include checking expiring dates, kit desiccant and interpreting the weak 
positive and negative results. This study highlights the need for all 3 key 
interventions (baseline assessments of end-user proficiency; development and 
testing of job aids and training coupled with job aids) to be considered for MRDT 
implementation. 
In South Africa no formal studies have been conducted to assess end-user 
proficiency to perform and interpret MRDTs. The exploratory study conducted in 
March 2006 as formative work for this thesis (see Chapter 3 for details) revealed 
huge uncertainty among health managers in the Limpopo Province about end-user 
MRDT proficiency, especially at the primary health care level. (7, 65) A study to 
determine the end user proficiency would therefore prove invaluable to determining 
the current levels of accuracy among end-users. This would also provide useful 
information to decision makers on key areas that need to be addressed to improve 
the performance of MRDTs at the PHC level, should there be a need. 
2.5 Quality control of MRDTs 
As discussed in sections 2.2.6 and 2.3.2 and under or over-diagnosis of malaria 
could have grave consequences. There is therefore a need to ensure that MRDT 
quality control is maintained according to the WHO acceptable criteria.(9) The WHO 
defines quality control as "all the activities taken by a laboratory to monitor each 
stage of a test procedure to ensure that tests are performed correctly, accurately 
and precisely." (66) 
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As explained in section 2.3 and Figure 5 MRDTs are lateral flow immuno-
chromatographic devices, which contain antibodies to capture specific antigens 
(HRPII or LDH). (6, 9) 
By virtue of this MRDTs can be degraded by heat or moisture and can deteriorate 
even in ideal conditions. A positive control line on the test kit confirms migration of 
the dye-antibody conjugate on the test strip. It does not confirm the ability of the 
antibodies to bind to malaria parasite specific antigens, nor adherence of the test-
line antibodies to the nitrocellulose, nor does it signal moderate de-conjugation of 
the anti-parasite dye antibody conjugate. An MRDT may still therefore show a 
positive control line despite inadequate sensitivity affected possibly by temperature 
and humidity. Temperature or vaccine vial monitors may be used to indirectly 
monitor temperatures of the test kit condition. Furthermore variation in MRDT 
accuracy in published trials and operational experience highlights the need for a 
system to monitor the accuracy of the tests after they have been dispatched from the 
manufacturer.(66) It is therefore of paramount importance to have some quality 
control system in place to ensure that the test kit is working post- field exposure. 
The WHO recommends the use of prepared quality control samples using wild type 
parasites for testing of malaria rapid diagnostic tests, especially at the laboratory 
level. (66) However the sophistication of the methods involved in preparing and 
storing wild type antigens puts this technology beyond the reach of district 
laboratories and remote health facilities - especially in developing countries where 
the malaria is most prevalent , hence justifiably this technique is not recommended 
by WHO for use in quality control. Ensuring MRDT quality at the post-manufacturing 
stages can be established in a central sophisticated laboratory with the necessary 
skills and the eqUipment, laboratory; however at the remote health facilities level 
alternative quality control interventions are required.(66) 
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There are a few possibilities available for remote quality control (assuring quality in 
the field only) testing of MRDTs as outlined by the WHO (66); these include: 
• Sentinel site quality control: Comparison of results in a small number of 
"sentinel" sites with microscopy, using slides stained on site and read 
centrally and MRDTs which have undergone typical storage and distribution, 
to ensure that they remain adequately sensitive; 
• Using record books: Health workers can record: symptoms, MRDT results, 
their interpretation of findings, treatment and outcome post follow-up - this 
can then be reviewed by a supervisor and 
• Positive Control Wells (PCWs), using lyophilized recombinant antigen, at first 
referral level. This could be used to periodically evaluate batch test 
performance over its shelf-life under local field and storage conditions. 
Sentinel site quality control assessments for remote health facilities, whilst possible 
in South Africa, may not be beneficial as faulty batches of MRDTs will not be 
detected instantaneously. Similarly the use of record books may result in delayed 
action to remove faulty batches of MRDTs from health facilities; moreover it would 
require additional human resources to undertake the supervisory roles. 
The use of PCWs, containing lyophilized recombinant antigens for assessing MRDT 
quality in the field is an attractive option for South Africa to consider.(67) The 
procedure once established will not require sophisticated technology and skills, 
although it will require that senior nursing staff at health facilities be trained on how 
to appropriately use the wells. 
PCWs are currently not being used in operational settings, as the stability of the 
wells are still being assessed.(67) Published studies on assessing the field stability 
and operational practicalities of PCWs are rare. One study was found in the 
literature, by Lon et. al. who used a commercially available pLDH PCW to assess it's 
ability to monitor MRDT sensitivity in a remote malaria endemic area of 
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Cambodia.(68) In brief antigen strength of the pLDH wells stored at 4°C at a 
centralised laboratory were compared with those un-used wells kept in the field. 
Their results showed that there was no significant difference in the intensity of the 
lines between the reconstituted wells stored centrally at 4°C and those stored in the 
field for 8 months. These results indicate that there is potential to use antigen-coated 
wells to monitor MRDT sensitivity in the field. However this pLDH positive control 
well testing system will not be appropriate for South Africa as the South African 
MRDTs are HRP 11- based, not LDH-based. 
Since 2006 a commercial company (National Bio-products Institute - South Africa) is 
manufacturing the HRPII antigen in the laboratory and has undertaken laboratory 
testing for temperature stability and to determine the appropriate diluent for 
reconstituting the antigen (citrated HRPII-negative blood or buffer). This therefore 
opens the way for the field testing of the HRP 1I antigen positive controls as a 
potential quality control tool for monitoring MRDT sensitivity at field sites in the 
Limpopo. 
The variability in MRDT sensitivity and specificity of HRP 11 found in African and non-
African studies and the implications of the consequences for misdiagnosis, justifies 
the need for a MRDT evaluation in South Africa. 
2.6 Aims of the study 
This study aimed to address 4 key research questions: 
(1) What are the key factors that affect the quality and use of MRDTs in the 
limpopo Province? 
(2) What is the field accuracy of the current MRDT test to diagnose 
malaria in the limpopo Province? What proportion of patients with a 
negative MRDT develop malaria? 
(3) What is the end-user's ability to accurately perform and interpret the 
MRDT results in limpopo? 
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(4) Whether pews could be considered for a quality control programme for 
routine sensitivity monitoring of HRP 11 antigen-detecting MRDTs in the 
Limpopo Province 
See Figure 7 for the conceptual framework for the study. 
48 
Fig 7: Conceptual Framework 
Field accuracy of the MRDT 
Measured by 
Field assessment 
• Sensitivity 
• Specificity 
• Positive predicative values 
• Negative predictive values 
• Proportion of negative and 
positive patients that 
develop malaria 
• Outcome on patient 
follow-up 
End-user Proficiency 
Measured by 
• End-users ability to 
conduct the test 
• End-users ability to 
correctly interpret the 
results 
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Field Reliability of MRDT 
Determining optimum 
method for quality 
Control (QC): 
• QC performed at 
district laboratory 
• QC performed at 
health facility 
After reviewing relevant literature (9) the two key issues that were deemed to be 
critical for correct MRDT performance and usage were MRDT quality and end-user 
proficiency; thus these were the focus of this study. Logistical and operational 
weaknesses identified in the exploratory study, such as stock-outs and temperature 
monitoring, though important, were communicated to the relevant policy makers at 
the Limpopo Provincial Department of Health, for remedying, and were thus not the 
main focus of this DrPH. 
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3.0 Chapter 3: Factors that affect the quality and usage of malaria rapid 
diagnostic tests in the Limpopo Province, South Africa 
3.1 Introduction 
This study was undertaken as formative work for this thesis. It aimed to identify the 
factors that, in the opinion of end-users (nursing staff) and other health care providers 
(key informants), affect the usage and performance of malaria rapid diagnostic test kits 
(MRDTs) at primary health care level. 
3.2 Methods 
This was a cross-sectional study,semi-structured interviews were conducted to obtain 
the perspectives of end-users and key informants. Responses were documented 
through notes taken during interviews. (69) Perspectives on purchasing, storage, 
transport, usage (including training, ease of use and confidence with results) and 
quality control in Limpopo were obtained. 
3.2.1 Sample 
The sample comprised a total of 20 end-users and 10 key informants. End-users 
comprised 17 clinic and three hospital nursing staff. The key informants included three 
hospital pharmacists, one regional pharmacy manager, one provincial malaria control 
programme manager, three district malaria managers and two researchers. The three 
district managers and the three hospital pharmacists were purposely selected from 
districts that had the highest number of malaria cases (Bohlabela, Mopani and Vhembe 
for the years 2002-2005). One district malaria manager was interviewed from each 
high risk district that had the highest incidence of malaria. The two researchers 
selected were purposefully selected from the national research laboratory- providing 
quality control support on MRDTs to the provincial malaria control programmes of 
South Africa. 
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A two stage sampling procedure was used to select PHC clinic staff.(70) All clinics and 
health centers within the three malaria-affected districts were listed. Clinics and health 
centers with fewer than 10 malaria cases per annum were excluded from the sampling 
frame. In the first stage of sampling, 10% of the clinics (10/100) and 20% of health 
centers (7/35) within each selected district were randomly selected (see Appendix 1). 
In the second stage of sampling one nursing sister was randomly selected from each 
selected health facility. Five referral hospitals were purposefully selected, one from 
each of the major municipalities that housed the selected clinics. 
3.2.2 Data collection and analysis 
The end-users and key informants were interviewed using a semi-structured interview 
schedule, with a separate interview schedule for each group (see Appendix 2). The 
interview schedule was developed after reviewing key WHO literature (9, 66) and other 
relevant published literature on MRDT end-user proficiency.(62, 63) Consultation with 
international experts, laboratory and malaria managers from the provincial and national 
levels also guided the development of the interview schedule. 
The end-user interview schedule was piloted on three nurses from non participating 
health facilities, prior to using them for data collection. Similarly the key informant 
interview schedule was piloted with two district malaria managers that were not 
selected for the study. 
The student conducted and transcribed all interviews and then ordered and coded the 
results in matricies, using the key categories of procurement & stock monitoring, 
storage, transport, quality control and end-user experiences with using MRDTs 
(including training, ease of use and confidence in results).(71) Nurses were asked to 
rate (as a percentage) their level of confidence with the MRDT results. Their 
responses were divided into three groups; low confidence was less than 50%; 
medium confidence was 50-80% and high level of confidence was greater than 80%. 
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3.3 Bias 
Information bias may have occurred during the interviews as participants may not have 
trusted the student (interviewer), as participants knew that the interviewer worked at 
the Ministry of Health, and some may have felt that the interviewer (student) required 
information for the media or for the National Department of Health.(72) The interviewer 
attempted to overcome the information bias by adequately introducing the purpose of 
the study, allowing the respondents to ask questions and assuring the respondents of 
the confidentiality of their information.(69) All the interviews were conducted by the 
student (OM) and therefore there is no inter-observer bias. Intra-observer bias was 
minimized by asking all questions in exactly the same order and by using the same 
phrases and questions for each interview (see Appendix 2 for interview schedules).(73) 
Ethics 
No personal identifiers were attached to any of the materials used for semi-
structured interviews. Confidentiality was maintained at all times, whereby all data 
materials were locked in steel cabinets and the student had access to this 
information only. The University of Limpopo Research Ethics Committee (project 
number 32/2006) and the Limpopo Department of Health and Welfare (ref 4/2/2) and 
the London School of Hygiene and Tropical Medicine (reference 3058) granted 
approval for this component of the study. Informed consent was acquired from all 
participants using participant information sheets and consent forms (see Appendix 
3). 
3.4 Results 
Nurses informed the student that in a routine set-up, MRDTs are used as a routine 
diagnostic tool for malaria, and all treatment was based on MRDT result. As per the 
malaria diagnosis protocol in the Limpopo province a thin and thick blood film were 
subsequently made on every MRDT positive patient for malaria and sent to the 
malaria control progamme for confirmation of diagnosis. 
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3.4.1 Procurement and stock monitoring 
Nursing staff reported that they were monitoring and ordering their stocks and 
checking the expiry dates regularly. The process predominately involved ordering 
either from the hospitals, in the case of Vhembe and Mopani districts or ordering 
from the amalgamate pharmacy stores at the provincial depot in Polokwane, for the 
Botshabelo district. Only 20% of the health facility nursing staff were aware of the 
seasonal increase in malaria cases and these stated that they ordered more MRDT 
stock before and during the season (September to May). Stock monitoring ranged 
from stock cards (paper based) to electronic systems. Pharmacy staff reported that 
pharmacy assistants were sent to some clinics and health centres to assist with 
ordering of pharmaceuticals, including MRDTs. Some hospitals e.g. Phalaborwa 
Hospital in Bohlabela district had a barcode system for ordering pharmaceutical 
supplies and it was working very efficiently. 
In spite of all the systems in place, 55% of the nursing staff indicated that their health 
facilities ran out of stock during the peak malaria transmission periods. Most of 
these nurses stated that during stock-outs there were plans in place to get additional 
stock in an emergency, from the next clinic or from the hospital, Malaria managers 
confirmed the clinic-level stock-outs in the 2005/2006 season (July to June). 
Managers indicated that they alerted the necessary authorities (district managers) to 
take action. Malaria managers transported the malaria kits to the clinics and health 
centers during the epidemic periods. However they stated unequivocally that it was 
the Primary Health Care Manager's responsibility, and not their responsibility to 
transport MRDTs; however they were willing to assist where possible. 
The regional pharmaceutical manager was not concerned about stock outs at the 
regional pharmacy level indicating that an electronic system was in place to increase 
supply as the demand for stock increased, and in most cases this was proportional 
to the seasonal increase in malaria cases. 
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3.4.2 Storage of MRDTs 
Sixty-five percent (13/20) of the end-users said that they stored MRDTs in an air-
conditioned room and regularly monitored temperatures, and seven (35%) had no 
access to an air-conditioned room. Of these seven, three (42%) did not have a 
thermometer for monitoring room air temperature and were very concerned about air 
temperature fluctuations in the storage room; whilst 4 of 7 reported that they 
monitored storage room temperature regularly and that this rarely went above 30°C. 
This was however not corroborated with any recorded data. 
The malaria management staff from the Vhembe district confirmed that some clinics 
did not keep the MRDTs in a cool environment; however they were not too 
concerned about this, stating that: "the kits did not stay in the clinics for too long due 
to their frequent use." 
The hospital pharmacists and regional pharmacy manager stored the MRDTs in an 
air-conditioned environment, at a room air-temperature ranging between 15-25°C. 
Monitoring charts were produced on request. 
3.4.3 Quality Control (accuracy of MRDT results) 
The majority of the nursing staff- 80%(16/20) - reported that they did not check the 
quality of MRDTs by comparing with any perceived Gold Standard, commenting that 
they "believed" the MRDT results. Four of the 20 nurses reportedly checked quality 
by looking at the agreement between their diagnosis based on signs and symptoms 
and the MRDT results. Two of these four indicated that they occasionally compared 
the MRDT results with those of blood smear results. 
Fifteen percent (3/20) of the nurses indicated that they occasionally gave 
antimalarial treatment to MRDT -negative patients on the basis of clinical signs and 
symptoms of malaria. Box 1 highlights the key challenges identified by nurses, 
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researchers and malaria managers relating to MRDT quality control including 
correlation with smears and clinical signs and symptoms. 
In summary, all managers were very concerned that MRDT quality was not being 
monitored at health facility level. One informant stated that, "MRDT quality control, 
both at the manufacturing side and at the testing stage, was lacking. The key [issue] 
is the end-user's ability to distinguish between positive and negative results". 
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Quality control from nurses' perspectives: selected quotes 
• "our results did not correlate with the patients' signs and symptoms" 
"our results did not correlate with the lab findings" 
"unsure of a negative results" 
• "we find it positive they (lab) find it negative" 
• "clinically suspected cases were negative on ROT but positive in the 
hospital" 
Quality control from the perspective of researchers and malaria 
control programme managers 
" ... accuracy of the test, we are not getting the required level of 
sensitivity; " 
"No commercial control is available;" 
"we are concerned about the stability of the quality control specimen;" 
" the key challenges are operator level efficiency, quality of the actual 
test, training instruction in the tests itself and performance of the test in 
the field" 
"finding the right specimens and sources of the specimens for quality 
control, poses a huge challenge" 
"it is difficult to try to tease out what the problem really is in doing the 
test, ensure that the variables are all the same when testing 
proficiency. " 
• "sometimes smears are done in parallel with the MROT and sometimes 
there is discrepancy." 
Box 1: Quality-related challenges: selected quotes by nurses, 
researchers and malaria control managers 
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3.4.4 End-user experiences with using MRDTs 
Forty percent (8 of 20) of the end-users (health workers) reported that they had 
received training in using MRDTs. However only two of eight trained users had 
received training from the malaria control programme, the remaining 6 users 
received regular in-house training from colleagues. 
Sixty percent (12/20) of the users said that they did not receive any outside training 
on MRDTs for malaria: however when probed, ten of the users (83%) said that they 
were aware of in-house training in MRDTs. 
The district and malaria managers reported that training did take place when MRDTs 
were first introduced; however subsequently limited training took place. This limited 
training was in high-risk clinics in response to requests from health facilities. 
Sixty five percent (13 of 20) of end-users said that they did not follow any provincial 
or district guidelines for using MRDTs. Most end-users including those who reported 
not using a provincial or district guideline reported using the package insert as a 
guideline for MRDT-use. 
One hundred percent of end-users indicated that they found the test very easy to 
use. When asked to rate the ease of use of the MRDT, 90% of nurses gave the 
ease of use five marks out of a total of five, whilst 10% gave the ease of use 4 marks 
out of a total of five. The 10% did not have any serious concerns but were reluctant 
to give full ratings. Thus in the view of the end-users (health workers) MRDTs were 
considered easy to use. 
End-users were confident with their ability to interpret results. Some of the concerns 
raised albeit rare, were that there was blurring of the test lines, or in one instance no 
lines appeared. The end-users reported that when a MRDT result was unclear they 
repeated the test and the results of the repeat test became clearer to interpret. 
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End-users were also asked to what extent they believed the MRDT results they 
obtained and responded as follows: 
Almost all (95%) of them said that they were confident with the MRDT results they 
obtained. 
Seventy percent of them (14) were more than 80% highly confident and the 
remaining 20% were 50-80% confident (the medium category confidence) with the 
results they obtained. There were no responses in the low category confidence 
levels. 
See Box 2 for some of the key concerns among respondents. 
• "Our rapid test results do not correlate with the patients signs and symptoms" 
• "Our rapid test results did not correlate with the lab findings" 
• .. We are confident with positive results but in 15% of the time we are unsure 
of negative results" 
• One respondent in the medium category (50%-80% confident) indicated that 
.. seventy percent of the time our results matched that of the hospital for 
positive cases and 30% of the time we find it positive they finding it negative" 
• One respondent from the medium category indicated that "I am 70% 
confident, as sometimes the clinically suspected cases were negative on 
MRDT but positive in the hospitaf' 
Box 2: Key concerns from nursing staff regarding confidence with 
MRDT results 
Although there was indeed a high level of reported confidence in the use of MRDTs 
and in their results, false positive and false negatives were key challenges 
experienced by the end-users. In some instances results were as much as 30% 
discrepant (laboratory findings did not agree with MRDT results). 
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All the participants fully agreed that the MRDT was easy to use, rapid and could be 
used in the primary health care setting with immediate benefit to the patients - see 
Box 3 for some of their key responses. 
"It is rapid easy to use and it can enable treatment and can prevent 
complication. " 
'Test is easy to use a nurse can make a diagnosis without involving the 
doctor and treat the patient". 
"The community is aware that such a test exists, they come to clinic and 
ask for a malaria test." 
"We can do the test at the clinic no need to go to the hospital. " 
"I can praise it because it can save someone's life. " 
Box 3: Nursing staff responses to positive aspects of using MRDTs 
The end-users reported the following negative aspects of the MRDTs 
• Accuracy of result was the key concern for 35% (7/20) of the respondents, 
false positive and negatives were major challenges. 
• Three participants were keen to get test kits that could detect malaria in less 
than 15 minutes. 
• Three participants mentioned that mixed infections were a challenge. 
• Two participants were concerned with the buffer being inadequate for the test. 
Malaria managers commented that reading and interpreting MRDTs were often 
problematic, stating that "the fault could have been due to the clinic staff not reading 
the test in time." One key informant (laboratory staff) felt that the end-users were not 
doing the test properly stating that "When we receive the test back we see that they 
are putting too much blood." 
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3.5 Discussion 
3.5.1 Procurement and stock monitoring 
It was apparent that ordering and monitoring of MRDT supplies at the clinics were 
efficient, however the occasional MRDT stock-outs, is a cause for concern. 
Planning for having adequate stock especially over the peak transmission period is 
vital to preventing stockouts. Liaison with the hospital pharmacies and the depots is 
therefore crucial to ensure a steady stream of stock replenishment. 
3.5.2 Storage 
The manufactures recommendations for storage of ICT MRDTs was below 3SoC 
(ICT diagnostic package insert) as the heat stability tests showed consistent positive 
bands at 3SoC for storage periods for up to 0 and day 9 at parasite concentrations of 
200, SOO and 1000 per IJI of blood.(9) According to the WHO and other studies, 
temperatures above 30°C are considered inappropriate for storing MRDTs.(66, 74, 
7S) In the study sample only 6S% (n=20) of the clinics had air conditioners and 8S% 
(n=20) were monitoring temperatures. 
In the summer months during high rainfall and peak malaria transmission there is an 
increase in demand for MRDTs at the clinics and the average temperatures in the 
Vhembe district ranges from 38-42oC (South African weather Services). Increases in 
temperatures above 30°C can affect overall performance of MRDTs and the efficacy 
of drugs (including the anti-malarial drug Artemether-Lumefantrine) which is stored 
in the same room as MRDTs. It therefore becomes important that room 
temperatures are maintained below 30°C and temperature monitoring is takes place 
regularly in the MRDT storage room of all clinics. Those rooms that exceed 
temperatures of 30°C should be cooled with air-conditioning or similar cooling 
equipment, this being dependent on financial resources available to local health 
authorities in the study districts.(9) 
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3.5.3 Quality 
There was huge uncertainty in the quality control and accuracy of MRDTs by end-
users, malaria management staff and research laboratory staff. Furthermore, the fact 
that the nursing staff sometimes "believed the results", in spite of the test kit not 
having a positive control and their results being discrepant with the laboratory 
findings, is cause for concern. 
Discrepancies between the laboratory and end-user findings that were a concern for 
4/20 participants and 3 key informants could point to two challenges: either the test 
kits were not working or the end-user was not using the kits correctly.(9, 19, 59, 67) 
The practice of treating patients, who had a negative malaria rapid test, as reported 
by 15% of the partiCipants, raises the possibility of lower sensitivity of the existing 
MRDT (false negatives among MRDTs). This may be either as a result of faulty 
MRDT or incorrect use of the test by the end-users, these hypotheses require 
investigating. 
Due to uncertainty around the quality of the test and lack of confidence in some 
instances of interpreting the results, respondents reported referring patients to the 
next level of the health care system as per the current malaria treatment and 
prophylaxis guidelines.(8, 76) This may cause overload at the next level and may be 
detrimental to the patients if they were not correctly treated prior to, or at referral. 
Detrimental effects could lead to rapid disease progression and even mortality, due 
to either long waiting times (peripheral hospitals in the Vhembe district is often 
understaffed and see large numbers of patients - personal communication with the 
Vhembe District Health Manager) or failure of the patient to go to the next referral 
level (hospital).(9, 59, 67) 
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3.5.4 End-user experiences 
External training was not being conducted for the end-user and in-house training 
was not based on a standardised curriculum using standardised materials and 
methods. There is also uncertainty on the quality of existing in-house training for 
MRDTs. A standardised training guide for in-house training may need to be 
considered.(9, 59, 63) 
Although package inserts are useful it would be easier for end-users to have posters 
or job aids so that the test procedure and can be easily visible and interpretation of 
results easily read especially during busy periods and late in the night. (9, 59, 67) 
The uncertainly about the skills of end-users to use MRDTs from both the malaria 
managers and the laboratory staff is indeed a cause for concern. Proficiency testing 
should be considered, to scientifically evaluate the skills of end-users. 
3.6 Conclusions 
It is clear that the value of the MRDT for diagnosis of malaria at the primary health 
care level was understood by all the categories of respondents: end-users, malaria 
managers, pharmacy managers and laboratory staff. 
In this exploratory study the procurement management and distribution of MRDT 
tests was found to be efficient. The storage of malaria rapid test kits was not entirely 
satisfactory: temperature monitoring will need to be conducted to bring this 
component to more acceptable standards. 
The key challenges for malaria MRDT in the Limpopo are the accuracy of the kit, the 
proficiency of end-user and quality control to ensure that the kits are working post-
field exposure. 
See Appendix 22 for scientific publication of this chapter. 
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4.0 Chapter 4: Accuracy of malaria rapid diagnostic tests in South Africa 
4.1 Introduction 
The current malaria treatment policy in South Africa, stipulates that treatment for 
malaria, should be administered to patients, subsequent to definitive diagnosis. (8) 
High levels of sensitivity (>95%) and specificity (>90%) of MRDTs are key to 
ensuring accurate malaria diagnosis. The reported sensitivity and specificity of 
MRDTs, from other settings varied substantially.(29, 31, 37-40,45,47, 77, 78) Thus 
a field evaluation to determine the accuracy of the MRDT currently used in South 
Africa is needed to inform policy on the diagnosis of malaria. Such an evaluation will 
set precedence for, and guide future tender evaluations of MRDTs by the National 
Ministry of Health - a process that occurs every 2 years and has until now occurred 
without field evaluations of the MRDTs on tender. 
This chapter provides a detailed report on assessing the accuracy of the MRDT 
currently used in South Africa (ICT Pf- Global Diagnostics) and on the treatment 
outcomes of cohorts of MRDT-positive and negative patients. 
4.2 Study Objectives 
4.2.1 The primary study objective was to: 
• determine the field accuracy of MRDTs (ICT Pf Global diagnostics) used in 
South Africa. 
4.2.2 The secondary objectives were to: 
• determine the accuracy of MRDTs in a low density malaria setting; 
• describe the clinical outcomes of Malaria RDT - positive and negative patients 
and 
• determine clinical predictors of malaria in this study population. 
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4.3 Study Methods 
4.3.1 Study design and sites 
This study had two components. The first component was a cross-sectional study of 
patients, presenting to selected health facilities, with suspected malaria to determine 
MRDT accuracy. The second component was a prospective observational cohort 
study to determine the clinical outcomes among MRDT-positive and MRDT-negative 
patients (sick with malaria, hospitalized or dead). MRDT positive and MRDT 
negative patients were followed up at the health facility or located at their homes on 
day seven post MRDT testing. 
The Vhembe district was chosen because it had the highest incidence of malaria for 
the past nine years (see Figure 3) prior to the start of this study.(1 0) Two clinics from 
the Vhembe district: Madimbo and Mulala were selected (see Appendix 4), based on 
the highest and second highest mean number of malaria cases over the 3 years 
prior to the commencement of this study, this was determined using national malaria 
notification data. 
4.3.2 Study population including, inclusion and exclusion criteria 
For the cross-sectional component of this study, the study population comprised 
consecutively-selected, male and female cases of suspected malaria (fever or 
headache or chills) - in keeping with the national malaria treatment guidelines for 
South Africa - attending the study clinics for an initial visit and who consented to 
participating in the study. Patients attending the study clinics for a follow up visit, 
severely ill patients needing referral, patients with an obvious cause of fever, and 
pregnant women were excluded from the study. 
For the second component of this study, all MRDT positive patients and 10% of the 
MRDT negative patients detected during the cross-sectional component described 
above were followed up on day seven post malaria rapid testing and treatment, to 
determine their clinical outcomes. 
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4.3.3 Sample Size 
It was assumed that the sensitivity of the MRDT should be 95%, the level 
recommended by WHO to be useful. To estimate 95% sensitivity with 95% 
confidence limit of +/- 3%; 203 cases of suspected malaria per clinic. - giving a total 
sample size of approximately 405 for two clinics - see Appendix 4.(79) 
4.3.4 Data Collection 
The author (OM) developed standard operating procedures (SOPs) and data 
collection tools to ensure collection of good quality data (see Appendicies 5-8). 
Each patient was given a unique identification number (ID) and this was used to 
label the data collection forms. the MRDTs and the thin and thick blood smears (see 
Appendix 5). At enrolment demographic information, clinical symptoms and signs 
and the results of the MRDT were recorded on standard recording forms: one form 
for the initial visit and a second form for the patient follow-up visit (Appendix 8). 
Nurses performed an MRDT on each patient who met the inclusion criteria after 
obtaining a written informed consent (Appendix 9). Nurses also made thin and thick 
blood films after performing an MRDT. Blood films were sent to two specialized 
trained malaria microscopists at the Limpopo Department of Health (Thulamela 
health center at the Vhembe District) for staining and microscopy.(34, 80) 
Patients were given recall cards that were also developed in the local language 
(Tshivenda) to remind them about the date on which they needed to return to the 
clinic for a follow-up visit (see Appendix 7). 
Blood films were stained with giemsa using the standard WHO protocol Two 
hundred thick film oil immersion high-power fields were examined before a slide was 
interpreted as microscopy negative for malaria. Parasite densities were calculated 
by counting the number of asexual parasites and multiplying this figure by the 
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standard white blood cells count (80001 ~I of blood) and the resulting value was then 
divided by the total white blood cells counted during the microscopic examination. 
Two field microscopists who were blinded to the MRDT results read the thin and 
thick blood films independently. When there was discordance between microscopists 
and MRDT results, a third highly skilled microscopist (based at a reference centre) 
blinded to the MRDT and the field microscopists readings, read the discordant 
slides. Discordance was settled by the microscopy results obtained by the highly 
skilled microscopist from the reference laboratory.(34, 70) To determine the 
agreement of slide results between microscopists (field and reference centre), 
Cohen's Kappa statistic was used to determine microscopy reader reliability, a score 
of ~ 0.8 was considered reliable.(9, 81) 
4.3.5 Data management and analysis 
The primary outcomes to assess the accuracy of MRDTs were sensitivity, specificity, 
positive and negative predictive values, The results of the ICT Pf (P falciparum) was 
compared against blood microcopy, the latter being considered as the gold standard. 
(9) 
The key variables used to measure MRDT positive and negative outcomes were: 
days to recover and unresolved malaria (including symptoms of fever chills, 
sweating, headache, nausea or vomiting). 
Data were managed using EPI data version 3.1 and analysed using STATA 8.1. 
4.3.6 Analysis strategy 
Mean and standard deviations, or median and inter-quartile ranges were used to 
describe continuous variables. The following continuous variables were transformed 
into categorical variable by grouping: 
• parasitaemia S 500/~1, 501-50001 ~I or> 50001 ~I: 
• age S24 or >24 and 
• temperature s37.50C or >37.50C. 
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To determine ICT Pf MRDT sensitivity and specificity by level of parasitaemia, the 
parasitaemic readings were stratified into three categories (S 500, 501-5000, >5000). 
Results of the stratified sensitivity and specificity were compared with the WHO 
acceptable levels of accuracy. 
To determine clinical predictors of malaria, uni-variate analysis, followed by 
modeling (Iogistical regression) was performed. 
For uni-variate analysis, each explanatory variable was separately cross-tabulated 
with the outcome (positive microcopy result). Significance was judged using the 
Pearson's chi squared (X2) measure of association. Mantel-Haenszel (MH) odds 
ratios (OR) and 95% confidence intervals were used to determine the magnitude of 
association for single variable and bi-variable analysis. Logistic regression was 
performed to determine the main predictors of malaria. All variables of clinical 
importance or those that were significant on uni-variate analysis or thought to be a 
predictor of malaria were included in the logistic regression model. A forward fitting 
analysis model was used, fitting one explanatory variable at a time to determine the 
main predictors of malaria in this population. Variables were judged for Significant 
association (p<0.05) with the exposure, by using the Likelihood Ratio Test. 
4.3.7 Ethics 
Ethical approval was obtained from the London School of Hygiene and Tropical 
Medicine, (reference: 5061, 22 November 2006), Limpopo Health and Social 
Welfare Research Committee (reference: 4/2/2) and the University of Limpopo 
Research Ethics and Publications Committee (MR 123/2006). Nursing sisters at the 
health centres and clinics were informed of the study after ethical approval and 
approval by the Head of Health in the Limpopo Province. 
Informed consent was obtained from each participating patient (written or thumb-
prints where patients were unable to sign). Anti-malarial treatment was provided to 
all patients with a positive MRDT. See Appendix 9, 10 and 11 respectively for patient 
information sheet and informed consent. 
68 
Patient information was kept confidential, locked in a cabinet and was accessible 
only to the principal investigator (DM). 
4.3.8 Potential bias 
Observer bias could have been a possibility in this study when the Microscopists 
read slides. MRDT end-users (nurses) and Microscopists were blinded to results of 
each method. Microscopists examined slides at sites that were different to the sites 
where the MRDTs were conducted.(79) 
4.4 Results 
4.4.1 Description of the study population 
A total of 405 participants were enrolled in this study, from 01 December 2006 until 
30 June 2007. Table 3 describes selected characteristics of the study population. 
The median age of study participants was 24.5 years old, ranging from 1 to 81 years 
old, (n=396). More male participants (-56%) were recruited into the study compared 
to females. Approximately 47% (N=402) of participants presented with fever - the 
median temperature of the participants was 37.5 DC (n=402); 29% (n=394) of the 
participants presented with chills, whilst 84% (n=399) of the participants presented 
with headache. The differences in sample sizes for each variable were due to 
missing values. 
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Characteristic N n (%) 
Range 1-81 yrs (9*) 
Age 396 
Median 24.5 yrs 
Sex Male 225(56) 
399 
Female 174(44) 
Temperature Range 35-40uC 
402 
Median 37.5°C (3*) 
Presence of Fever 402 189 (47.01) 
Presence of Chills 394 114 (29) 
Presence of Sweating 394 112 (28) 
Presence of Headache 399 337 (84) 
.. Footnote: The totals for Individual variables <405 was due to missing values; * = IOR 
Table 3: Distribution of selected characteristics in the participants 
4.4.2 MRDT findings 
Of the 405 patients tested, 198 (49%) were positive by leT Pf and 191 (47.16%) 
were positive by microscopy, see Table 4. The kappa statistic comparing the two 
microscopists results were 0.95%; p<0.001 , indicating good reliability. There was 19 
discordant microscopy results between the first and second microscopy readers, 
these were settled when a very experienced 3rd microscopist at the reference 
laboratory read the slides. 
Type of test Malaria Positive N (%) Malaria Negative Total 
leT Results 198 (49.0%) 207 (51.1) 405 
Microscopy 191 (47.16) 214 (52.84) 405 
Results 
Table 4: MRDT and mlcroscopy results in the study population 
Among the 191 patients positive for Pf on malaria microscopy, 190 were positive for 
leT Pf test (P<0.001), this represented 1 false negative result by the leT Pf test, 
(Table 5). Among the 214 patients negative for slide microscopy, 206 were negative 
by leT Pf test and this represented 8 false positive results by leT Pf test. 
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Results of Microscopy 
ICT P. fa/ciparum P. fa/ciparum totals 
Rositive negative 
P. fa/ciparum 190 8 198 
positive 
P. fa/ciparum 1 206 207 
negative 
Total 191 214 405 
Table 5: Microscopy versus ICT results 
4.4.3 Sensitivity and Specificity of ICT Pt Test 
The overall sensitivity of the ICT Pf malaria test was 99.48%; P<0.001 (99% Cl 
96.17-100%; p<0.001), whilst the specificity was 96.26% (99% Cl 94.7-100%; 
P<0.001) , the positive predictive value of the test was 98.48 (99% Cl 98.41-
100.00%; p<0.001) and the negative predictive value for the test was 96.26% (99% 
Cl 91.53-98.79; P<0.001) . The J index for the test was 0.98; P<0.001 and the LRT 
test was 24.75-postive and 0.01-negative. 
Sensitivity and specificity was calculated for three categories of parasitaemia (500, 
501-5000; >5000 parasites/ I-JI of blood), in an attempt to determine the threshold for 
ICT detection. The sample size was too small for this analysis because parasite 
counts were only determined for 61 slides as thick films were not always correctly 
prepared by nursing staff, in spite of 2 follow-up visits conducted by the 
microscopists and the Principle Investigator (student) . Furthermore there was only 
one false negative ICT Pf result and therefore there were no substantial 
observations in this analysis. The median paraSitaemia calculated among the 61 
slides were 25 680 parasites per I-JI of blood, ranging from 440 to >20 000 parasites 
per I-JI of blood. The sensitivity was 100% for all categories, see Table 6. 
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Parasitaemia Microscopy No Sensitivity Specificity PPV 
(parasites/1J1 No. of positive 95% Cl (95% Cl) (95% Cl) 
of blood) specimens 
0-500 2 2 100.00% - 100.00% 
(7.07- (7.07-
100.00%) 100.00%) 
501-5000 15 15 100.00% - 100.00% 
(0.50- (0.50 
100.00) 100.00) 
>5001 44 44 100.00% - 100.00% 
(88.66- (88.66-
100.00) 100.00) 
Table 6: Sensitivity and specificity of MRDT by levels of parasitaemia. 
4.4.4 Clinical predictors of malaria 
It was interesting to note that study participants positive for malaria were mainly 
older that 16 years of age (Table 7) , however this finding was not statistically 
significant (p=0.2) . In this study population there was a significant association 
between gender and malaria. The proportion of male participants having malaria 
was higher than female patients (56.0% vs 36.8.0%; p<0.001). The odds of malaria 
were approximately 2 times (95% Cl 1.44 - 3.30, P < 0.001) more likely among the 
males compared to the females (Table 7) . 
A higher proportion of participants reporting a history of fever had malaria than those 
not having a history of fever (68.8% vs 27.7%; p<0.001). The odds of participants 
having malaria (microscopy slide positive Pf) was 5.6 times higher 
95% Cl 3.6 - 9.2, p<0.001) in those having a history of fever than those who did not 
have a history of fever (Table 7) . 
Participants having a temperature of >37.5 DC were more likely to have a slide 
positive malaria than those had a fever s 37.5DC. In fact the odds of malaria (slide 
positive Pf) in patients with a temperature> 37.5DC was 4 times higher (95% Cl 2.5-
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6.3; P <0.001) than in those who had temperatures ~ 37.SoC than those whom had 
temperatures of less than s 37.50C (Table 7). 
Participants reporting chills, sweating or headache had a higher likelihood of malaria 
than those that did not report these symptoms (Table 7): The odds of malaria (slide 
positive Pt) in patients with chills were 4.7 times (95% Cl 2.8-7.9; P <0.001) higher 
than in patients who did not have chills. The odds of malaria in patients with 
sweating were 8.9 times (95% Cl 4.9 -16.3; P <0.001) higher than the odds in 
patients who did not have sweating. The odds of malaria in patients who had 
headache were 5.1 times (9S% Cl 2.4 - 10.3; P <0.001), higher than those patients 
without headache. 
4.4.5 Modeling 
Bivariate and multivariate analysis was used to determine the symptoms that best 
predicted malaria in the study population, whilst controlling for other variables. 
Sweating was considered to be a key predictor because it had the highest 
magnitude of association (OR) in uni-variate analysis and is one of the self-reported 
symptoms of malaria. The remaining predictors were fitted in the model in the 
following order: fever, headache, chills, temperature, sex and age. All the variables 
were serially fitted into the model. Age and chills were retained, despite it not being 
statistically significant as they were a priori predictors of malaria (as stipulated in the 
South African Malaria Treatment Guidelines).(8) 
It was postulated that there was an interaction between sweating and fever Le. that 
the relationship between sweating and malaria varies depending on the presence or 
absence of fever. Furthermore, that in the presence of fever sweating was more 
strongly associated with malaria (higher OR). In the absence of fever, sweating was 
due to another cause and was not associated with malaria. An interaction variable 
(sweating*fever) was added to the model in view of the above hypothesis, but this 
was found not to be statistically significant, and did not significantly change any of 
the ORs. Similarly there was no interaction between fever and headache, i.e. the 
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relationship between headache and malaria did not vary depending on the presence 
or absence of fever. 
After fitting a" the variables into the model sweating was considered to be the 
strongest predictor of malaria in the study population (OR 5.0; p<0.001; 95% Cl 2.4-
10.2). See Table 8 for the details of the regression analysis findings. 
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Predictors of malaria Microscopy Microscopy Odds Ratio Adjusted Odds Ratio· 
positive for negative for 95% (Cl) (95% Cl) 
malaria malaria (Final model) 
<5 years 10(34.5) 19 (65.2) 1.0 1.0 
Age 6-15 years 37 (58.7) 26(41 .3) 
16-49 years 131 (47.1) 147 (52.9) 
~ 50 years 11 (42.0) 15 (58.0) 1.8 (0.8-4.0) 1.0 (0.4-.3.1) 
Sex Female 64 (36.8) 110(63.2) 1.0 1.0 Male 126 (56) 99 (44.0) 2.2 (1.4-3.3) 2.4 (1.4-4.1) 
Fever No 59 (27.7) 154 (72.3) 1.0 1.0 
Yes 130 (68.8) 59 (31.2) 5.6 (3.6-9.2) 2.9 (1 .5-5.5) 
<37.5uC 62 (31 .2) 137 (68.8) 1.0 1.0 
Temperature ~37.5-39uC 105(61.7) 65 J38.3) 
>390C 19 (86.4) 3 (13.6) 4.0 (2.5-6.3) 2.1 (1.1-3.7) 
No 100(31 .0) 179 (69) 1.0 1.0 
Chills Yes 
82 (72 .8) 31 (27.2) 4.7 (2.8-7.9) 1.2 (0 .6-2.4) 
No 93 (32.6) 190 (67.4) 1.0 1.0 
Sweating Yes 91 (81.2) 21 (18.8) 8.9 (4.9-16.3) 5.0 (2.4-10.2) 
Headache No 11 (17.7) 51 (82.3) 1.0 1.0 Yes 176 (52.3) 161 (45.7) 5.1 (2.4-1 0.3) 4.0 (1 .6-9.7) 
Footnote: · Odds ratio of relationsh ip between sweating and malaria adjusted for age, sex, fever, temperature, Chi lls, and headache 
Table 7: Crude and adjusted odds ratio for all predictors for malaria 
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OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) 
Sweating 8.94 5.3 4.5 4.2 5.2 4.8 5.0 
Yes vs no (4.92-16.2) (3.0-9.48) (2.47- 8.2) (2.2-8.2) (2.8-9.9) (2.3-9.8) (2.4-10.2) 
p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
Fever 3.4 3.7 3.4 2.7 2.9 2.9 
Yes vs no (2.1-5.5) 2.2-6.0 (2.0-5.8) (1 .5-4.8) (1 .5-5.2) (1 .5-5.5) 
p<0.001 p<0.001 P <0.001 p<0.001 p<0.001 p<0.001 
Headache 3.4 3.4 3.7 4.1 4.0 
Yes vs no (1 .6-7.1) (1 .6-7.1 ) (1.7-8.08) (1 .8-9.5) (1 .6-9.7) 
p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
Chills 1.2 1.1 1.2 1.2 
Yes vs no (0.67-2.4) (0.5-2.2) (0.6-2.4) (0.6-2.4) 
p=0.45 p=0.7 p=.06 p=0.6 
Temperature 1.9 2.0 2.1 
~37 . 5OC vs (1 .1-3.3) (1.2-3.7) (1 .1-3.7) 
<37.SoC p=0.02 p=0.01 p<0.001 
Sex 2.5 2.4 
Male vs (1 .5-4.2) (1.4-4.1 ) 
female p<0.001 p<0.001 
Age 1.0 
~6 years vs (0.4-.3.1 ) 
<5 p=.O.06 
Table 8: Multivariate analysis for key predictors of malaria 
76 
4.4.6 Sensitivity and specificity for predicting malaria 
The overall sensitivity, specificity and positive predictive values of individual 
symptoms for predicting P. falciparum malaria (using microscopy) are summarized in 
Table 9. Sweating had the highest sensitivity followed by chills, then fever (using 
temperatures >37.5° C) and then headache. 
77 
Presenting Malaria Not % Sensitivity % Specificity % PPV % NPV 
symptoms case malaria 
(99%CI; Lower- (99%CI; Lower- (990/0CI; Lower- (99%CI; Lower-
N(%) N(%) Upper) Upper) Upper) Upper) 
Sweating 91 (47.6) 21 (9.0) 81 .2 67.30 49.7 90.0 
N=394 (70.0-89.7) (59.7 - 74.7) (40.0-59.4) (83.5-94.6) 
Chills 82 (43.0) 100(47.0) 72.8 63.9 45.1 85.9 
N=394 (60.8-82.8) (56.1 - 71.2) (36.6-54.8) (77.9-90.9) 
Headache 176 (92.1) 62 (29.0) 52.2 82.3 94.1 24.0 
N= 399 (45.1-59.3) (66.7 - 92.7) (88.2-97.6) (16.9-32.4) 
Temperature 124(64.0) 68(31 .0) 64.6 68.8 66.7 66.8 
>3SoC vs (55.1-73.3) (59.7 - 77.01) (57.1-75.3) (57.8-75.0) 
35-37 
N=391 
Table 9: Sensitivity and specificity of reported symptoms for diagnosing malaria (positive using slide 
microscopy) among patients attending health facilities of Mulala and Madimbo clinics of the Vhembe 
districts 
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4.4.7 Patient follow-up 
Approximately 17% (68/405) of all the patients returned to the clinics for follow-up. 
All 41 patients who were leT negative on initial visit remained leT negative and 
microscopy negative on their return visit. Twenty three of the 27 patients who were 
leT positive on the initial visit remained leT positive on their return visit, however all 
27 were microscopy negative, see Figure 8. All the patients who returned and were 
positive for leT (n=23), recovered, none were sick and none had been hospitalized. 
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Yes 
n=27 
MROT 
positive; 
n=23 
Mic pos 
n=O 
Eligible patients meeting inclusion criteria ; n= 405 
No of patient having ROT test; n= 405 
Patients Returned 
Mic neg 
n=23 
MROT 
negative; 
n=4 
No 
n=171 
Mic pos 
n=O 
Patients Returned 
Yes 
n=41 
MROT 
positive 
n=O 
Mic neg 
n=4 
No 
n= 166 
MROT 
negative 
n=41 
Mic pos 
n=O 
7 day 
Follow-up 
post 
treatment 
Mic neg 
n=41 
Footnote: Mic pos= Microscopy positive; Mic negative= Microscopy: negative 
Fig 8: Patient follow-up with leT and ROT results 
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4.4.8 Comparison of demographical and clinical characteristics on the return 
day between MRDT-positive and MRDT-negative cohorts 
More MRDT positive patients reported a history of fever, chills , sweating and 
headache than those that were MRDT negative at the day of follow-up. However 
none of the MRDT positive patients were positive for malaria on slide microscopy, 
see Table 10. 
Characteristics MRDT positive MRDT negative P 
at day 7 n=23 day 7 n=41 value 
Median age in yrs 28 24 0.5 
Gender: Male 15 (62.5) 22 (53.6) 
Female 9 (37.5) 19 (46.3) 0.5 
Temperature ~37.5 4 (16.7) 27 (65.9) 
<37.5 20 (83.3) 14(34.1) 
History of Fever Yes 13 (56.5) 10 (23.2) 0.007 
No 10 (43.5) 33 (76.7) 
History of Chills Yes 9 (39.1) 6 (14.6) 0.02 
No 14(60.9) 35 (85.4) 
History of sweating Yes 8 (36.4) 3 (7.0) 0.003 
No 14 (63.6) 38 (93.0) 
History of headache Yes 23 (100) 28 (68.3) 0.003* 
No 0 13 (31 .7) 
Blood Slide positive for malaria 0 0 
Negative for malaria 23 41 
Footnote: *Flsher's exact test 
Table 10: Comparison of demographic and clinical characteristics on day of 
follow-up between MRDT -positive MRDT negative patients 
4.5 Discussion 
4.5.1 Demographic and clinical characteristics 
The study population (with suspected malaria) had more males (225) than females 
(174) . This could be attributed to that fact that the study was conducted in a 
population that includes migrant Labourers from surrounding malaria-endemic 
countries doing manual work on farms in the Limpopo province; hence more males 
take on these types of jobs. The prevalence of malaria was also highest amongst 
males than females . This is probably because the manual labour performed by most 
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males would expose them to mosquitoes especially at dawn and dusk periods 
where the mosquito vector are most active.(76) 
The national treatment guidelines for malaria in South Africa stipulate that clinical 
judgment should be applied in the absence of malaria diagnostic tests.(8) The WHO 
stipulates that when there is a high clinical index of suspicion but a negative malaria 
diagnostic test, treatment for malaria should be administered whilst confirmatory 
diagnosis is being pursued.(9) Predictors for malaria therefore become very 
important if clinical judgments are to be made. 
The IMCI guideline for management of childhood illness in South Africa (used for 
clinical diagnosis of malaria in children age five years and below - before diagnosis 
with ROTs) stipulates that fever (temperature ~ 37.SoC) is the main predictor for 
malaria.(82) Temperature ~ 37.SoC was not the main predictor of malaria in this 
study population. Sweating and headache were much stronger predictors of malaria 
than elevated temperature in this study population. Although the sample is not 
representative of the facilities of the Vhembe district, data from this study suggest 
that symptoms such as sweating, headache and chills should be considered for 
clinical judgement of malaria. 
All the signs and symptoms (tiredness, myalgia, abdominal pain, diarrhoea, loss of 
appetite, nausea, vomiting and cough) of malaria were not recorded in this study, 
hence a comprehensive judgement of them was not possible for the analysis. (8) A 
study should therefore be conducted to determine which of the clinical signs and 
symptoms of malaria would be key predictors of malaria in the South African setting 
and a clinical algorithm should then be generated to guide health care workers on 
making clinical discussions.(8, 83, 84) 
A clinical algorithm should be considered in the South Africa setting when there is a 
high clinical index of suspicion of malaria and slide microscopy or MRDTs are 
unavailable or MRDT is negative, especially at health care facilities are far away 
from secondary care hospitals. 
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4.5.2 Agreement between microscopists 
There was reasonable agreement in the slide reading by the 2 microscopists 
(kappa=0.95). However an analysis of the 5% of the discordant microscopy results 
between the first and 2nd microscopist showed that 94% (n=19) of the first 
microscopists readings were false negatives and 6% false positive. Parasite counts 
were only conducted in approximately 52% (10/19) of the discordant results. 
Parasite counts could not be confirmed on nine slides as the slides were poorly 
stained or prepared. However those slides that did have parasites counts showed 
high level parasitaemias (range: 560 - > 20000 parasitesl 1-11 of blood) by the second 
and third readers, implying that these were missed by microscopist one. Some 
studies have found that the sensitivity of microscopy starts to decline with low level 
parasitaemias <100 parasites 1 1-11 of blood (67, 85, 86); however in the current study 
most of the malaria positive slides that were missed had >100 parasites per 1-11 of 
blood. This findings, begs the question of whether microscopy quality within the 
malaria affected areas of the Limpopo are adequate for diagnosis of malaria. An 
assessment of proficiency of microscopy within the malaria affected provinces 
should be considered by the health authorities, should there be a deficiency in the 
quality of microscopy then action would need to be taken to remedy this service. s 
4.5.3 Sensitivity leT Pf test 
The overall sensitivity of the ICT Pf in this study was high viz. 99.48, P<0.001 these 
findings are consistent with that of other ICT Pf studies.(37, 38) However it was not 
possible to assess the MRDT sensitivity at a parasite density of 100 parasites 1 1-11 of 
blood, in accordance with WHO criteria for judging the sensitivity of an RDT.(9, 23) 
This was due to the fact that malaria parasitaemia levels were assessed only on 61 
slides due to poor quality staining and poor slide preparation by nursing staff. Among 
the 61 slides assessed for parasitaemic levels all the slides had more than 100 
parasites per 1-11 of blood. The sensitivity was 100% from all categories of 
parasitaemias >100 1-11 of blood in the study. Whilst low level parasitaemias may 
have been picked up if all the slides had parasite counts, information from the 
malaria programme (personal communication malaria manager Limpopo province) 
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suggests that patients presenting to health facilities present late; thus few would 
have had low levels of parasitaemia. Assuming this was true, then low levels 
parasitaemic patients will be very few even if there was parasite counts in all 
participants. This would then make the current estimation of the parasite detection 
level to be reasonable. 
An alternative approach to determining parasite detection levels by the ICT Pf MRDT 
is to use laboratory dilution of wild type parasites, similar to that conducted by other 
authors.(56) The Medical Research Council of South Africa evaluated the ICT MRDT 
tested in this study in the laboratory, when this study was in progress, for parasite 
detection limit, using the protocol by Craig et al. (87) The results from the laboratory 
studies showed that the ICT Pf test gave 100% sensitivity at a parasite density of 70 
parasites per IJI of blood.(9) Although laboratory investigations is not ideal for 
determining MRDT parasite detection limit, the MRC's finding does however give 
some indication of ICT Pf sensitivity and specificity at low parasite densities.(9, 22, 
39). 
The overall results of the ICT test showed that there were one false negative result 
from the ICT test and 8 false positive results. These findings are discussed below: 
4.5.4 False negatives 
The false negative rate is defined as, the proportion of infected individuals being 
missed by the ICT Pf test and falsely ascribed a negative status. (9,22, 39) 
According to the published literature there could be a series of reasons for the false 
negative results, these include: 
• reduced level of parasites in circulating blood or reduced sensitivity of 
microscopy at low parasite levels, (40, 44, 88-90) 
• decreased antigenaemia post treatment of patients, (28, 44, 91-95) 
• probable poor end-user interpretation of weak positive results, (93) 
• weak levels of antigens at early stages of infection (36) and 
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• negative results in view of sexual stages of the parasites. (52) 
The only false negative case seen in this study was in a slide that had 1 920 
parasites per! j..Il of blood and the patient was not on treatment for malaria. Other 
studies have also reported similar findings where, false negative results did occur 
with high parasitaemias.(42, 96-98) Wongsrichanalai et al. from a study in Thailand, 
when comparing leT ROTs with microscopy, found that they had one false negative 
MROT result in a patient that had a parasitaemia of 18 000 parasites per j..Il of 
blood.(95) Similarly Forney et al. found in a multi-site field study in Peru and in 
Thailand noted that the parasite density ranged from 201- >5000 parasites!j..Il of 
blood among 9 patients who had false negative result when tested with parasite F 
test. (96) The median parasitaemia levels in these patients were 16 and 203 
parasites!j..Il of blood in the 2 respective studies. 
Whilst one cannot be certain of the reasons for the false negative results in this 
study by leT Pf, in the presence of a high level parasitaemia, some possible 
explanations could be: 
• that there was HRP 11 antigen variation in the blood sample from those 
designed to be captured by the monoclonal antibodies of the leT Pf testing 
system. (99) 
• that anti-HRPII-Pf antibody potentially blocked immuno-detection by the leT 
Pf testing system. (100, 101) 
• antigen accelerating HRPII-Pf clearance occurred.(95) 
Whilst MROT false negative results were rare in this study, health workers should 
remember that a negative result reduces the chances of, but does not absolutely 
rule out the likelihood of malaria. Furthermore false negative rates are likely to 
increase if the MROTs are stored for longer periods in field conditions. 
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4.5.5 False positive results 
The false positive rate was calculated as the proportion of individuals without 
infection being missed by the test and falsely ascribed a positive status.(9, 39) 
There were eight false positive leT Pf results in this study. Some of the reasons for 
the false positive results could be due to the following: 
• patients previously treated for malaria, could still having circulating antibodies 
which can persist for weeks after treatment as seen in other studies.(35, 40, 
42) It was unlikely in this study for patients presenting to clinics as first time 
visitors after receiving malaria treatment as it was standard practice for 
patients to be followed up by slide microcopy at the health centers. Secondly 
patients who had recent malaria or had recently been on malaria treatment 
were excluded from the study. 
• episodes of recent fever could also produce false-positive results due to high 
levels of circulating non specific heterophile antibodies.(102) 
• rheumatoid factor could cause false positive results with some RDTs. The 
effect of rheumatoid factor was not measured in this study, however 
according to the manufacturers package insert, rheumatoid factor has not 
been shown to give false positive results.(1 03) 
• RDT can yield false positive results in patients with P. falciparum malaria 
where the parasites are sequestered out of the patient's circulation, such as 
during pregnancy.(67) In this study it is unlikely that this occurred, as none of 
the patients whom were recruited in the study were recorded as being 
pregnant. According to the national malaria treatment guidelines in South 
Africa, all patients whom are pregnant with malaria should be referred to 
hospital, further obviating the reason for false positive results with leT Pf in 
this study.(8) 
A highly sensitive test such as the leT Pf test as seen in other studies and in this 
study will yield lower specificities, especially in patients with low parasitaemias. 
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(38, 67) Whilst microscopy can detect low level parasitaemias (10-50jJl) in 
specialized centres, microscopy of blood films in malaria endemic areas has 
been shown in other studies to miss cases with low density parasitaemias.(104) 
The quality of microscopy and the slides prepared in this study was not optimal, 
hence lower density parasitaemias could have been missed by slide microscopy 
questioning the gold standard and making this the most likely reason for false 
positive ICT Pf results in the study. 
4.5.6 Specificity 
Specificity is the ability of the test to detect individuals without infection as negative. 
(9, 39) The specificity of the test was 96.26%. The relatively lower specificity than 
sensitivity, in this study is similar to other studies.(37, 40, 48) Having a relatively 
lower specificity which leads to over-diagnosis and to over treatment of non malaria 
cases (19) is considered less serious than having a lower sensitivity.(38) The low 
specificity could possibility be explained by poor quality slides resulting in lowering of 
the sensitivity of microscopy, or very low parasite densities that were undetectable 
by microscopy.(9, 67) 
4.5.7 Positive predictive values 
Positive predictive value of the ICT Pf test is defined as: the proportion of the test's 
positive readings which are truly positive.(9, 39) The positive predictive value of the 
ICT Pf malaria test was 98.48%. The false positive rate of the test contributed to a 
lowering positive predictive value of the test. However a positive test in the study 
setting contributed to having reliably diagnosed malaria parasites with a low risk of 
error.(38) The Positive Predictive Values of a test correlates with prevalence of 
disease in the population being tested.(79) Compared with low transmission 
settings, in high transmission settings positive predictive values of the ICT pf test are 
usually lower (because of the higher prevalence and larger numbers of false 
positives, larger denominator and smaller numerator) (32, 33) In low transmission 
settings positive predictive value are usually high.(26, 28) In this study the incidence 
of malaria was low - 3.28 per 1000 population at risk - and the positive predictive 
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value of the ICT pf test was high, with good accuracy. Whilst every attempt should 
be made to undertake feld evaluations on MRDTs the findings of this thesis imply 
that other malarious provinces within SA and countries with similar malaria 
transmission as South Africa can adopt or consider adopting ICT pf as a diagnostic 
test for malaria. 
4.5.8 Negative predictive values (NPV) 
The negative predictive value of a test is the proportion of negative readings which 
are truly negative. In the study the negative predictive value was 96.26%, p<0.001. 
The risk of missing a negative case in the study setting is very small. This high 
negative predictive value allows health workers to confidentially exclude malaria if 
the ICT test was negative. These findings correlate well with low prevalence malaria 
transmission settings, making it an ideal test for implementation in similar 
settings.(26, 28) 
4.5.9 J Index 
The J index of the test is the overall measure of reliability of the diagnostic test which 
summarizes both sensitivity and specificity. The J index lies between 0 and 1 - when 
the J-index approaches 1, the overall diagnostic ability of the test approaches the 
ideallevel.(39, 105) The J index of the ICT Pf test was 0.98, making the test ideal for 
malaria diagnosis in this study setting. 
4.5.10 LRT test 
The positive likelihood ratio was 24.75, this is indicative that a positive rapid test 
result implies a high probability to having disease, due to the likelihood ratio being 
>10. Conversely the negative likelihood ratio of 0.01 implies that test excludes 
malaria when it is negative.(106) 
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4.5.11 Patient follow-up 
The main reasons hypothesized for the low turn out patients was that they were 
likely to be illegal immigrants possibly from Zimbabwe (close proximity to the clinics) 
and that that many could have been arrested and repatriated, others may have not 
returned home or were too scared to return to the clinic when they felt better 
(personal communication Provincial Malaria manager Limpopo). 
ICT positive results in returning patients that were positive for malaria is consistent 
with other studies where HRP 11 takes weeks to disappear.(9, 106, 107)s This finding 
is consistent in that ICT Pf test can only be used as a screening test and not a test to 
monitor treatment. The South African malaria treatment guideline for patient follow-
up is therefore justified in stating that patients should be followed up with slide 
microscopy after being diagnosed with ROTs. 
The favourable clinical outcomes for ICT positive patients are an indication of 
parasitological cure. However as the numbers for the returning of patients were 
small it would be difficult to determine the numbers of those patients whom were 
misdiagnosed (false negatives) and went on to developing malaria. 
It is not known how many patients who did not return for their follow-up visit had 
been hospitalised and how many had died. Attempts were made to trace patients in 
the local hospital, and to peruse death certificates at the local housing office, but 
none of the patients lost to follow-up were found. In view of this high loss to follow-
up, it is likely that the follow-up do not reflect the true outcomes amongst ICT-
positive and ICT -negative patients. Therefore follow-up data should be interpreted 
with caution and conclusions cannot be drawn from them. 
The more symptoms of malaria reported in the MRDT positive cohort versus the 
negative cohort on day of return could have been due to malaria patients recall bias. 
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4.6 Conclusions 
The study revealed that the leT Pf test is an appropriate test to use in the field, 
where laboratory facilities are not available. The test has a high degree of sensitivity 
and acceptable level of specificity against the WHO criteria. Sensitivities could 
however, not be established at low levels of parasitaemia, viz. <100 parasites/IJI of 
blood in field conditions. The low parasite detection limit (100% sensitivity at 70 
parasitesl IJI of blood by the leT Pf at the laboratory setting) suggests that leT Pf 
test is appropriate for use in South Africa. 
The leT Pf can be reliably used as screening test for diagnosis of P. fa/ciparum 
ma/aria, the test however, cannot be used for patient follow-up and for monitoring 
therapeutic responses due to the persistence of HRPII positive results post 
treatment. 
Sweating and headache were stronger predictors of malaria than a history of fever 
and these symptoms merits consideration for inclusion in the IMCI guidelines for 
management of febrile illness in children. 
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5.0 Chapter 5: MRDT end-user proficiency study 
5.1 Introduction 
One of the factors that can affect the outcome of the MRDT result is end-user 
proficiency i.e. the ability of the end-user to perform the MRDT and interpret the 
results.(9, 22, 59, 60, 62) As stated in chapter 2, MRDTs have been implemented 
for malaria diagnosis in South Africa since 2001; however the level to which end-
users were proficient in MRDT use has not been determined.(3, 7) 
This study was therefore conducted to assess the end-user proficiency in the 
Vhembe district in the Limpopo Province of South Africa. 
5.2 Objectives 
The key objectives of the study were to determine the end-user's ability to: 
(1) prepare the MRDTs; 
(2) perform the MRDTs and 
(3) interpret the MRDT results 
5.3 Methods 
This was a cross sectional observational study to determine whether health workers 
performed the MRDTs and interpreted the results correctly at one point in time. 
The study was conducted among professional nursing staff that were responsible for 
using MRDTs in clinics and health centers of the Vhembe District. Based on the 
average annual malaria cases reported from 2004 to 2006, all health facilities (clinics 
and health centres N=50) were classified into low transmission (10-19 malaria cases 
per year), medium transmission (20-50 cases per year) and high transmission (>50 
malaria cases per year). Fifty percent of clinics and health centres (n=25) were 
randomly selected from each group (11/22 from low; 5/10 from medium, and 9/18 
from high transmission health facilities). From each selected health facility one 
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MRDT end-user was selected using random numbers, (see Appendix 12 for clinics 
and health centres selected). Data on demographics and professional experience 
were collected from all selected end-users. The participants' ability to perform the 
MRDT test was assessed using a non-patient volunteer (known MRDT negative 
person). A checklist of observations, adapted from previously studies and 
information extracted from the manufacturers package insert was developed by the 
student.(9, 63} See Appendix 13, for the checklist on end-user ability to perform 
MRDTs on a non-patient volunteer. The checklist included the end-users' ability to 
prepare the volunteer for collecting blood sample using sterile techniques, and to 
perform the test according to the manufacturer's instructions. 
The end-users abilities to interpret the MRDT results were assessed using 
photographs of pre-prepared RDT results (see Appendix 14). In total there were ten 
photos - 4 strong positive, 4 weak positive, 1 negative and 1 ambiguous result (no 
control line with test line positive). All end users were shown the same photographs, 
and in total end-users should have interpreted 200 photographs as being positive 
(25 end-users interpreting 8 positive photographs), 25 as being negative and 25 as 
being invalid. Using the pre-prepared test results as the gold standard the sensitivity, 
specificity and the predictive values of the end-users' interpretation of the test results 
was calculated. 
The main outcome measures for the study analysis were performance score and 
interpretation score. Performance score measured the extent to which end-users 
performed all the 15 steps when doing a rapid test. A score of 1 was allocated if 
each of the 15 steps were correctly performed and a score of 0 was allocated if each 
step was not or incorrectly performed. The maximum performance score was 15. 
Thus the performance score of each end-user (out of 15) measured the extent to 
which they followed 15 essential steps when doing the MRDT. 
The interpretation score was developed by determining the extent to which end-
users correctly interpreted the photographs of the battery of ten pre-pared MRDT 
results. A score of 1 was allocated each time a test was correctly interpreted and a 
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score of 0 was allocated each time a test was incorrectly interpreted. Thus the 
maximum interpretation score was ten (for then correctly interpreted results). The 
interpretation score measured the extent to which the end-users correctly interpreted 
the results of photos of 10 prepared MRDTs. 
5.3.1 Data analysis strategy 
Data checking and editing to identify missing data and errors was performed by 
examining frequencies and cross tabulation for categorical variables. Range checks 
were used for continuous variables, to identify values falling outside the expected 
ranges. Histograms were also used to identify outliers that looked extreme relative to 
the rest of the data.(71, 81) 
During data analysis, frequencies of various participant characteristics viz: socio-
demographic; educational level; treatment experience; MRDT experience training 
with MRDTs; clinic; test type and performance scores were run. Variables were re-
categorised to dichotomize the data these include participant age; performance 
scores and interpretation scores. Means and standard deviations were used to 
describe normally distributed data whilst median and inter-quartile range was used 
for non-parametrically distributed data. 
The performance scores were dichotomized based on the median scores and uni-
variate analyses were conducted to determine the association between the 
performance score and the following variables: 
• the type of test used (leT or Makromed); 
• clinic cases (Iow, medium, high); 
• participant's age; 
• training on use of MRDT and 
• experience. 
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The median was used as a cut off instead of another critical score as it was believed 
that each step in the checklist used to observe end-users was of equal importance, 
non-performance of anyone step could have deleterious consequences; thus no 
step or combination of steps was more critical than others. Furthermore it was 
equally important to correctly interpret each test from the battery of pre-prepared 
tests, thus dichotomization based on the median yielded an adequate sample size in 
each category to conduct further analysis and to compare groups. 
Mantel-Haenzel odd ratios and Pearson's Chi-Square (X2) tests were used to 
determine the association between key categorical variables and a p value of <0.05 
was regarded as statistically significant. 
The validity of end-users interpretation of the 200 positive, 25 negative and 25 
ambiguous results were assessed by examining the sensitivity and specificity of their 
interpretation of MRDT results. The reliability of end-users was tested by 
determining the absolute agreement- interclass correlation coefficient for a two-way 
random model (as the end-users - participants- were randomly selected). It was 
thought that this analysis would be useful to compare the mean interpretation score 
for each participant (which ideally should be the same), and determine the extent to 
which they absolutely agreed, and to identify those participants that need retraining 
as they reduce the intra-class correlation coefficient, and thus the reliability. 
5.4 Ethics 
Informed consent (written) was obtained from each participant (See Appendix 15 
and 16). Participant information was kept confidential, locked in a cabinet and 
accessible only to the Principle Investigator. Participants were and will not be 
identified in any reports or communications. 
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5.5 Results 
5.5.1 Characteristics of the participants 
The total number of participants in this study was 25 (5 male and 20 female); 18 
were nurses and seven were nursing assistants (Table 11). The median age of the 
participants was 40 (IQR=10). All nurses included in the study had experience in 
malaria diagnosis and treatment, and their mean years of experience were 5 years. 
The 7 nursing assistants had experience in malaria diagnosis but not treatment. This 
is in keeping with current South African malaria policy that only professional nurses 
are allowed to treat patients.(8) All the study participants had experience in using a 
MROT with a median of five years (IQR) experience. However only 24% (6 of 25) 
received external training on MROT use through the malaria control programme - the 
remaining 76% received in-house training from colleagues at their health facility. 
Thirty two percent of the clinics used (eight of 25) ICT diagnostic test whilst the 
remaining 68% (17/25) used the Makromed. This was because ICT tests were still 
being introduced to the clinics at the time of this study, whilst Makromed was being 
phased out. This provided a unique opportunity to compare end-users proficiency 
on each test. 
Characteristic N (%) 
Total number of participants 25 
Age in years Median [IQR] 40 [10] 
Gender 
Male 5 (20) 
Female 20 (80) 
Qualification 
Nurse 18 (72) 
Nursing assistant 7 (28) 
Has previous experience in 18 (72) 
treating malaria experience 
Has used Malaria ROT 25 (100) 
Mean years experience in using 4.4 (SO=1) 
of ROT use 
Has received training on MROTs 6 (24) 
.. Table 11: Participant characteristics 
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5.5.2 End- user proficiency: individual steps 
None of the participants completed all steps successfully; a median score of 11 out 
of a total of 15 was obtained by end-users to correctly perform the MRDTs. The end-
user performance on each step is summarized in Table 12. 
5.5.3 Recording patient information 
Ninety two percent of the participants did not write the patients name on the test 
cassettes, however 72% participants entered information in a patient's register. 
5.5.4 Preparing MRDT before the conducting the test 
Although 80% of the participants were able to assemble the test kit, 16 (64%) 
participants did not check the expiry dates on the test packages. 
5.5.5 Using sterile procedures to conduct the test 
Sixty eight percent of participants did not use gloves when they performed the test 
and 20% of the participants did not clean the volunteer's finger with an alcohol swab. 
5.5.6 Adherence to test procedures 
Seventy six percent (19 of 25 end-users) used the lancet enclosed in the kit whilst 
the remaining 24% used sterile clinical needles to prick the volunteer's finger. The 
reasons given by the participants for this practice were that they did not get sufficient 
blood for performing the test, when they used the lancet from the kits. Ninety two 
percent of the participants added the blood to the correct window, although 16% did 
not use the correct amount. 
Sixty eight percent of participants used the correct amount of buffer to conduct the 
test; the remaining 32% each used 3 drops instead of the 6 for Makromed test-kit. 
Seventy six percent of the partiCipants waited 15 minutes to read the test, the 
remaining 24% each waited 3 minutes only. 
5.5.7 Interpretation of actual test result 
Seventy six percent of participants correctly read MRDT results (performed on the 
known MRDT negative volunteer), however the remaining 34% read the results as 
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being ambiguous. Interestingly, all 34% participants were those who used sterile 
needles for pricking the finger of the volunteer instead of the lancet provided in the 
test kit. 
Steps in Test procedure N=2S(%) 
Assemb le the new test cassette, 20 (80) 
Put on a new pair of gloves 8 (32) 
Check expiry date on the test package to make sure test is still valid 9 (36) 
Write patient name on the device 2 (8) 
Clean f inger with alcohol swab 20 (80) 
Allow finger to dry before pricking it 17 (68) 
Using a sterile lancet, puncture the side of the ball of the finger 19 (76) 
Dispose of lancet in sharps bin immediately after pricking finger 16 (64) 
Touch one end of the sample applicator pipette (straw) to the blood on the 21 (84) 
fi nger prick for Makromed or draw up to the first line in the pipette for ICT 
Using the pipette, immediately touch the tip of the pipette with the blood in 23 (92) 
Window A on the test device 
(smaller hole in case of ICT) 
Dispense 6 drops of buffer (MAKROMED) or 5 drops of (ICT) 17 (68) 
Wait 15 minutes before read ing the results 19 (76) 
Read test results correctly 19 (76) 
Record results in register 18 (72) 
Dispose gloves, wrappers, alcohol swab, loop, desiccant and cassette in non- 21 (84) 
sharps container 
Table 12 Adherence to the test procedure by the participants 
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5.5.8 Interpretation of prepared test results 
The interpretation results were grouped into the categories of: i) weak positive, ii) 
strong positive, iii) negative and iv) ambiguous. See Table 13 for a breakdown of the 
end-user interpretation of the scores. 
The overall median interpretation test scores (calculated from a possible total score 
of 10 correct responses where a score of 1 was assigned if interpretation was 
correct and a score of 0 was assigned if interpretation was incorrect) was 9 (IQR=2). 
Seventy-eight out of a total of 100 weak positive MRDT results were correctly 
interpreted by the participants. From the remaining 22, 10 were interpreted , as 
negative and 12 as ambiguous. Ninety-nine of the 100 strong positives were 
interpreted as positive and 1 was interpreted as negative. Twenty-four of the 25 
negative results were interpreted as negative and 1 was interpreted as ambiguous. 
Of the 25 ambiguous results, 15 were interpreted as ambiguous, 8 as negative and 2 
as positive. The sensitivitya of end-users interpretation of positive test results was 
85%. The specificityb of end-users MRDT result interpretation was 96% and the 
probability of correctly identifying ambiguous results was 60%. 
True results Participant's responses 
Positive Negative Ambiguous Total no. observations (n) 
Weak Positive 78 10 12 
Strong Positive 99 0 1 
Negative 0 24 1 
Ambiguous 2 8 15 
.. Table 13: Agreement between the true results and the partIcIpants 
interpretation scores 
5.5.9 Reliability analysis 
100 
100 
25 
25 
Reliability analysiS showed poor reliability of a single end-user (participant! nurse) -
ICC (2,1) of 0.54, and increased reliability when the scores of all end-users 
(participant! nurse) were considered together. The resultslinterpretation of a single 
• Probability that end-users correctly interpreted a result as being positive when it was truly positive 
b Probability that end-users correctly interpreted a result as being negative, when it was truly 
negative. 
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end-user is not reliable and end-users cannot be interchanged. Data were 
interrogated to determine whether one particular end-user reduced the reliability. 
Analysis showed that end-users 2, 4, 7, 20, 21 and 24 and 25 varied in their 
interpretation of MRDTs reliability. Five of these seven end-users received no 
training on MRDTs, co-incidentally their mean years of working with MRDTs was 4.5 
(SD=1.39). This finding highlights the need to address end-user training. 
5.5.10 Frequencies of key variables against performance outcomes 
Table 14 presents distribution of the performance and interpretation scores by the 
MRDT type, clinic transmission, age of participant, qualification of participant, 
training on MRDT and participant treatment experience. 
The median participant scores for all two outcomes (performance and interpretation 
scores) were higher for the ICT MRDT than the Makromed ICT. 
The performance scores were higher in the high malaria case load clinics (> 50 
malaria cases per year) than the medium and low malaria transmission clinics. The 
median participant interpretation scores were lowest in the low malaria case load 
clinics (10 -19 Malaria cases per annum). The lowest median interpretation scores 
were in the nurse age category 40-59 years. The median performance scores and 
interpretation scores of the end-user were higher in qualified nursing staff than 
unqualified staff. Nurses who were trained on MRDT had slightly higher 
interpretation scores than those untrained. Nurses who had no treatment experience 
had slightly better performance scores than those who had treatment experience. 
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Characteristics of MRDT and participants Median Median 
Performance Interpretation 
score (IQR) score (lQR) 
MRDT test type ICT 11 .5 (1.5) 9.5 (1.5) 
Makromed 10.0 (2.0) 9.0 (3.0) 
Clinic transmission Low transmission 10.0 (4.0) 7.0 (4.0) 
settings Medium Transmission 10 (3.51 9 (2.0) 
High Transmission 11 (3.0) 9 (1.0) 
Age of participants: 20-39 11(1 .5) 9 (1.5) 
40-59 9 (4.0) 9 (2 .0) 
Nurses qualification Qualified Nurse 11 .0 (3.0) 10.0 (3.0) 
Nursing assistant 10.5 (4.0) 9 (0.0) 
MRDT training Yes 
11 .0(2.0) 10.0 (1 .0) 
No 11 .0(4) 9.0 (3.0) 
Treatment Experience Yes 
10.5 (3) 9.0 (3.0) 
No 11 .0 (3) 9.0 (1.0) 
Table 14: Distribution and performance and interpretation scores by type of 
MRDT and participants characteristics. 
5.5.11 End-user performance of MRDTs 
There was no significant association between performance scores and test type, 
age, MRDT training , qualification and clinic malaria risk- see Table 15. 
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Characteristics of MRDT Performance Odd Ratio 
and participants scores 
above the [95% Conf. 
median Interval] 
Makromed n=17 3 (17.6) 1 
ICT Pf n=8 4(50) 4.67 (0.61-35.18) 
Low/medium case load 1 (14.3) 1 
clinics n=7 
High case load clinics 6(33.3) 0.331 (0.03 -3.8) 
n=18 
Age 40-59 n=13 3 (23.08) 1 
Age 20-39 n=12 4 (33.3) 0.6 (0.1-3.6) 
No training n=19 4 (21.0) 1 
Had MRDT training n=6 3 (50.0) 3.75 (0.4- 29.5) 
No treatment Experience 3 (42.9) 1 
n=7 4(22.2) 0.38 (0.05- 2.6) 
Had treatment Experience 
n=18 
Nursing assistant n=1 0 2( 20) 1 
Qualified Nurse n=15 5 ( 33.3) 2.0 (0.29-14.0) 
. .. Table 15: AssociatIOn between charactenstics of MRDT/partlclpants and the 
performance scores 
5.5.12 Interpretation of MRDT results 
Nurses trained in MRDT use had significantly better interpretation scores than 
untrained nurses (OR=2.9 95%CI 0.25-33.1; p=0.003). There was no significant 
association between interpretation scores and test type, low versus high 
transmission clinics, younger versus older nurses, nurses with treatment experience 
and those without and professional nurses versus staff nurses (Table 16). 
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Characteristics of MRDT Interpretation Odd Ratio 
and participants scores above 
the median [95% Conf. 
Interval] 
Makromed n=8 6 (75.0) 1 
leT Pf n=17 11 (65.7) 0.6 (0.1-3.3) 
Medium/Iow case load 10(5.55) -
clinics n=18 7(100) 
High case load clinics 
n=7 
Age 40-59 n=13 8 (61 .6) 1 
Age 20-39 n=12 9 (75.0) 1.9 (0.2-14.3) 
No training n=19 12(63.16) 1 
Had MRDT training n=6 5 (83.3) 2.9 (2.5- 33.15) 
No treatment experience 6 (14.3) 1 
n=7 
had treatment experience 11(61.1) 0.3 (0.02- 2.9) 
n=18 
Nursing assistant n=1 0 8 (80) 1 
Qualified Nurse n=15 9 (60.0) 0.37(0.59-2.6) 
. .. Table 16: Association between the characteristics of MRDT/partlclpants and 
the interpretation scores 
5.6 Discussion 
Although the sample in this study is small , it was carefully chosen using multi-stage 
stratified random sampling; this increases the likelihood that the study population is 
representative of end-users in the study area. The study has shown that a large 
percentage of end-users did not receive standardized training on MRDTs. 
Standardised training of the end-user is critical to addressing the weaknesses in 
end-user proficiency with the use of MRDTs.(9) 
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5.6.1 End-user performance 
All the key activities viz; recording patient information, preparing the test kit, 
using correct sterile procedures, adhering to the test instructions and correctly 
interpreting the MRDT results can be improved, with a view to improving end-user 
performance and reducing malaria-related morbidity and mortality. One 
consequence of not using proper sterile procedures is the possibility of cross 
infection with other diseases. The Vhembe District is a high HIV risk district in South 
Africa, with HIV prevalence being 11.1% (108); thus poor adherence of end-users to 
sterile procedures is of grave concern. The use of too much blood on the MRDT test 
strip by some participants is cause for concern, as weak positives, in early stages of 
the infection could be overlooked.(9) This was corroborated by this study as data 
indicates that end-users who used too much blood interpreted the results as 
negative. The inadequate amounts of buffer used by' some participants, could lead to 
poor clearing of the patient's blood across the test strip, this could cause false 
negative results.(67) The short time to read the MRDT as practiced by some 
participants could result in false negatives and have disastrous consequences for 
the patients, especially those that would be at the early stages of the infection with 
low levels of parasitaemia.(9, 66) 
The tendency for performance scores to be better for ICT Pf than Makromed can be 
attributed to 2 key steps in the testing procedure. Firstly ICT Pf makes use of a 
specialized pipette, enabling end-users to draw up 5 1-11 of blood and a specialized 
dropper to deliver 5 drops of buffer. This prevented the nurses from making errors as 
they did with Makromed test-kit. The ICT Pf test had a higher odds ratio (4.67) for 
performance scores when compared with the Makromed test however the wide 
confidence intervals point to the study possibly having low power thus contributing to 
a statistically non significant finding (p=0.096). 
The significantly better performance and interpretation scores of trained nurses 
compared to those untrained nurses (p=0.0038) shows that even though more 
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participants were trained in-house than using the standardized external training, they 
were more proficient than nurses receiving no training. Once again the wide 
confidence intervals point to insufficient power in the study, due to small sample 
size. This finding can be corroborated with similar findings in other studies that 
training can improve end-user proficiency. (9, 59, 62) Job instructions or job aids 
such as wall charts should be considered for implementation in the study setting and 
must make provision for pictures on weak positive and ambiguous results, similar to 
those in other studies.(9, 59, 62) It is crucial that end-users are trained prior to and 
during the supply of newly introduced MROTs as this is likely to improve 
performance. (59, 60, 62) 
5.6.2 Interpretation of the battery of tests 
The 15% false negatives resulting mainly from the poor interpretation of the weak 
positive photographs, are concerning. The end-users probably expected the strength 
of the test line to be as strong as the strength of the control line in order to interpret 
the results as positive Bell et. al. state in their review on ensuring quality of 
diagnostics that weak positives occur during the early stages of malaria infections, 
thus determining and treating malaria at this stage is critical to preventing serious 
morbidity.(67) South Africa can be considered as a country with low level of malaria 
transmission, hence low level symptomatic parasitaemias are highly likely especially 
during the early stages of the infection.(3) 
The findings on the interpretation of weak negative pre-prepared photographs are 
similar to that documented in other studies.(59, 60, 109) A study from Switzerland 
on volunteer's ability to interpret malaria ROT results showed a false negative 
interpretation rate of 72% of one test and 29.6 of another test - these tests were 
prepared from patients with low parasitaemias «0.1% blood parasites).(60) 
Trachsler et. al. in another study from Switzerland, observed 160 participants for 
their ability to interpret 800 prepared malaria rapid test results.(62) Participants 
correctly interpreted 70.6%, there were no false positives however there was 14.1% 
false negatives, 6% of which were from weakly positive malaria rapid tests. (62) 
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Rennie et aI., in a study from the Philippines, tested community health workers who 
performed and interpreted malaria rapid tests and interpret results; they also used a 
battery of prepared results. (59) They found that the true positivity rate was between 
63-66% from their 2 study groups; most of their false negatives were actually weakly 
positive test lines. 
The study had two main limitations: Firstly the sample size was small; thus 
generalizations about the study results need to be interpreted with caution. However, 
the sample was carefully chosen using multi-stage stratified random sampling, and 
is thus representative of ROT end-users in the study area. Moreover the study does 
raise similar concerns about weak positive results as other studies (59, 62), and thus 
the findings may be relevant to similar settings in South Africa and in Africa where 
ROTs are being used. It was not possible to increase the sample size for logistical 
and operational reasons - clinics were in very remote parts of the Limpopo Province 
and could only be accessed by dirt road; the student was asked not to disturb 
service delivery in the clinics and had to wait for up to 3 hours to interview one of the 
end-users - and because of financial constraints. 
Secondly the use of photographs of a pre-prepared battery of tests as a gold 
standard to determine sensitivity and specificity of end-user interpretation may have 
been a limitation. Photographs may not be the best gold standard as they may have 
captured the test lines differently to what end-users were used to. Photographs of 
weak positive results may have appeared lighter than what they truly where - and 
this could have distorted end-user's interpretation of the results, and in particular, of 
weak positive results. The actual tests (instead of photographs) could not be used to 
assess end-user performance as the signals on these test deteriorate over time, 
making it difficult to use acual tests to assess end-user interpretation. This is 
especially so for weak negative results. Thus photographs of a battery of pre-
prepared tests were used to assess end-user MROT interpretation. 
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5.7 Conclusion 
The end-user proficiency (performance and interpretation of results) for MRDT in the 
Vhembe District of the Limpopo requires improvement. This study has indicated that 
those end-users who were trained were more proficient at using MRDTs than those 
who were not trained. End-user training should therefore be one of the key factors 
for health authorities to consider when addressing the challenges of end-user MRDT 
proficiency in the Vhembe District. 
The key gap identified was adherence of end-users to the key steps in the MRDT 
test procedures and mis-interpretation of weak positive and ambiguous test results. 
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6.0 Chapter 6: An assessment of the feasibility of PCWs for MRDT Quality 
control 
6.1 Introduction 
Quality control of MRDT is important for optimising accuracy of MRDTs and 
ultimately improving malaria diagnosis.(9, 22, 67) An appropriate quality control 
system for the South African setting would be to use positive control wells (peWs). 
(66, 68)The currently available pews in South Africa is manufactured by National 
Bio-products Institute, did undergo laboratory evaluations for signal strength and 
stability, with favourable outcomes (personal communication with manufacturer- no 
published data was available as pews were still being finalized at the laboratory 
level at the time of this study). However it was not tested to determine its reliability 
under field conditions. Therefore an assessment of the pew to determine its 
applicability for routine quality controlling of MRDTs in the field was carried out. 
6.2 Objectives 
(1) To determine the reliability of pews in field conditions. 
(2) To compare the reliability of HRPII negative blood versus citrate buffer 
for diluting pews 
6.3 Study methods 
The study was conducted on 18 randomly chosen clinics and 5 corresponding 
referral hospital laboratories in the Vhembe district, (see Appendix 17). A centralized 
approach and a' remote testing approach was used to determine overall reliability of 
pews in field conditions. In both approaches MRDTs that were used were stored at 
the clinic level thus only the pews were stored differently. In the remote approach 
pews and MRDTs were stored and tested at the selected clinics. In the centralised 
approach pews were stored at a referral hospital laboratory and tested in the 
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hospital laboratory using selected MRDTs obtained from the clinic. The brand of 
MRDTs tested where those that existed at the clinics at the time of the study. 
6.3.1 Approaches to quality control 
6.3.1.1 Remote testing approach to quality control 
Two pews were transported to each of the 18 study clinics and stored at room 
temperature for a period of approximately 1 month. MRDTs were stored at clinics as 
per the clinic protocol. After a period of one month, 4 MRDTs were randomly 
selected from the stored batch of the tests and tested in the laboratory, according to 
the study protocol (see below). 
6.3.1.2 Centralised approach to quality control 
2 pews each were transported and stored in 5 selected laboratories (see Appendix 
17) for a period of one month. After one month four unopened and unused MRDTs 
were randomly selected from the oldest batch of the MRDTs stored at each of the 18 
study clinics and transported to the central referral hospital laboratory and tested in 
the laboratory, according to the study protocol (see below). MRDTs were 
transported in cooler boxes, according to the manufacturer's recommendation. 
6.3.2 Study protocol for MRDT testing of pews 
Under field conditions at clinic and hospital levels the following was performed: 
• The first MRDT was tested using a known HRPII positive blood sample to 
establish if the batch was working, 
• The second MRDT was tested using the citrate buffer only (which was 
negative for malaria) to establish if the batch was working, 
• the third MRDT was tested with the stored pew diluted with known HRP 11 
negative blood sample (stored in an EDTA tube) and 
• the fourth MRDT was tested with the stored pew diluted with citrate buffer 
(provided by the manufacturer). 
All results were recorded on a data recording sheet (See Appendix 18). 
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If the first or second MRDT gave a false positive or negative result, respectively then 
remaining 2 MRDTs were not tested, further, as it was assumed that the batch was 
'not working'. The storage condition and duration of storage of each MRDT in the 
study clinics were observed and documented. 
The strength of the MRDT result was assessed using a colour intensity chart (see 
Appendix 19) adapted from Lon et al. and other reports: (9, 68) 
• no colour (negative) =0; 
• barely visible = 0.5; 
• weak positive =1 and 
• strong positive =3. 
6.3.3 Data analysis 
The main aim of the study was to determine whether PCWs could be considered for 
a quality control programme for routine sensitivity monitoring of HRP 11 antigen-
detecting MRDTs in the Limpopo Province. Eighteen clinics were randomly selected 
and 5 hospital laboratories were purposively selected so that reliability under 
different conditions could be assessed. Results are presented for the overall sample 
(PCWs in clinic and hospital laboratories). The reliability of PCWs was assessed 
using the signal strength. Factors that could affect the reliability of PCWs such as 
type of MRDT, distance of clinic from the referral hospital laboratory, storage 
temperature and type of diluent (blood or citrate buffer) used to dilute the PCWs are 
described and were taken into account in this analysis. Factors that could affect the 
outcomes of the PCWs were selected from WHO manuals and published literature 
and communication with the manufacturer of the PCW.(9, 68) 
6.4 Ethics 
Although the student performed all tests, informed consent for this aspect of the 
study was obtained from chief technologists in each laboratory, from the head of 
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each selected laboratory and from senior nurses from health facilities respectively, 
see Appendix 20 and 21 for study information sheets and informed consent forms. 
6.5 Results 
6.5.1 Description of key variables and outcomes. 
In the 23 sites health facilities (18) and hospital laboratories visited (5), 7 had leT 
diagnostic testing kits and 16 had Makromed kits. The median distance between the 
clinics and nearest the hospital laboratory was 42.5 km (IQR=19). The median 
number of days for which PCWs were stored at the health facilities was 33 (lQR=2), 
with the median temperatures of the facilities being 21°C (IQR=4). One hundred 
percent (23/23) of the known Pf positive blood samples were positive on the MRDTs 
(leT and MAKROMED), thus indicating that the test kits were working and the 
batches were validated as being effective. A negative control (buffer run alone on 
the test strip) tested negative for each batch the MRDTs that were used. Sixty 
percent of the pews (clinic and lab) diluted with the HRP 11 Negative blood was 
positive; whilst approximately 9% of PCWs (clinic and lab) diluted with citrate buffer 
was positive. See Table 17 and 18 for detailed findings. 
Variable Description 
I· N(%) Total 
Type of tests used ICT 7 (30.43) 
Makromed 16 (69.57) 23 
Testing approach Clinics 18 (78.25) 23 
Hospitals 5 (21.74) 
median distances from hospital 42.5 (19*); range 8-87km 18 
laboratories 
Median storage days of PCWs at 33 (2*); range 17-38 days 23 
clinics centres 
Median temperatures 21 (4*); range 20-33°C 23 
Footnote: *=IQR 
Table 17: Description of key QC variables 
110 
Outcome Variables N (%) N 
Test results with positive blood sample Pas 23 (100) 23 
Test results with citrate buffer Neg 23 (100) 23 
PCW results diluted with HRP II Neg 9 (39.1) 23 
negative blood Pos 14 (60) 
PCW results diluted with Citrate buffer Neg 21 (91 .3) 23 
Pos2 (8.7) 
.. Table 18: PosItive control well outcomes 
6.5.2 Comparing test outcomes with different diluents 
Diluting the PCWs with HRP 11 negative blood, proved better than diluting with citrate 
buffer - the citrate buffer diluent yielded more false negatives than the HRP II 
negative blood diluent. This difference was consistent for all the factors affecting the 
outcomes of PCWs (Table 19). The following are key findings: 
• Using the Makromed test kit (n=16) all 16 PCWs diluted with citrate buffer 
tested negative whilst 4/16 (25%) diluted with MRDT negative blood tested 
negative. 
• When tests on PCWs stored for up to 33 days were performed (n=15) all 15 
PCWs diluted with citrate buffer were negative compared to 4/15 (27%) 
diluted with HRPII negative blood. 
• When tests on· PCWs stored at >26oC were performed (n=5) all 5 PCWs 
diluted with citrate buffer were negative compared to 3/5 (60%) diluted with 
HRP 11 negative blood. 
• Lab stored PCW's (n=5) diluted with citrate buffer HRPII yielded 20% (1/5) 
negative results whilst PCWs diluted with HRP 11 negative blood gave no 
negative results. 
• Of PCWs stored at clinics (n=18) 50% (9/18) diluted with citrate buffer were 
falsely negative whilst 44% (8/18) diluted with HRPII negative blood, were 
falsely negative. 
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Factors Affecting the 
• 
Malaria Positive pew diluted with PCW diluted wHh 
quality of pews . blood sample HRP 11 negative cltrate buffer test , 
(test positivel total blood (false negatfveJto181 
tested) (false negative/total tested) 
I ~ • tested) 
. ~"~ .. -~ 
Brand of 
MRDT ICT 7/7{100%) 5/7 (71.4%) 5/7(71.4%) 
Makromed 16/16 (100%) 4/16 (25%) 16 (100%) 
Type of facility 
Hospital 
Lab · 5/5 (100%) 0 1/5 (20%) 
18/18 (100%) 8/18 (44.4%) 9/18 (50%) 
Clinic 
Number of 17-30 3/3 (100%) 1/3 (33.3%) 3/3 (100%) 
days stored in 
the clinic/ 31-33 12/12 (100%) 3/12 (25%) 12/12 (100%) 
Hospital 
34-38 8/8 (100%) 4/8 (50.0%) 6118 (75%) 
Median 18/18 (100%)' 6/18 (33.3) 16/18 (89.2%) 
storage 20-25 
temperature 
26-30 4/4 (100%) 2/4 (50%) 4 (100%) 
31-33 1/1 (100%) 1 (100%) 1(100%) 
. . . Table 19: Comparison of test outcomes of PCWs uSing different diluents 
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6.6 Discussion 
All the MRDTs tested were in good working condition as all 23 MRDTs collected 
from the clinics were strongly positive (tested against the positive colour chart) when 
using the known positive HRP " stored blood. Similarly the buffer when tested alone 
(negative control) on the MRDT test strips was consistently negative when tested 
each time the pews were being evaluated. 
pew performed better when diluted with HRP " negative blood than diluted with 
citrate buffer. The reasons for this could be that the MRDTs were designed to test 
blood samples (personal communication Dr Martin Bubb, National Bio-products), 
hence the poor overall performance of the citrate buffer. The WHO states that citrate 
buffer will ideally last longer than blood, as a diluent.(66) However, in this study 
blood was a better diluent for the pew. Logistically it would not be that difficult for 
health facilities to store HRP " negative blood as they are all equipped with 
refrigerators and malaria control teams visit clinics once per week hence the HRP 11 
~ ; ; 
negative blood samples could be replenished. However the challenge still remains :' 
for the development of a suitable synthetic buffer for diluting pews as this will be an 
ideal diluent- as the shelf life to the diluent is longer than that of whole blood. 
6.6.1 pew diluted with HRP 11 negative blood 
The MRDT kit type was not initially chosen as one of the variables when the study 
was designed, however during the course of this study it was noted that some clinics 
had retained the Makromed testing kits as they were in surplus and, hence were still 
using them. This provided an opportunity to compare the pew results and signal 
strengths on the Makromed Kit with the leT diagnostic test kits. One of the possible 
reasons for the Makromed kit performing better than the leT kit when testing the 
pews (after diluted with negative HRPII blood) could be due to the antigenic 
variation. Lee et al. observed a Significant difference in the reactivity of the same 
monoclonal antibodies (MAB) to different P. fa/ciparum isolates. (99) When the 
target epitopes of three MASs were determined and mapped onto the peptide 
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sequences of the field isolates, significant variability in the frequency of these 
epitopes was observed. (110) Antigenic variation would therefore need to be 
addressed when developing pew's, such as that used in this study, so that at least 
WHO approved MRDTs can be quality controlled using this method .This should 
include leT Pf and the Makromed testing kits currently used in South Africa. MRDT 
trials that have been reviewed on acceptable MRDTs are available on WHO MRDT 
website hence pew manufactures should consider selecting from this list. (24) 
This study showed variability on the signal strength when pews were stored for 
more than 30 days. In the study setting it is possible for pews to be replenished 
every 2 weeks, hence the current pew can be used, however, health facility 
managers, would need to ensure that pew expiry dates are regularly monitored, 
similar to that of the MRDT kits. 
6.6.2 PCW diluted with citrate buffer 
The two pews diluted with citrate buffer that were positive after storage of 34-38 
days, could be due to non specific reactions (personal communication with PCW 
manufacturer), especially due to the fact that all those stored at s 33 days were 
negative. Citrate buffer quality for contamination over 30 days would need to be 
tested if it is to be further considered for use as a diluent for PCWs. 
6.7 Conclusions 
This evaluation of PCWs shows that PCWs can be used as a tool for monitoring 
MRDT quality at the field level (clinic level) and suggests that HRP 11 negative whole 
blood is a better diluent than citrate buffer. pews will need to be further developed 
before routine implementation at clinic level, operational issues such as training of 
the end-user (clinic staff) and transport logistics and storage of PCWs will also need 
to be addressed. The use of citrate buffer needs to be further explored as a diluent; 
blood is not ideal due to challenges with storage and transport logistics. 
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7 Chapter 7: Discussion and Conclusions 
The early and accurate diagnosis of malaria is important to ensuring prompt 
treatment for malaria.(111) Several methods exist to diagnose malaria and each 
method has useful applications in specific settings.(9, 67) Whilst the gold standard 
for malaria diagnosis remains malaria microscopy its applicability to the fieldl primary 
health care settings is questionable. (12, 57, 112, 113) This is due to skilled 
microscopists and reliable equipment not being available and microscopy taking time 
to conduct. 
MRDTs are the second best malaria diagnostic tool that can be deployed in large-
scale in primary health care settings.(12, 22) Whilst MRDTs are an efficient tool for 
diagnosis of malaria, there are several factors that can affect its accuracy.(9, 67) As 
treatment at the primary health care levels in South Africa is based on definitive 
diagnosis using MRDTs, ensuring quality and accuracy of MRDTs at field level 
becomes extremely important.(8) In this study the key factors, in the opinion of the 
end-users that could affect the quality and usage of MRDTs was determined. 
Subsequently the field accuracy of MRDTs used in South Africa and the proficiency 
of end-users were evaluated. Finally the feasibility of setting up a quality control 
system was assessed. 
In this chapter the limitations of the study, the key observations and their public 
health implications are discussed. 
7.1 Temperature monitoring of MRDTs 
The lack of cooling facilities to store MRDTs was noted as a challenge, Eighty five 
percent of clinics in malaria areas had air-conditioning equipment and were 
monitoring temperatures. However both MRDTs and PCWs that were stored at more 
that 25°C showed a tendency for weaker to no signals. Chiodini et al. and 
Jorgensen et al; have shown in their heat stability studies of HRP 11 based MROTs 
that the performance of malaria ROTs can be adversely affected at the temperatures 
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to which they will be exposed when transported to, and used in the field.(74, 75) 
These studies and others suggest that random checking of temperatures in 
pharmaceutical storage rooms of clinics would be an important step in MRDT quality 
assurance.(54) Coupled with this, MRDTs should be considered for batch testing 
prior to being received by the pharmaceutical depots at the districts and subsequent 
to field exposure and field conditions, by reference laboratories. The standard WHO 
guideline should be considered to undertake batch testing.(54) 
7.2 Sensitivity of leT Pf test 
The overall sensitivity of the ICT Pf test is above the threshold of 95% that is 
recommended by the WHO.(9) However the sensitivity at 100 parasites/ 1-11 of blood 
could not be ascertained in this study as all the slides did not have parasitaemia 
counts conducted on them due to the poor quality of slides. Among those slides in 
which parasite counting was possible none had parasite levels of 100 parasites/ 1-11 of 
blood and below. Late presentation of malaria patients to the health facilities which 
often occurs in the district, could be one possible explanation for this. Laboratory 
parasite dilution studies did reflect that the ICT Pf test was 100% sensitive at 70 
parasites IJI of blood.(87) Whilst this evidence maybe sufficient to support the 
usefulness of the ICT Pf test, health authorities should consider a larger study with 
more clinics and increased sample size to test the accuracy of ICT Pf to diagnose 
malaria with a parasite density of :Si 100 parasites/ IJI of blood. 
7.3 False negative MRDTs 
False negative malaria diagnosis was low in this study (1/405 patients tested), 
however applying this level of false negative rate to 51 712 febrile patients per year 
reported in the study clinics suggests that there could be 128 false negative false 
negative diagnoses per year. 
Although the number of malaria related deaths in the false negative patient's in the 
study was zero, the true mortality from the study population could not be ascertained 
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as all the patients did not return for follow-up. Thus, the possible deaths among the 
assumed "128 false negative results" cannot be estimated. The reasons for false 
negative diagnosis of malaria therefore become critical and should be determined, in 
the study population. The end-user interpretation of results and the quality of 
microscopy are factors needing improvement. In particular the operational deficiency 
among the end-users such as usage of inadequate amounts of buffer and incorrect 
reading times to read the MRDTs and poor interpretation of weak-positive MRDTs 
results should be addressed. 
7.4 False positive ICT results 
Whilst false positive diagnosis of malaria can result in over-treatment and possible 
drug resistance, altering the physical test mechanism by the manufacturer may not 
be appropriate.(16, 22) Several authors have found that in a highly sensitive test, 
specificity tends to decrease. In the case of the ICT Pf test the specificity of 96% 
was above WHO acceptable criteria.(9) Again the quality of the gold standard, viz 
microscopy needs to be improved as the weak positives could be missed even by 
very skilled microscopists.(9, 22) 
7.5 Quality of microscopy 
The quality of microscopy by field microscopists showed deficiencies, despite the 
quality of microscopy slides not being optimal. The discordance between field 
microscopists of approximately 5% is cause for concern, especially when high level 
parasitaemias were missed. This is contrary to what other studies have found, where 
low level parasitaemias were missed by microscopy.(85, 86) It is therefore 
imperative for health authorities of the Vhembe district to conduct a study on the 
status of malaria microscopy at the field level, especially when microscopy is 
sometimes used to confirm diagnOSis and to monitor patient treatment responses. 
(8) 
7.6 Predictors of malaria 
As the diagnosis of malaria in South Africa especially at the primary health care level 
is made mainly by nurses using MRDTs, the challenge lies in situations where 
patients are ICT negative but there is a high malaria clinical index of suspicion. (8) 
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The situation becomes more complicated when health facilities are a considerable 
distance away from laboratories. The guidelines for the treatment of malaria and the 
Integrated Management of Childhood Illnesses chart booklet state that in such 
cases the treatment for malaria should be administered and the patient should be 
referred to the hospital.(82) Ndyomungyenyi et al. has noted in their study Uganda 
that fever may not be the main predictor of malaria.(21) Their study found that 
headache (84.4% n=633) followed by joint pain (78.1 %; n=586) were stronger 
predictors for malaria and then followed by fever (72, 2%; n=579) in their study 
population. Although headache had lower sensitivity (52.23%) than fever (64.58%) 
for predicting malaria), sweating (81.25% n=394) and chills (72.83%; n=394) showed 
higher sensitivities. This emphasizes the point that clinical predictors may differ from 
one setting to another and are not very useful for making diagnostic and treatment 
decisions. The accuracy component of the study showed that patients' reporting a 
history of sweating is a significant predictor of malaria. Therefore, the validity of the 
perceived patient symptoms of malaria in the Vhembe district needs to be robustly 
evaluated and the guidelines for testing patients for malaria should be revised 
accordingly. 
7.7End-User Performance 
Training of end-users was observed as a challenge. Interestingly, the nurses who 
had received training were 3.75 times more likely to perform the MRDTs and 2.9 
times more likely to interpret the results better than those who did not receive 
training. Training to ensure that malaria ROTs are optimally used and interpreted 
has been advocated by several studies and reports. (9, 46, 59, 64, 67, 114) Health 
authorities in the Vhembe district should therefore make training a key activity in 
their operational planning. Training guides are available to guide health managers 
on how to use and interpret MROTs. Interpretation of weak/faint positive MRDTs 
needs to be highlighted in the training.(9) 
118 
7.8 Quality control for MRDTs 
Positive control wells are a novel method for addressing the quality control of 
MRDTs after exposure to field conditions.(9) The PCW evaluated for the quality 
control component of this study has shown some promise for use at the clinic level, 
similar to the findings of Lon et al.(68) However the stability of the PCW- after 
storage at field level without significant loss of antigen activity is a crucial step before 
this technology can be considered for wider field implementation. In this study the 
field stability of the antigen with the HRP 11 negative blood diluted PCW (better of the 
2 diluents) showed variability in signal strength; hence this would be the key issue 
that needs to be addressed before conSidering field application. The practicalities 
for implementing pews at the field level will also need to be assessed, issues of 
storage environment and usage by end-users will be important. 
7.9 Conclusions 
The exploratory study revealed that MRDT storage, quality control, end-user training 
and use of MRDT results for clinical decision making in primary health care facilities 
in study setting need to be improved. Furthermore detailed studies on MRDT 
accuracy; end-user performance and developing quality control for MRDTs are 
needed. For this reason subsequent studies on evaluation of the field accuracy of 
ICT Pf test and end-user performance in conducting and interpreting MRDT results 
and to determine whether positive controls could be used to routinely monitor MRDT 
quality in the field, were conducted. 
The overall diagnostic accuracy of ICT Pf MRDT, judged by the sensitivity and 
specificity of the test, is of acceptable levels as measured against the WHO 
standards. However the sensitivity of the ICT Pf at the field level, at 100 parasites/IJI 
of blood was not determined in this study and would need to be ascertained in a 
larger study with a representative sample. These findings were communicated to the 
Department of Health in South Africa and malaria managers are confident to 
continue with using the ICT Pf diagnostic test. The protocol for this study was also 
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shared with the Malaria Control Programme in the Limpopo Province - which has 
undertaken to regularly monitor the field accuracy of MRDTs; determine the lower 
parasite density detection limits and compare it with the WHO acceptable limits 
(S100 parasites /1-11 of blood). 
The MROT findings using the ICTpf diagnostic test (from Global diagnostics in South 
Africa), shows a high level of accuracy - sensitivity and specificity and good positive 
and negative predictive values. Countries with similar malaria transmission patterns 
and in same geographical locations such as South Africa (e.g. Botswana, Namibia, 
Swaziland, Zimbabwe) can consider using the ICTPf test for diagnosis. Due to the 
relatively low malaria transmission in parts of these countries there maybe 
insufficient positive samples to evaluate the ICTPf test, hence the finding from this 
study becomes important when they considering adoption of this test for diagnosis of 
malaria in their countries. 
The effect of the environment on the quality ICT Pf MROT requires further study as 
heat instability during transport and storage of MRDTs was not determined in this 
study. 
Inter-observer variability among microscopists was reliable. However 5% 
disagreements especially on slides with a parasite density >100 parasites I 1-11 of 
blood is a concern. Thus microscopists would require retraining and regular quality 
assurance assessments. 
Training of end-users on operational aspects and interpretation of results should be 
considered as a priority by district health managers in the Vhembe districts. The use 
of standardized guidelines needs to be considered as this will ensure quality results 
by all levels of ROT end-users, both experienced and new staff members. 
This study found that after controlling for other reported symptoms of malaria, 
patients presenting with sweating were 5 times more likely to be slide positive for 
malaria than those whom did not have sweating. As fever is the main clinical criteria 
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for testing patients for malaria in the IMCI guidelines for South Africa and the 
National Malaria Treatment Guidelines, malaria could be under-diagnosed in 
patients presenting with other reported symptoms and no fever. A broader study 
using all the signs and symptoms of malaria therefore needs to be considered for 
determining predictors of malaria especially for situations where there is a high 
clinical index of suspicion of malaria, laboratories are not readily accessible and 
ROT results are negative. 
PCWs are a novel way of achieving field based quality control. Quality control of 
MROTs after exposure to the field is crucial to ensuring accurate diagnosis. This 
study shows that PCWs may be used for quality control of MRDTs and has made a 
start to addressing quality control of MROTs at the clinic level but it would need to be 
taken further to determine its operational and technical feasibility for wide scale field 
application. The malaria control programme of the Limpopo Province will need an 
interim quality control system to monitor their MRDTs post-field exposure, whilst 
PCWs are being optimized. Given the current options available the prepared quality 
control sample using wild type antigens as suggested by WHO should be considered 
for interim use. The quality control sample can be prepared at a central reference 
laboratory (at the National Institute for Communicable Diseases-that has the 
technology and skills) and transported and stored at district hospital laboratories in 
the Limpopo. MRDTs could then be randomly selected from the clinics, transported 
and assessed at district hospital laboratories, with support from the district malaria 
control programme officers. 
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9.0 APPENDICES 
endix 1: Clinics and Health Centres visited for the 
DISTRICT FACILlTYNAME 2002 2004 Ave e 
MOPANI BA-PHALABORWA 43 24 51 39.33 
MOPANI BA-PHALABORWA 126 125 61 104 
MOPANI BA-PHALABORWA 13 13 20 15.33 
MOPANI BA-PHALABORWA 107 106 131 114.66 
MOPANI GREATER GIYANI 56 44 18 39.33 
MOPANI GREATER GIYANI 12 54 80 48.66 
MOPANI GREATER GIYANI Kremetart Clinic 0 11 46 19 
MOPANI GREATER GIYANI Mavambe Clinic 11 16 3 10 
MOPANI GREATER GIYANI Tomo Cl inic 176 249 114 179.66 
GREATER GIYANI 72 396 411 293 
MUSINA 146 202 121 156.33 
MUSINA 336 307 315 319.33 
MUSINA 18 21 42 27 
MUTALE 87 70 96 84.33 
THULAMELA 99 129 32 86.67 
THULAMELA 21 40 16 25.67 
THULAMELA 18 16 6 13.33 
THULAMELA 229 450 181 286.66 
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9.2 Appendix 2: Interview Schedules for exploratory study to determine which 
factors affect the accuracy of MRDTs 
Key informants 
Group1: Operational and Pharmaceutical service managers at district and 
Provincial level (n=18). 
Group 2: Nursing sisters working in clinics and health care centers (n=17). 
Group 3: Scientists in Research Institutes (n=2). 
Group 1. 
For Key Informants: 
1. What processors were used to decide on policy for using RDTs 
2. What are the criteria used for purchasing Rat's for malaria diagnosis in your 
province/district/locality? 
3. Could you list the manufactures of the RDTs that you purchased from, over 
the last one-year period and how long each type of RDT was used for? 
4. Could you list the suppliers of the RDTs that you ordered over the last one 
year period? How long has these supplies been around for? 
5. What is the range of prices of MRDT's that you ordered last year? 
6. Could you describe the procedures for distribution of MROT's to clinics, health 
centers and hospitals? 
7. Did you have adequate supplies of RDTs throughout the year? 
8. Do you have a contingency plan to ensure the rapid distribution of ROTs if 
they are needed during an outbreak? Describe this plan 
9. Could you describe the procedures for storing RDTs? (at the central depot 
and at a clinic?) 
10. How are the expiry dates of RDTs monitored? 
11. Do you follow any guidelines for ROT use? If yes, which guidelines do 
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you follow? Have these guidelines been adopted for use in your district? 
12.00 you test the quality of ROTs? If yes, what procedures are used for testing 
ROT quality? 
13. Where there any reports of failures of ROTs? 
14. 00 you do any further tests to confirm failure of ROTs? 
15.ls there an operating procedure for testing quality of ROTs? 
16. Are any confirmatory tests used? If yes, what criteria are used to determine 
when they should be used? What confirmatory tests are used? 
17 .In your opinion, does the staff at the health centers and clinics have adequate 
skills for using ROTs? 
18. Has there ever been a formal assessment of staff skills on ROT procurement 
and use? If yes, where and when was this done, how was it done and what 
were the results 
19. In your opinion do staff strictly follow the guidelines for interpreting ROTs 
results? 
20.ln your experience, what do staff do if the ROT results are negative? 
21. How often is training provided for staff to perform ROTs? Which staff are 
trained? Are trained staffs expected to train other staff at their facilities or are 
all staff trained at a central point? 
22. How often is staff followed up? What is done on follow-up? What have been 
the findings during such follow-up? 
23. What do you feel are the strengths of using ROTs? 
24. What are the challenges with using ROTs? 
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Group 2 
End-users: 
1. Where are malaria ROTs stored? 
2. How are malaria ROT stocks monitored? 
3. Do you check the expiry dates of ROTs in stock? If yes how often? 
4. What is the procedure for ordering malaria ROTs? 
5. How do you estimate the quantity of ROTs you need for each ordering cycle? 
6. Do you test the quality of ROTs? If yes how often do you test the quality? 
7. How is ROT quality (accuracy - whether they work) monitored at the clinic! 
health care center? 
8. How confident are you with the results of the MROT's you use? 
9. Have you given antimalarials to a patient whose ROT test was negative? If 
yes. How often patients with negative MROT's receive treatment? 
10. Do you always give an antimalarial to a patient whose ROT test is positive? If 
no; how often patients with positive MROT's did not receive treatment? 
11.ln your opinion, are ROTs easy to use? If, yes, on a scale of 1-5 how easy are 
ROTs to use - 5 is very difficult and 1 is very easy 
12. Are you confident in interpreting the ROT results? 
13. When did you receive training (the last one if more than one) in testing for 
malaria using ROT? 
14.ls the ROT used in your clinic/He the same on which you were trained? 
15. What further support you receive for using MROT's? If yes who gives it and 
how often? 
16. What do you do when you run out of stock of ROTs? 
17. Have you ever run out of stock of ROTs? When? For how long did this last? 
What did you do? 
18. Do you have a plan for ordering ROTs in an emergency? What is this plan? 
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19. Do you follow any guidelines for ROT use? If yes. which guidelines do you 
follow? 
20. What can you describe as positive aspects of using ROTs? 
21. What can you describe are the negative aspects of using ROTs? 
Group 3 
Research Institutions: 
1 What is your experience with Quality Control of malaria ROTs? 
2 What is the process of testing ROTs after they are purchased from the 
suppliers/manufactures? 
3 Are ROTs from different manufacturers regularly tested and compared? 
4 Are ROTs from different manufacturers and suppliers of similar quality? 
5 What is the level of skills for ROTs testing at the laboratory and the field level? 
6 Is there existing capacity at the field level and Laboratory level adequate?, for 
testing ROT quality. If no what training would be required. 
7 What confirmatory tests are performed to validate the MROT's results? 
8 In your opinion, does the appropriate Infrastructure and technology exists for 
ROT testing at laboratory level? If no, what changes are needed to ensure that 
the appropriate infrastructure and technology exists? 
9 What do you perceive as a strengths/opportunity for quality control of ROTs at 
the laboratory and field level? 
10 What would you say are some of the challenges for quality control of ROTs at 
the laboratory and the field level? 
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9.3 Appendix 3: Participant information sheet - Exploratory study 
Information Sheets & Consent forms 
PARTICIPANT INFORMATION SHEET 
TITLE OF RESEARCH PROJECT: 
Factors that affect the quality of Malaria Rapid Diagnostic tests, in the Limpopo 
Province of South Africa 
Prinicipal Investigator: 
Devanand Moonasar: National Department of Health South Africa and London 
School of Hygiene & Tropical Medicine, UK 
Contact Information: 
Tel: +27 (0) 123120102 
Fax: +27(0) 12 3123113 
e-mail: moonad@health.gov.za/patrick.moonasar@lshtm.ac.uk 
WHY ARE WE DOING THIS STUDY? 
Malaria is a disease that can be treated and cured. Early diagnosis and treatment is 
important for preventing severe or complicated malaria and death. Since Rapid 
Malaria Tests are being used for Malaria diagnosis in your area, it is important for 
these tests to be accurate and easy to use. We are doing this study to determine 
what are the factors that affect the accuracy of Rapid diagnostic tests and to 
determine how well the test performs under field conditions. Before starting a large 
study we would like to find out what are your views on Rapid Diagnostic Tests to 
detect where problems may lie. This information given by you will help us to develop 
a larger study to address the questions on the use of Rapid diagnostic tests. The 
interview will last approximately one hour. We are planning to interview about 28 
people who are involved with Rapid Diagnostic tests for diagnosis and management 
of malaria. 
DO I HAVE TO TAKE PART? 
It is entirely up to you to decide whether or not to take part in this study. If you 
decide not to take part, this will not affect you in any way. If you do decide to take 
part you will asked to sign a consent form. You are still free to withdraw at any time 
and without giving a reason. 
IF I TAKE PART IN THIS STUDY, WHAT WILL HAPPEN? 
After you have had a chance to ask questions, and have signed the informed 
consent form, we will ask you some questions for approximately 1 hour. If you give 
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your permission, we will tape record the interview. If you do not give permission, we 
will take notes on paper. We will ask you about issues that help you and issues 
about Rapid Diagnostic Tests, e.g. how you use them, what problems you find with 
them. You are free to stop the interview at any time or to not answer any questions 
that you feel uncomfortable with. 
WHAT ARE THE RISKS AND BENEFITS OF TAKING PART IN THIS STUDY? 
There are no risks in taking part in this study, but we would ask for about 1 hour of 
your time today. This study may not benefit you right now, but the results of the 
study will help us to know what difficulties you have with Rapid Diagnostic tests and 
how we might improve this. It will also help sisters in this clinic and health centres to 
use Rapid Diagnostic test with ease and managers to purchase the best tests for 
your setting. 
WHAT ARE THE COSTS TO ME? 
There is no cost to you for participating in the study. 
WILL MY TAKING PART IN THIS STUDY BE KEPT CONFIDENTIAL? 
All information collected, as part of this study will be kept securely and confidentially. 
Mr Devanand Moonasar the lead researcher for this study will be responsible for 
this. Your name will not be recorded in this interview. You will not be personally 
identified in any report about this study. All information will be kept in a locked and 
secured cabinet. 
WHAT IF I HAVE MORE QUESTIONS I WISH TO ASK ABOUT THIS STUDY? 
If you have any questions about this study, please ask us now. We will also give you 
a copy of this information sheet, which explains the study to take away with you. If 
you have questions later you can telephone Mr. Devanand Moonasar on 012 312 
0102. The committees giving ethical approval for this study are the Research 
Ethics Committees of the London School of Hygiene and Tropical Medicine, UK and 
the Medical University of South Africa. 
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CONSENT FORM 
Title of project: Factors that affect the quality of Malaria Rapid Diagnostic 
tests, in the Limpopo Province of South Africa 
Investigator: 
Devanand Moonasar: National Department of Health South Africa and London 
School of Hygiene & Tropical Medicine, UK 
CONSENT TO PARTICIPATE IN THE RESEARCH STUDY 
• I have read the information sheet about this study and I understand what will 
be required of me and what will happen to me if I take part in the study. 
• I understand that I may withdraw from this study at any time without giving a 
reason and without affecting my normal care and management. 
• I agree to take part in the study 
to be circled) 
YES I NO (answer 
Participant's signature : ______________ _ 
Date: ______ _ 
Participant's name: ________________ _ 
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9.4 Apppendix 4: Selected Clinics and sample size calculation for Accuracy 
study (Component 1) 
Municipality Malaria Cases 
Pislrict Name Clinic Name 2002 2003 2004 2005 Average 
Madimwo/Madimbo 
~HEMBE MUSINA Clinic 146 202 121 104 156.3 
i'iHEMBE MUTALE Mulala clinic 157 239 168 164 188 
The number of malaria patients that were needed to be included in the study to 
determine sensitivity and specificity was based on the 6 month average malaria 
clinic prevalence amongst patients with suspected malaria for both clinics - which 
was 4.95%; an additional 10% was added for loss to follow-up, bringing the final 
sample size to 406, see box 4. 
Sample size 
To determine sensitivity and specificity 
n~ (1 .96)2 p( 1-p) .-----------------., 
where: 
(1 .96) 2(0.95) (1-0.95) 
:: ---------------------------
(0.1) 2 
= 18.25 MRDT-positive patients 
p= suspected MRDT sensitivity 
= 95% 
X = 10% or 0.1 (confidence 
interval within which the test 
sensitivity will be measured). 
I needed to recruit 18.25 MRDT-positive patients to determine sensitivity to 
within 10%. 
Number of patients with suspected malaria over a 6-month period = 4000 (2 
clinics: Mulala and Madimbo) 
The number of malaria positive cases in these 2 clinics over the same six 
months was 198 
Thus the prevalence of malaria amongst patients presenting with symptoms 
suggestive of malaria was 4.95 % (198/4000* 100) over a 6-month period. 
This implies that [(100/4 .95)*18.25] = 369 patients with symptoms of malaria 
need to be screened to get 18.25 MRDT-positive cases per site 
Thus the total sample size for two clinics was calculated as 369. 
Allowing for a 10% loss to follow-up I increased the total sample size to 405. 
Reference for malaria prevelance. (115) 
Sample size calculation for accuracy study 
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9.5 Appendix Icroscopy recor 109 s ee s 5 M· d· h t 
PAGE 1. Evaluating the Performance and Usage of ICT Pf Malaria Rapid Diagnostic Test, 
in the Limpopo, South Africa 
Blood Smear Results: MADIMBO Clinic 
Study ID Number Thick Smear results Comments 
MAD 001 
MAD 002 
MAD 003 
MAD 004 
MAD 005 
MAD 006 
MAD 007 
MAD 008 
MAD 009 
MAD 010 
MAD 011 
MAD 012 
MAD 013 
MAD 014 
MAD 015 
MAD 016 
MAD 017 
MAD 018 
MAD 019 
MAD 020 
MAD 021 
MAD 022 
MAD 023 
MAD 024 
MAD 025 
MAD 026 
MAD 027 
MAD 028 
MAD 029 
MAD 030 
MAD 031 
MAD 032 
MAD 033 
MAD 034 
MAD 035 
MAD 036 
MAD 037 
MAD 038 
MAD 039 
MAD 040 ....... etc. 
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Evaluating the Performance and Usage of ICT Pf Malaria Rapid Diagnostic Test, 
in the Limpopo, South Africa 
Blood Smear Results: Mulala Clinic 
Study ID Number Thick Smear results Comments 
MUL 001 
MUL002 
MUL 003 
MUL 004 
MUL 005 
MUL 006 
MUL 007 
MUL 008 
MUL009 
MUL 010 
MUL 011 
MUL 012 
MUL 013 
MUL 014 
MUL 015 
MUL 016 
MUL017 
MUL018 
MUL 019 
MUL020 
MUL 021 
MUL 022 
MUL023 
MUL 024 
MUL 025 
MUL026 
MUL 027 
MUL028 
MUL 029 
MUL030 
MUL 031 
MUL 032 
MUL033 
MUL034 
MUL 035 
MUL036 
MUL037 
MUL038 
MUL039 
MUL040 
MUL 041 
MUL042 
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9.6 Appendix 6: Standard operating procedure 
Roles and Responsibilities of nurses in the DoH malaria study 
Introduction 
This study aims to determine the management of patients with fever, headache and / 
or chills in the Limpopo Province. We hope to determine the accuracy of malaria 
rapid test kits and how patients with fever are managed and what their outcomes 
are, with a view to improving health service delivery and patient care in the Limpopo 
province and in South Africa. Your assistance in this study is thus very important for 
South Africa. 
You will need to undertake 3 main tasks for the successful completion of this study: 
• Identifying eligible patients 
• Obtaining informed consent 
• Obtaining and documenting data 
A. IDENTIFYING PATIENTS 
When to recruit 
1. After you have managed / diagnosed / treated the patient for their presenting 
illness, focus on recruiting them for this malaria study. 
Who to recruit 
2. Do not recruit very sick patients, patients with danger signs or patients with 
coma/ unconsciousness / pneumonia / diarrhea or children with severe IMCI 
classifications. So - if your patient has any danger sign or a severe IMCI 
classification or pneumonia or diarrhea then he/she should not be recruited 
for this study. You should give these patients the routine care that is provided 
in your clinic. 
3. Discuss the DoH malaria study with each patient that has the following signs / 
symptoms: fever, chills, sweating and headache. 
B. OBTAINING INFORMED CONSENT 
What should you tell patients 
4. Explain to each patient with these signs/symptoms that a study is being 
conducted to determine how patients with fever or headache or chills or 
sweating) symptoms are managed and what their outcome will be. 
5. Explain that their participation in the study will assist to improve the care of 
people in the Limpopo. The study will also help them by following them up 
and making sure that they receive optimal treatm~nt. It will also help other 
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patients in Limpopo because the results of the study will be used to improve 
health care for adults and children with fever or headache or chills. 
6. Answer all the patient's questions about this study. 
7. Ask whether each identified patient will be willing to participate in the study. 
Explain that participation means that: 
a. The patient will receive routine care 
b. The patient may be asked to come back for follow-up 
Informed consent 
8. Make sure that all willing identified patients give informed consent to 
participating in the study. You will need to make sure that the consent form 
that is filled in for a willing patient is signed or has the patient's thumb print. 
What should you tell patients who do not want to participate in the study? 
9. Reassure all patients who are not participating in the study (either because 
they do not have the above-named signs, or because they are not willing to 
participate) that they will receive routine health care. 
What care should you provide to participating and non-participating patients ? 
10. Provide optimal health care for all participating and non-participating patients 
C. OBTAINING AND DOCUMENTING DATA 
Filling in the form on the first visit 
1. Write clearly 
2. Each study form will be numbered with a clinic number and the patient 
identification number .. The patient study ID will be consecutively numbered 
Clinic Clinic Code Numbers start from 
to 
Madimbo MAD 1-500 
Mulala MUL 501-100 
3. Remember to write the date 
4. Remember to write the patients date of birth as date/month/year 
5. Tick all appropriate boxes 
6. Record the presenting signs and symptoms (tick the "yes" column if a 
sign/symptom is present and "no" if it is not present) 
7. Record whether an MRDT was done (tick the yes OR no column) 
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8. If an MRDT was done, record the result. The test line AND the control line 
must be rated as 0, 1 or 3 using the standard chart provided. The results must 
be entered on the form as either positive or negative. All invalid tests must be 
repeated. 
9. A thick and thin blood film must be done on each patient that has an MRDT; 
the slides must be labeled with the unique patient identification number. 
(Follow the SOP for Malaria slide preparations). 
10. After recording the MRDT result, then give ALL patients a date to come back 
for a review / follow-up in 7 days time. You must ask the patient to come 
back, even if his {her malaria test was negative. 
11. If no malaria test was done, then do not ask the patient to come back. 
12. Emphasize that it is very important for the patient to come back so that he can 
be managed appropriately. 
13. Explain that even if the patient is feeling better on his appointment date, 
he/she should still come back. 
14. Explain that the patient should come back immediately if he/she is feeling 
sicker i.e. if his symptoms get worse, or if his fever persists or if he is vomiting 
everything or has convulsions, or if he is unable to drink or if he starts 
breathing faster or has difficulty breathing. Patients who are getting sicker 
should not wait for their 7 -day follow-up to return to the clinic. 
15. Record all the treatments that you gave to the patient 
16. Thank the patient and, if you have asked them to come back for follow-up, 
then reassure them that you are looking forward to seeing then on follow-up. 
Remember that only patients without MRDT test results do not come back. All 
patients with MRDT test results (positive or negative) should be asked to 
come back to the clinic for follow-up. 
Filling in the follow-up form (page 2): 
1. Write clearly 
2. Remember to write the date 
3. Remember to write the patients date of birth as date/month/year 
4. Tick all appropriate boxes 
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5. Record the Outcome (sick or hospitalized) presenting signs and symptoms 
(tick the "yes" column if a sign/symptom is present and "no" if it is not present) 
6. Record whether an MRDT was done (tick the yes OR no column) 
7. If an MRDT was done, record the result 
8. If the result is positive then take a specimen of blood and make a slide. 
(Follow the SOP for malaria slide preparation) 
9. The test line and the control line must be rated as 0, 1 or 3 using the standard 
chart provided. The results must be entered on the form as either positive or 
negative. All invalid tests must be repeated. 
10. A thick and thin blood film must be done on each patient that has an MRDT; 
the slides must be labeled with the unique patient identification number. The 
patients unique identification number must be accompanied by a capital "Rn to 
indicate that it is a repeat. E.g. 50R or 501 R 
Check if patients have returned for follow-up 
11. Every week check whether each patient has returned for follow-up. 
For all patients that do not come back to the clinic for follow-ups, make a copy of 
their data collection form and send it to the malaria team (name the person / give 
details etc» so that the local malaria team can follow them up at home. When 
the teams retrieve their information data should be recorded in the original form 
General 
Each clinic will have 4 files, one for each form; one file will have a blank form for the 
accuracy study, whilst the second will have the completed forms for the MRDT 
study. The third file will have the slide referral forms, which must accompany the 
slides when sent to the malaria teams. The fourth file will be for obtaining informed 
consent. All the files must be locked in a cupboard when the field officer leaves for 
the afternoon. 
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STUDY 
Evaluating the performance of leT Pf Malaria Rapid Diagnostic Test, in 
Limpopo 
Standard Operating Procedure for making thick and thin Blood films for 
Malaria Microscopy: 
After the patient's information is recorded on the patient information form , make the 
blood films as follows: 
1. With the patient's left hand palm facing upwards, select the third finger from 
the thumb (the big toe can be used for infants). Never use the thumb for 
adults and children. 
2. Clean the patients finger with a alcohol swab, then dry the finger with 
cotton wool. Use firm strokes to increase blood circulation. 
1 
With a sterile lancet puncture the ball of the finger. 
2 
4 By applying gentle pressure to the finger express the first drop of blood 
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and wipe it wi th a dry cotton wool swab. Make sure no cotton wool remains on 
the finger. 
5. Remove 2 blood slides from the slide box and label them with the same 
Number. The number should correspond with the number at the top of the 
patient information and MRDT results forms. One slide will be for the thin film 
and the other for the th ick film . Make sure the number on the slide 
corresponds with that of the patient study ID number. Eg. MUL 050 for a 
patient from Mulala Clinic or MAD 100 for Medico clinic. 
6. Working quickly and handling the glass slides only at the edges make the 
blood sl ides as follows: 
For the first slide: The Thin film 
Apply gentle pressure to the finger and collect a small drop of blood, 
(about this size . ) one centimeter from the edge of the glass (make 
sure that it does not touch the labeling). This is for the th in film . 
. I 
3 
For the second slide: The Thick Film 
Apply further pressure to express more blood and collect 3 large drops 
(about this size e ). Separate each drop in the center of the slide in a 
triangular pattern . 
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3 
6. Wipe the remaining blood away from the finger. 
7. THIN FILM: using another clean slide as a uspreader" and with the blood 
drops resting on a flat , firm surface, touch the small drop of blood with the 
spreader and allow the blood to run along its edge, keeping the spreader 
at 45 degree angle. Make sure that the spreader is in even contact with 
the blood when it is spread . 
8. THICK FILM , always handle slides at the edges or by corner and make 
the th ick fi lm as follows : 
Using the corner of the spreader, quickly join the drops and spread 
them in a 1 cm diameter circle to make a thick film . The blood must not 
be spread for too long , using a circular movement spread for 3-6 times. 
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For the thick film to be correctly spread , one must be able to read a 
typed document through it. 
Examples of a Good Thin Film : 
Examples of a Good Thick Film: 
9. Wash the spreader with saline and dry it with clean cotton wool , for every new 
patient. 
10 Stick the blood slides with selo tape at the back of the patient microscopy 
result forms . The blood films must be on the inside of the form and the 
selo tape at the back of the slide. 
11 . keep the forms with the slides in designated box for collection by the 
malaria teams. 
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9.7 Appendix 7: Patient Recall Cards 
PATIENT RECALL CARDS 
IN ENGLISH 
STUDY ON: EVALUATION OF MALARIA RAPID DIAGNOSTIC TESTS 
PLEASE CAN YOU RETURN TO THE CLINIC ON: 
DATE: ______________ _ 
TIME: ____________ _ 
IT IS IMPORTANT FOR YOU TO COME BACK, EVEN IF YOU FEEL BETTER 
IN TSHIVENDA 
GARATA YA THANGANEDZO 
TSEDZULUSO DZA NDINGO DZA TSHIHADU DZA DALI 
RI HUMBHELA URI VHA DOVHE VHA VHA VHUYE KILlNIKI NGA: 
DATUMU ____________________ _ 
TSHIFHINGA _____________ _ 
NDI ZWA NDEME URI VHA DOVHE VHA VHUYE NAHO VHA TSHI PFA VHA 
KHWINE 
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9.8 Appendix 8: Patient Data Sheets: 
Accuracy Component Form 1 Page 1 
where appropriate, tick the most appropriate box 
Evaluating the Performance and Usage of ICT Pf Malaria Rapid Diagnostic Test, in the Limpopo, South Africa 
Data Collector: Name I Surname and qualifications 
Patient Study ID 
No. __________ _ 
PATIENT DETAILS 
Name __________________ _ 
Address _______________________ _ 
Clinic Symptoms 
Fever 
Chills 
Sweating 
Headache 
Others 
Treatment 
ACTI Coartem® 
Primaquine 
NO Yes 
NO Yes 
Duration 
of illness 
in days 
Date_'_' ___ _ 
dd mm yyyy 
I Clinic ID 
No: 
Time ................................ . 
_D_a_t_e_o_f B_i_rt~h_~' _1 ____ AGE ____ (in yrs) 
dd/mm/yr 
Temperature, _____ deg 
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I I 
M F 
Sex DJ 
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Accuracy Component Form 1, Page 2 
PATIENT FOLLOW-UP STUDY 
where appropriate, tick the most appropriate box 
Evaluating the Performance and Usage of ICT Pf Malaria Rapid Diagnostic Test, in the Limpopo, South Africa 
Patient Study ID 
No. ___________ _ Date ~_I _ __ _ 
Recovery 
Sick 
Hospitalised 
Death 
NO Yes 
if yes specify reasons for 
1------+-------4 hospitalisation 
'--___ ---'-____ ---' if yes specify reasons for death 
What where the symptoms if Sick, Hospitalised or dead: 
Fever 
Chills 
Sweating 
Headache 
Others 
No Yes 
Time ................................ . 
if patient is sick and has either fever, chills, sweating or headache repeat MRDT, record on FORM 3 
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Malaria Rapid Test kit Result Form 2 
Evaluating the Performance and Usage of leT Pf Malaria Rapid Diagnostic Test, in the Limpopo, South Africa 
Patient Study ID No. __________ _ Date _,_, ___ _ 
dd mm yyyy 
Time Blood taken ________ _ 
I Test Line I Control Line 
Use the standard chart provided to rate the test and control 
lines Ratings: 
(0) = No band; 
Band 
I Results 
Negative 
157 
(1+) = weak 
(3+) strong Band 
Positive 
I Clinic ID No: 
Time ................................ . 
REPEAT Malaria Rapid Test kit Result Form 3 
Evaluating the Performance and Usage of leT Pf Malaria Rapid Diagnostic Test, in the Limpopo, South Africa 
Make a thick and thin blood film of all ROT study patients, and carefully label the slides with the study ID 
above 
Patient Study ID 
No. __________ _ 
Time Blood taken, ________ _ 
Date_'_' ___ _ 
dd mm yyyy 
I Test Line I Control Line 
Use the standard chart provided to rate the test and control lines 
Ratings:(O) = No band; (1+) = weak Band (3+) strong Band 
I Results 
Negative Positive 
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Clinic ID 
No: __ _ 
Time ........ . 
Microscopy Result form 4 
Evaluating the Performance and Usage of ICT Pf Malaria Rapid Diagnostic Test, in the Limpopo, South Africa 
Microscopist: Name I Surname and qualifications 
I 
Clinic ID 
No: _____ _ 
= 
Patient study ID No. __________ _ 
Time slide stained 
Time Blood 
Date _of Microscopy-'_' ___ _ taken, ________ _ 
Neg Pos 
Microscopy 
results 
'--_-'--__ --'1 if positive: ID Species* __ P. 
* if positive Calculate parasite density 
Asexual Parasites Counted 1-1 __ -, 
D X 8000 WBCIJ-1 = 
wec counted 
UQQJ 
Sexual Parasites Counted ~
= ~ 8000 WBCIJ- D 
= 
wec counted 1 200 I 
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D Parasites 1J-1 
D Parasites 1..l-1 
9.9 Appendix 9: Participant information sheet and informed consent: Field 
accuracy study (Component 1) 
Information sheet: 
PARTICIPANT INFORMATION SHEET 
TITLE OF RESEARCH PROJECT: Evaluating the performance and usage of ICT 
pt Malaria Rapid Diagnostic Test, in the Limpopo, South Africa 
Prinicipal Investigator: 
Devanand Moonasar: National Department of Health South Africa and London 
School of Hygiene & Tropical Medicine, UK 
Contact Information: 
Tel: +27 (0) 12 3120102 
Fax: +27(0) 12 3123113 
e-mail: moonad@health.gov.za/patrick.moonasar@lshtm.ac. uk 
WHY ARE WE DOING THIS STUDY? 
Malaria is a disease that can be treated and cured. Early diagnosis and treatment is 
important for preventing severe or complicated malaria and death. Since Rapid 
Malaria Tests are being used for Malaria diagnosis in your area, it is important for 
these tests to be accurate and easy to use. We did a study in March 2006 and the 
key findings from that study indicated that there were key concerns with the 
accuracy of the Malaria Rapid Diagnostic test. We are therefore doing this study to 
determine the accuracy of Rapid diagnostic tests under field conditions. 
DO I HAVE TO TAKE PART? 
It is entirely up to you to decide whether or not to take part in this study. If you 
decide not to take part, this will not affect you in any way. If you do decide to take 
part you will asked to sign a consent form. You are still free to withdraw at any time 
and without giving a reason. 
IF I TAKE PART IN THIS STUDY, WHAT WILL HAPPEN? 
After you have had a chance to ask questions, and have signed the informed 
consent form, we will take your blood and test you for malaria. If you do not give 
permission, we will still test you for malaria but will not include you in the study. The 
test will take 15 minutes to complete. We will make a slide from your blood and may 
take some of your blood in a little tube for testing. We may ask you to return, to see 
if you are well. If you are not well, we will do more tests and give you medicine if 
needed You can decide to withdraw from the study if you like and if you are 
uncomfortable then feel free to ask questions. 
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WHAT ARE THE RISKS AND BENEFITS OF TAKING PART IN THIS STUDY? 
There are no risks in taking part in this study, but we would ask for about 15 minutes 
of your time today. This study may not benefit you right now, but the results of the 
study will help us to know what the accuracy of the Rapid Diagnostic tests are and 
how we might improve this. It will also help sisters in this clinic and health centres to 
be confident with the use and results of the Rapid Diagnostic tests. If they are 
satisfied with the results you do not have to go to the he hospital for retesting. 
WHAT ARE THE COSTS TO ME? 
There is no cost to you for participating in the study. If you agree to the study then 
you need to sign a consent form. 
WILL MY TAKING PART IN THIS STUDY BE KEPT CONFIDENTIAL? 
All information collected, as part of this study will be kept securely and confidentially. 
Mr Devanand Moonasar the lead researcher for this study will be responsible for 
this. You will not be personally identified in any report about this study. All 
information will be kept in a locked and secured cabinet. 
WHAT IF I HAVE MORE QUESTIONS I WISH TO ASK ABOUT THIS STUDY? 
If you have any questions about this study, please ask us now. We will also give you 
a copy of this information sheet, which explains the study to take away with you. If 
you have questions later you can telephone Mr. Devanand Moonasar on 012 312 
0102. The committees giving ethical approval for this study are the Research 
Ethics Committees of the London School of Hygiene and Tropical Medicine, UK and 
the Medical University of South Africa. 
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9.10 Appendix 10: Tshivenda translation: 
THOHO YA PHUROJEKE 
U lungulula ku shumele na ku shumisele kwa (ICT pf Malaraia) Ndingo ya tshihadu 
Limpopo Africa Tshipembe. 
NOI NGANI RI TSHI TEA U ITA NOINGO ? 
Dali ndi vhulwadze vhune hanga ilafhea ha do yha ha fhola 
U tavhanya u wanala na u ilafha ndi zwa ndeme u thivhela u hulela ha Dali na lufu ( 
kana u lovha). 
U bva tshe ha thoma u shumiswa ndingo dza tshihadu dza vhulwadze ha Dali hu u 
itela u wana u yha hone ha vhulwadze ha Dali kha vhupo ha havho, Ndi zwa ndeme 
uri ndingo hedzi dzi vhe dzi vhe kwadzo na u shumisea nga u leluwa 
Ndi ngazwo ri tshi tea u divha vh di ha ku shumele kwa ndingo idzi. 
NDI NGA DZHENELA NAA ? 
Zwi bva kha vhone vhane uri yha a funa u dzhenelela kha tsedzuluso idzi. Arali yha 
tshi pfa yha sina dzangalelo la u dzhenelela izwo a zwi nga yha vhangeli thaidzo 
hunwe fhethu. Arali yha yha na dzangalelo la u dzhenelele, yha do humbelwa u 
saina fomo ya u sumba uri vhone yha na dzangalela. Vhana ndugelo dza u sa tsha 
isa phanda na tsedzuluso idzi tshifhinga tshinwe na tshinwe 
HU DO ITEA MINI ARALI NDA DZHENELELA TSEDZULUSO 
Nga murahu ha musi vho wana tshifhinga tsha u vhudzisa mbudziso na u saina fomo 
ya tsumbo dzangalelo, Ri do dzhia malofha a vho ra yha lingulula Dali. Arali yha sa ri 
nea thendelo ri do yha dzhia malofha u lingula Dali fhedzi a yha nga vhi murado wa 
tsedzuluso. Ndingo dzi do dzhia minethe ya fumi na mitanu u fhela. Ri do dzhia 
malofha avho ra ita tshilaidi ( u rothisela malofha kha ngilasi) ra dovha ra rothisela 
shotha kha tshipida tha Bambiri. Vha nga kha di di bvisa kha tsedzuluso idzi arali 
yha tshi funa nahone yha tshi pfa yha songo dzudzanyea kha yha vho fholowe u 
vhudzia mbudziso. 
VHUOI NA VHUVHI HA U OZHENELELA TSEOZULUSO 
A huna khombo kha u di dzhenisa kha tsedzuluso fhedzi ri do humbela mithethe ya 
fumi na mitanu kha tshifhinga tshavho namusi. Hedzi tsedzuluso zwi nga itea dza sa 
yha vhuyedze tshithu zwa zwino fhedzi mvelelo dza tsedzuluso dzi do ri thusa u di 
yha vhukoni ha dingo dza tshihadu na uri ri nga khwinifhadza hani, Zwi do dovha 
zwa tshusa vhaongi yha ino kiliniki na dzi Health Centres u yha na u fhulufhela kha u 
shumisa na mvelelo dza ndingo dza tshihadu, Arali vhaongi yha fushea nga Mvelelo 
dza ndingo , A vho nga tsha tea uya sibadela u dovholola ndingo. 
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MBAOELO KHA NNE NOI OZI FHIO ? 
A huna mbadelo musi yha tshi dzhenela kha tsedzuluso. Arali yha tshi tendelana na 
tsedzuluso yha tea u saina fomo ya u di dzhenisa 
U OZHENELE HANGA TSEOZULUSO ZWI DO VHA TSHI OZUMBE NAA ? 
Vhutanzi hothe ho kuvhanganywaho sa tshipida tsha tsedzuluso vhu do yha 
tsireledzeaho ha dovha ha yha ha tshipiri. Vho Devanand Moonasar, muhulwane wa 
tsedzuluso heyi, yha do yha vhone muthu a hwalalo vhu di fhinduleli hothe. 
Zwidodombedzwa nga ha vhone a zwi nga andazwi kha ripoto inwe na inwe nga 
tsedzuluso idzi. Vhutanzi hothe nga ha tsedzuluso idzi vhu vhewa ha kwinetshelwa 
fhethu ho tsireledzeaho. 
ZWINO ARALI NDI ND DZINWE MBUDZISO NDI TSHI TAMA U VHUDZISA 
NGA HA TSEDZULUSO NI ? 
Arali yha na dzinwe mbudziso, vhanga founela vho Devanand Moonasar kha 012 312 
0102. Dzi komiti dzi neaho tendelo dza Pfanelo dza vhuthu dza tsedsuluso idzi ndi 
komiti ya tsedzuluso ya Pfanelo dza vhathu ya tshikolo tsha mutakalo na zwa 
mishonga ya Tropika tsha London, UK na gudedzi la mishonga na dzilafho la Afrika 
Tshipembe. 
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9.11 Appendix 11: Consent Form Field accuracy study 
CONSENT FORM 
Title of project: Evaluating the performance and usage of ICT Pf Malaria 
Rapid Diagnostic Test, in the Limpopo, South Africa 
Investigator: 
Devanand Moonasar: National Department of Health South Africa and London 
School of Hygiene & Tropical Medicine, UK 
CONSENT TO PARTICIPATE IN THE RESEARCH STUDY 
• I have read the information sheet about this study and I understand what will 
be required of me and what will happen to me if I take part in the study. 
• I understand that I may withdraw from this study at any time without giving a 
reason and without affecting my normal care and management. 
• I agree to take part in the study 
to be circled) 
YES I NO (answer 
Participant's signature/ Thumb print : ______________ _ 
Date: _____ _ 
Participant's name: _______________ _ 
Informed Consent, Thivenda Translation; 
Patient ID No ___________ _ 
Fomo ya thendelo ya tsedzululo dza vhukoni kha mupo 
FOMO YA U NEA THENDELO 
Dzina la tshipida tsha mushumo wa tsedzuluso: U SEDZULUSA MASHUMELE NA KU 
SHUMlSELE KWA lCT Pf MALARIA, NDlNGO YA U WANULUSA YA TSHlHADU 
THENDELO YA U DZHENELELA KHA NGUDO TSEDZULUSI. 
l.Ndo vhala vhutanzi kha bambiri nga ha tsedzuluso idzi nahone ndi Pfesesa zwine 
zwa todea kha nne na zwine zwa do todea kha nne na zwine zwa do bvelela kha 
nne musi ndi tshi dzhia tshipida kha tsedzuluso idzi. 
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Ndi pfesesa uri ndi nga di bvisa kha tsedsuluso idzi tshifhinga tshinwe na tshinwe 
ndi songo nea tshiitisi zwine zwa sa do kwama ku togomelelwe kwa Kwanga Ndi a 
tenda u dzhia tshipida ( dzhenelela ) kha tsedzuluso idz; 
EE! HAI 
(Phindu/o i tangeledzwe) 
TSAINO YA MUDZHELEO / U GANDISA GUNWE _______ _ 
DATUMU _________________ __ 
MADZINA A MUDZHENELEU ____________ _ 
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9.12 Appendix 12: Clinics and Health Centres selected for testing 
uledza Clinic 
n\Al''''t1'71 Clinic 21 
31 
ulala clinic 
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9.13 Appendix 13: Check list for end-user observations. 
I I Table B: Interpretation of results 
Table A: Observation of tests 
Observer Date obMfWCI User# U.erSIll User All't Education Malaria Ix 1IlCI)8IIerce? ROT Use? 
I I I I [lJM (1) (1) Yes (lJYes User First Name (2) (2) No (2) No 
Site (3) 
Day Month Year (2)F How many monthS? How many months? (4) 
Observation Number 1 2 3 Comments 
Was this test done on a real patient? Circle the correct answer: 1=Yes 2=No 1 Y 2 N 1 Y 2 N 1 Y 2 N ASK atend-
Was patient febrile? Circle the correct answer: 1=Yes 2=No 3=Not applicable (if not a real 1 y 2 N 3 1 Y 2 N 3 1 Y 2 N 3 if they knew patient) 
For .. ch st.p b.,ow. clrcl.1 "th. HW performed the step correctly. c/rcl. 2 "th. HW perform.d the step Incorrectly. clrcl. 3 if the HW sklpp.d the step 
1. Assemble new test packet, swab. lancet & gloves. 1 2 3 1 2 3 1 2 3 Date Y N 
2. Put on new pai r of gloves. 1 2 3 1 2 3 1 2 3 
3. Check 9lIpiry date on test package to make sure test Is still valid. 1 2 3 1 2 3 1 2 3 
4. Write patient's name on device 1 2 3 1 2 3 1 2 3 
5. Clean finger with alcohol. 1 2 3 1 2 3 1 2 3 
6. Allow finger to dry before pricking it. 1 2 3 1 2 3 1 2 3 
7 . Using a sterile lancet, puncture the side of the ball of the finger. 1 2 3 1 2 3 1 2 3 
8. Dispose of lancet In sharps b in Immediately after pricking finger. 1 2 3 1 2 3 1 2 3 
9. Touch the tip of the tube to the blood until the tube Is half full 1 2 3 1 2 3 1 2 3 
10. Using the loop. Immediately touch the tip of the tube with blood in the smalier hole 1 2 3 1 2 3 1 2 3 
11. Dispense 5 drops of clearing buffer into the larger hole 1 2 3 1 2 3 1 2 3 
12. Wait 15 minutes before reading results. 1 2 3 1 2 3 1 2 3 
13. Read test results correctly. 1 2 3 1 2 3 1 2 3 
14. Record results in CHW register. 1 2 3 1 2 3 1 2 3 
15. Dispose of gloves, wrappers, alcohol swab, loop, desiccant & cassette in non-sharps 1 2 3 1 2 3 1 2 3 
container. 
Row Total: 115 11 5 115 
Battery # 1 2 3 4 5 6 7 8 9 10 
Tnt ..... 1I (WIfe an "JC" i'I IhfJ approplfale boIC below eacII rest number 10 Indicate If lhe HW i'I/eIpIeIs /he lesl result as 'Poslive' 'Negative' or 'Ambiguous, 
Positive 
Negative 
Ambiguous 
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9.14 Appendix 14:Colour chart for Interpreting MRDT results 
j~ ... 
~ a: ::: 
""" 
11 
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9.15 Appendix 15: Participant information sheet: End-user ability to conduct 
the test and interpret the results 
PARTICIPANT INFORMATION SHEET 
TITLE OF RESEARCH PROJECT: Evaluating the performance and health 
worker usage of ICT pt Malaria Rapid Diagnostic Test, in a field setting in the 
Limpopo, South Africa 
Prinicipal Investigator: 
Devanand Moonasar: National Department of Health South Africa and London 
School of Hygiene & Tropical Medicine, UK 
Contact Information: 
Tel: +27 (0) 12 3120102 
Fax: +27(0)123123113 
e-mail: moonad@health.gov.za/patrick.moonasar@lshtm.ac.uk 
WHY ARE WE DOING THIS STUDY? 
Malaria is a disease that can be treated and cured. Early diagnosis and treatment is 
important for preventing severe or complicated malaria and death. Since Rapid 
Malaria Tests are being used for Malaria diagnosis in your area, it is important for 
these tests to be accurate and easy to use. We are doing this study to determine 
the proficiency of the end-user to conduct the test and interpret the result. This 
information given by you will help us to determine if further training will be needed to 
assist the end-user to effectively use the MRDT. The testing should take a maximum 
of 45 minutes. We are planning to test about 20 users who are involved with Rapid 
Diagnostic tests for diagnosis and management of malaria. 
DO I HAVE TO TAKE PART? 
It is entirely up to you to decide whether or not to take part in this study. If you 
decide not to take part, this will not affect you in any way. If you do decide to take 
part you will asked to sign a consent form. You are still free to withdraw at any time 
and without giving a reason. 
IF I TAKE PART IN THIS STUDY, WHAT WILL HAPPEN? 
After you have had a chance to ask questions, and have signed the informed 
consent form, you will conduct 2 MRDTs and interpret the results, whilst being 
observed and we will take notes on paper. 
WHAT ARE THE RISKS AND BENEFITS OF TAKING PART IN THIS STUDY? 
There are no risks in taking part in this study, This study may not benefit you right 
now, but the results of the study will help us to know what the level of skills are to 
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conduct and interpret the results of an MRDT and how we may improve the training 
of the end-user for your setting. 
WHAT ARE THE COSTS TO ME? 
There is no cost to you for participating in the study. 
WILL MY TAKING PART IN THIS STUDY BE KEPT CONFIDENTIAL? 
All information collected, as part of this study will be kept securely and confidentially. 
Mr Devanand Moonasar the lead researcher for this study will be responsible for 
this. You will not be personally identified in any report about this study. All 
information will be kept in a locked and secured cabinet. 
WHAT IF I HAVE MORE QUESTIONS I WISH TO ASK ABOUT THIS STUDY? 
If you have any questions about this study, please ask us now. We will also give you 
a copy of this information sheet, which explains the study to take away with you. If 
you have questions later you can telephone Mr. Devanand Moonasar on 012 312 
0102. The committees giving ethical approval for this study are the Research 
Ethics Committees of the London School of Hygiene and Tropical Medicine, UK and. 
the Medical University of South Africa. 
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9.16 Appendix 16 : Consent form End-user ability to conduct the test and 
Interpret the results 
CONSENT FORM 
Title of project: Evaluating the performance and health worker usage of ICT Pf 
Malaria Rapid Diagnostic Test, in a field setting in the Limpopo, South Africa 
Investigator: 
Devanand Moonasar: National Department of Health South Africa and London 
School of Hygiene & Tropical Medicine, UK 
CONSENT TO PARTICIPATE IN THE RESEARCH STUDY 
• I have read the information sheet about this study and I understand what will 
be required of me and what will happen to me if I take part in the study. 
• I understand that I may withdraw from this study at any time without giving a 
reason and without affecting my normal care and management. 
• I agree to take part in the study 
to be circled) 
YES I NO (answer 
Participant's signature : ______________ _ 
Date: ______ _ 
Participant's name: ________________ _ 
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endix 17: Quali Assurance stud sites 
2003 2004 
1 21 
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9.18 Appendix 18 Data recording sheet for QC study: 
Quality Control Result form 5 
Tick Appropriate boxes 
Evaluating the Performance and Usage of ICT Pf Malaria Rapid Diagnostic Test, in the Limpopo, South Africa 
Clinic ID No: 
Clinic 
LAB 
MRDT results 
MRDT Batch ID 
Negative 
Positive 
if positive barely visible 
weakly positive 
strong positive 
PCW results 
Negative 
Positive 
if positive barely visible 
weakly positive 
strong positive 
Date ~_I _ __ _ Time ................................ . 
dd mm yyyy 
Nearest Hospital Lab ________________ _ 
Distance from Lab _______________ kms __ 
Average Clinic Temp: Deg 
none Fair Good Excellent 
Experience with using MRDTs 
Storage period of PCW --------------------------------days 
I Sample 1= Blood Sample, Sample 2 = positive control 
well sample (PCW). Clinics should only fill in results 
for Sample 2. 
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9.19 Appendix 19 Standardized Charts for interpreting line intensity of positive 
quality controls for MRDTs. 
Strong Positive 
Weak Positive 
- - - - --~ - -- - ---
~ . 
C'II- ' " ID Q. : :: 
~ 
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9.20 Appendix 20: Participant Information sheet: Quality assurance for routine 
sensitivity monitoring of HRP 11 antigen 
PARTICIPANT INFORMATION SHEET 
TITLE OF RESEARCH PROJECT: Evaluating the performance and of ICT Pf 
Malaria Rapid Diagnostic Test in the Limpopo, South Africa 
Prinicipal Investigator: 
Devanand Moonasar: National Department of Health South Africa and London 
School of Hygiene & Tropical Medicine, UK 
Contact Information: 
Tel: +27 (0) 123120102 
Fax: +27(0) 12 3123113 
e-mail: moonad@health.gov.za/patrick.moonasar@lshtm.ac.uk 
WHY ARE WE DOING THIS STUDY? 
Malaria is a disease that can be treated and cured. Early diagnosis and treatment is 
important for preventing severe or complicated malaria and death. Since Rapid 
Malaria Tests are being used for Malaria diagnosis in your area, it is important for 
these tests to be accurate and easy to use. We are doing this study to compare 
which setting will be most effective to conduct quality control on MRDT through the 
use of a positive control sample. This study will assist the malaria control 
programmes to implement a routine positive malaria controls for testing MRDT, with 
the aim of ensuring that there is accurate diagnosis for malaria at the primary health 
care level. We are planning to conduct a series of MRDT tests at the district 
laboratory and at selected clinics. Your laboratory/clinic has been selected to be part 
of this study. 
DO I HAVE TO TAKE PART? 
Your laboratory/clinic has been selected to be part of this study. 
If you decide not to take part, this will not affect you in any way. If you do decide to 
take part you will asked to sign a consent form. You are still free to withdraw at any 
time and without giving a reason. 
IF I TAKE PART IN THIS STUDY, WHAT WILL HAPPEN? 
After you have had a chance to ask questions, and have signed the informed 
consent form, we will ask you to store the Malaria HRP 11 positive control in your 
laboratory or in the clinic for up to 3 months, every month a technician from your 
laboratory will have to test the sample using whole blood or citrate as a diluent. 
Results of this test should be recorded in a data sheet. 
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WHAT ARE THE RISKS AND BENEFITS OF TAKING PART IN THIS STUDY? 
There are no risks in taking part in this study, but the testing of the MRDT should 
take you approximately 30 minutes once a month for 3 months. This study may not 
benefit you right now, but the results of the study will help us to know which site 
would be optimal to run a routine MRDT quality check. It will ensure that there 
confidence in the results of the MRDT and there will be few referrals to hospitals as 
doubtful results would be resolved with a positive control. 
WHAT ARE THE COSTS TO ME? 
There is no cost to you for participating in the study. 
WILL MY TAKING PART IN THIS STUDY BE KEPT CONFIDENTIAL? 
All information collected, as part of this study will be kept securely and confidentially. 
Mr Devanand Moonasar the lead researcher for this study will be responsible for 
this. You will not be personally identified in any report about this study. All 
information will be kept in a locked and secured cabinet. 
WHAT IF I HAVE MORE QUESTIONS I WISH TO ASK ABOUT THIS STUDY? 
If you have any questions about this study, please ask us now. We will also give you 
a copy of this information sheet, which explains the study to take away with you. If 
you have questions later you can telephone Mr. Devanand Moonasar on 012 312 
0102. The committees giving ethical approval for this study are the Research 
Ethics Committees of the London School of Hygiene and Tropical Medicine, UK and 
the Medical University of South Africa. 
176 
9.21 Appendix 21: Consent form Quality assurance for routine sensitivity 
monitoring of HRP " antigen 
CONSENT FORM 
Title of project: Evaluating the performance and health worker ICT pt Malaria 
Rapid Diagnostic Test, in the Limpopo, South Africa 
Investigator: 
Devanand Moonasar: National Department of Health South Africa and London 
School of Hygiene & Tropical Medicine, UK 
CONSENT TO PARTICIPATE IN THE RESEARCH STUDY 
• I have read the information sheet about this study and I understand what will 
be required of me and what will happen to me if I take part in the study. 
• I understand that I may withdraw from this study at any time without giving a 
reason and without affecting my normal care and management. 
• I agree to take part in the study 
to be circled) 
YES I NO (answer 
Participant's signature : ______________ _ 
Date: ______ _ 
Participant's name: ________________ _ 
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9.22 Appendix 22 An exploratory studY- of factors that affect the performance 
and usage of rapid diagnostic tests for malaria in the 
Limpopo Prov,i'1ce, ~ouJhAfricC! 
" , 
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Abstract 
Background: Malaria rapid diagnostic tests (ROTs) are relatively simple to perform and provide 
results quickly for making treatment decisions. However. the accuracy and application of ROT 
results depends on several factors such as quality of the ROT. storage. transport and end user 
performance. A cross sectional survey to explore factors that affect the performance and use of 
ROTs was conducted in the primary care facilities in South Africa. 
Methods: This study was conducted in three malaria risk sub-districts of the limpopo Province. 
in South Africa. Twenty nurses were randomly selected from 17 primary health care facilities. three 
nurses from hospitals serving the study area and 10 other key informants. representing the 
managers of the malaria control programmes. routine and research laboratories. were interviewed. 
using semi-structured questionnaires. 
Results: There was a high degree of efficiency in ordering and distribution of ROTs. however only 
13/20 (65%) of the health facilities had appropriate air-conditioning and monitoring of room 
temperatures. Sixty percent (12120) of the nurses did not receive any external training on 
conducting and interpreting ROT. Fifty percent of nurses (10/20) reported ROT stock-outs. Only 
3/20 nurses mentioned that they periodically checked quality of ROT. Fifteen percent of nurses 
reported giving antimalarial drugs even if the ROT was negative. 
Conclusion: Storage. quality assurance. end user training and use of ROT results for clinical 
decision making in primary care facilities in South Africa need to be improved. Further studies of 
the factors influencing the quality control of ROTs. their performance of ROTs and the ways to 
improve their use of ROTs are needed. 
178 
Page 1 of 5 
(page number not for cJtallon purposes) 
Malaria Jouma12007. 6:74 
Background 
The South African National Malaria treatment guidelines 
stipulate that malaria treatment (using artemesinin-based 
combination therapy) should be based on definitive diag-
nosis using microscopy or malaria rapid diagnostic tests 
(ROTs) (1). South Africa has been implementing RDTs to 
diagnose malaria within malaria endemic areas since 
2001 (2). In a primary health care setting, ROTs are most 
appropriate: they are easy to use, do not require sophisti-
cated technology and give rapid results [3]. The function-
ing and accuracy of ROTs can be affected by several 
factors, including manufacturing defects, storage, trans-
port, and end-user performance (4). Malaria diagnostic 
tests need to be highly accurate because false negative and 
false positive diagnoses have medica\, socia\, and eco-
nomic consequences such as prolongation of illness, 
increase in morbidity and mortality and loss in credibility 
of health services [5,6]. 
The Limpopo Province, is one of three malaria endemic 
provinces in South Africa and has the highest malaria inci-
dence [2]. Figure 1 provides a map showing magisterial 
areas. Although ROTs was introduced for malaria diagno-
sis in Limpopo in 2003, operational issues relating to its 
performance and use have not been rigorously investi-
gated. A study was therefore undertaken in the Limpopo 
Province to determine which factors affected q~ality and 
usage of ROTs. 
Methods 
Purposefully selected key informants and randomly 
selected nurses at the primary health facility level were 
interviewed using a semi-structured questionnaire. Key 
informants included three hospital pharmacy staff, one 
regional pharmacy manager, three district malaria manag-
ers, one provincial malaria control manager and two 
researchers. Among the nurses interviewed, 17 were from 
primary health care (PHC) clinics and three were from 
hospitals. 
A two-stage sampling procedure was used to select PHC 
clinic staff [7]. All clinics and health centers within the 
three malaria-affected districts were listed. Clinics and 
health centers with fewer than 10 malaria cases per 
annum were excluded from the sampling frame. In the 
first stage of sampling, 10% of the clinics (10/100) and 
20% of health centers (7/35) within each selected district 
were randomly selected. In the second stage, one nursing 
sister was randomly selected from each selected health 
facility. Interviews were transcribed, ordered and coded in 
matrixes, using the key categories of procurement & stock 
monitoring, storage, transport, quality control and end 
user experiences [8]. 
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Ethics 
The University of Limpopo Research Ethics Committee, 
the Limpopo Department of Health and Social Oevelop-
. ment and the London School of Hygiene and Tropical 
Medicine granted ethical permission for this study. 
Informed consent was acquired from all interviewees. 
Findings 
Procurement and stock monitoring 
In all health facilities, there was evidence that stocks and 
expiry dates were monitored regularly. Stock monitoring 
methods ranged from stock cards (paper based) to elec-
tronic systems. Nursing staff were aware of the seasonal 
increase in malaria cases and stated that they ordered 
more ROT stock before and during the season; however, 
only 20% of the nurses interviewed were able to accu-
rately give the limits of the malaria season (September-
May). More than half (55%) of the nurses indicated that 
stock-outs of ROTs occurred. However, they reported that 
this was rare (one or two times in a season) and contin-
gency plans existed to replace stock from either the nearest 
clinic or hospital pharmacies. Replacement of stock took 
place within 24 hours. District malaria managers reported 
ROT stock-outs in clinics in the 2005/2006-malaria sea-
son. They responded by alerting the necessary authorities 
(district hospital or regional pharmacy depots) or trans-
porting malaria kits to facilities. 
Pharmacy staff reported deploying pharmacy assistants to 
some health facilities to assist with ordering of pharma-
ceuticals including ROTs. One hospital had a bar code sys-
tem for ordering pharmaceutical supplies. At the regional 
pharmacy level an electronic system is in place to increase 
stock as demand increased, and in most cases this is pro-
portional to the seasonal increase in malaria cases. 
Storage of ROTs 
Sixty five percent (13/20) of the nurses reported that ROTs 
were stored correctly i.e. in an air-conditioned room with 
regular temperature monitoring. Among the nurses from 
the seven facilities that did not implement correct storage, 
three (42%) were very concerned with temperature fluctu-
ation as thermometers were unavailable for temperature 
monitoring. The remaining 4/7 (53%) indicated that 
although their clinics lacked air conditioning, room tem-
perature was monitored, and that it rarely rose above 
30·C. This however was not corroborated with any 
recorded data. 
Malaria managers (district and provincial) accepted that 
some clinics did not keep ROTs in a cool environment; 
however they were not concerned about this, commenting 
that • the kits did not stay in the clinics for too long", due to 
their frequent use. 
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Figure I 
Magisterial Districts of the limpopo Province. 
Phannacy managers in hospitals and regional depots 
stored RDTs in an air-conditioned environment (temper-
ature range IS-25°C) . Monitoring charts were produced 
when requested by the interviewer. 
Quality control of using RDTs 
Only 4/20 nursing staff said that they checked the quality 
ofRDTs, this they reported to have been done, by compar-
ing the agreement between a diagnosis based on clinical 
signs and symptoms and the RDT result. Two of 20 nurses 
reported that they used blood smear results to confirm the 
RDT results occasionally. Three (15%) nurses reported 
that they gave antimalarial drugs to RDT negative patients 
if the clinical presentation was suggestive of malaria. 
Figure 3 highlights the key challenges identified by nurses, 
researchers and malaria managers relating to quality. 
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In summary, managers were very concerned that RDTs 
quality were not being monitored at health fadlity level. 
One infonnant stated, • RDT quality control, both at the 
manufacturing side and at the testing stage, was lacking. The 
key is the end user's ability to distinguish between positive and 
negative results . • 
End User experiences In using RDTs 
Nursing staff had huge praise for the use of the ROTs, fig-
ure 4 highlights nurses' responses on positive aspects of 
using the ROTs. 
More than half the nurses (12/20) however reponed that 
they did not receive external training on RDT use; how-
ever, 10 nurses reported receiving in-house training. 
Almost all (19/20) nurses said that they were confident in 
using the ROT. 
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Figure 2 
Graph Showing factors affecting the quality and usage of 
ROTs. 
The accuracy of ROT result was the key concern for 35% of 
the respondents, false positive and negatives were stated 
as major challenges. 
Managers and laboratory technologists' views 
Malaria managers commented that ROT readings were 
problematic - "the fault could have been due to the clinic staff 
noc reading che tesc in cime." One laboratory technologist 
said that the nurses were not doing the test properly -
"When we receive the test back we see that they are putting too 
much blood." 
Discussion 
Although this study involved a small representative sam-
ple of users of ROT at the primary care facilities in South 
Mrica, it has revealed that (1) there are sporadic problems 
of stock-out of ROT during peak transmission seasons; (2) 
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Figure 3 
Quality-related challenges: selected quotes by nurses, 
researchers and malaria control managers. 
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Figure 4 
Nurses quotes on positive aspects of RDT and Summary of 
negative aspects of the RDTs. 
the storage facilities and monitoring is inadequate in 
many primary care facilities; (3) the accuracy of the ROT 
was tested on an adhoc basis leading to nurses sometimes 
offering antimalarials to ROT-negative cases on the basis 
of their clinical judgment; (4) there is a possibility that 
ROTs under-diagnose malaria in the current context and 
(5) there is very limited training on the use of ROT at the 
PHC level. 
According to the WHO, temperatures above 30·C are con-
sidered inappropriate for storing ROTs [4]. As tempera-
tures above 3~' C can affect overall performance of the 
ROTs, temperature-monitoring needs to take place in all 
clinics and environments. Air-conditioning or similar 
cooling equipment should be considered in those clinics 
that exceed the WHO recommended threshold [4]. ROT 
should be stored in a centralized store as long as possible 
and care should be taken during transport and storage at 
the health facilities to minimise degradation. Use of posi-
tive control wells and temperature monitors should be 
considered in South Africa to assure the quality of the 
ROTs and to build confidence of the users on ROT [9-11]. 
The quality of the ROT can be established at three levels: 
post-manufaaure level, end user level and through the 
use of positive control wells [9,12] . Due to theuncerta.inty 
of the quality of the test and lack of confidence in some 
cases ofinterpreting the results, patients were getting inap-
propriate treatment. For example some cases were given 
antimalarial treatment on clinical diagnosis even if the 
ROT was negative. It is possible to obtain false negative 
ROT results [6]. However there is no system of evaluating 
the performance of ROT in the routine health services and 
to build confidence among the users of ROT. Very few 
users at the primary health care clinics were formally 
trained in performing and interpreting RDTs. Thus an in-
service training and quality control system is needed 
urgently to ensure appropriate use of ROTs and effective 
treatment of malaria in South Mrica. Although package 
inserts are useful it would be easier for the end-user to 
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have posters or job aids so that the test procedure can be 
easily visible and read especially during busy periods and 
late in the night [13-15 J. End user proficiency testing such 
as those described in other studies may be consid-
ered[13,14,16). 
Conclusion 
This study in South Africa may not be applicable to other 
countries in Africa. However, the lessons on storage, qual-
ity assurance and training observed in this study would be 
applicable to most settings where ROTs are introduced. 
Further studies of the factors influencing the appropriate 
use of ROTs and the ways to improve the use of ROTs are 
needed in the study setting. 
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